query,response,reference,correctness_score,semantic_similarity_score,faithfulness_score,context_relevancy_score,answer_relevancy_score
What regulatory milestones has CytoSorb achieved in the United States?,"In the United States, CytoSorb has achieved Emergency Use Authorization (EUA) from the FDA for use in patients with COVID-19 infection, which was granted in April 2020. Additionally, while not approved for general use, investigational medical devices like CytoSorb may be made available for emergency use under the FDA’s Expanded Access Program (EAP).","CytoSorb has received FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery, and Emergency Use Authorization (EUA) for use in critically-ill patients with COVID-19 infection.",4.0,0.797070937604321,1.0,0.875,1.0
What are the commercialization strategies for CytoSorb in different regions?,"CytoSorb's commercialization strategy involves a mixed approach of direct sales and independent distribution, supported by strategic partnerships, particularly in regions that accept CE Mark approval. In EU countries, registration typically takes several months and facilitates quicker commercialization due to standardized processes. Outside the EU, the registration process is more variable, often taking several months to over a year, depending on country-specific documentation and clinical data requirements. This variability impacts the timing of commercialization and expected sales. The company actively supports distributors and strategic partners in the registration process and continuously evaluates new distribution and partnership opportunities in markets that accept CE Mark approval. Commercialization plans also include pursuing U.S. clinical trials to seek FDA approval. Overall, CytoSorb has established distribution in 67 countries worldwide, with a focus on expanding into new markets through direct and indirect channels.","CytoSorbents Corporation employs a mixed strategy of direct sales through its subsidiaries in key markets like Germany, Austria, and Switzerland, and distribution through strategic partners and independent distributors in other countries, leveraging CE Mark approval for European markets and actively seeking registrations worldwide.",4.5,0.7435345132446651,1.0,0.875,1.0
What are the financial implications of using CytoSorb in treating sepsis patients?,"Using CytoSorb in treating sepsis patients has significant financial implications. The therapy typically costs between $1,000 and $5,000 per treatment, depending on the number of sessions required. This cost is a fraction of the total expenses associated with sepsis treatment, particularly due to the high cost of ICU care, which is approximately $4,300 per day in the U.S. By reducing the severity of illness and potentially shortening ICU stays by one to two days, CytoSorb could lead to substantial cost savings for hospitals. Given that the average treatment cost for a severe sepsis or septic shock patient in the U.S. ranges from $45,000 to $60,000 without CytoSorb, the therapy could be cost-effective. The total addressable market for CytoSorb in treating sepsis in the U.S. and EU is estimated to be between $6 billion and $8 billion, reflecting its potential economic impact. Additionally, reducing ICU and hospital stays could result in significant savings for healthcare systems, although reimbursement in the U.S. remains unestablished and may require further clinical data.","The use of CytoSorb in sepsis treatment is expected to improve clinical outcomes and reduce the need for costly ICU care, potentially saving significant healthcare costs. The therapy typically costs between $1,000 to $5,000, representing a fraction of the average cost of treating a severe sepsis patient, which can range from $45,000 to $60,000.",4.5,0.876601961139345,1.0,0.875,1.0
What are the key risks associated with the discovery and development of our product candidates?,"The key risks associated with the discovery and development of product candidates include the high likelihood of failure due to the uncertain outcomes of preclinical studies and clinical trials. These processes are expensive, time-consuming, and difficult to design and implement. Delays in completing clinical trials or their termination can harm commercial prospects, increase costs, and hinder the ability to generate revenue. Additionally, the development process may be impacted by unforeseen safety issues, adverse side effects, or failures in companion diagnostics. Modifications to clinical trial protocols due to regulatory or institutional review board decisions, as well as ambiguous or negative interim results, can also lead to delays or denial of regulatory approval. The entire process is subject to extensive review and regulation by government authorities, requiring demonstration of safety, purity, potency, and an adequate risk versus benefit profile. Failure can occur at any stage of the clinical trial process, and the outcomes of earlier trials may not predict success in later stages.","The key risks include potential adverse impacts from COVID-19 on clinical trials, dependency on the success of lead product candidates, uncertainty of regulatory approval, and the high risk of failure in clinical trials.",4.5,0.6610711427906132,1.0,1.0,1.0
How does the COVID-19 pandemic affect our ability to conduct clinical trials?,"The COVID-19 pandemic affects the ability to conduct clinical trials in several ways. It can lead to delays or difficulties in enrolling patients and initiating clinical sites, including challenges in recruiting investigators and staff. There may also be delays in receiving supplies and materials due to disruptions in global shipping, which can impact the transport of clinical trial products. Changes in local regulations resulting from pandemic responses may require modifications to trial protocols, leading to unexpected costs or even discontinuation of trials. Additionally, the diversion of healthcare resources away from clinical trials, including the reallocation of hospitals and staff, can hinder operations. Key trial activities, such as site monitoring and subject visits, may be interrupted due to travel restrictions or the classification of certain procedures as non-essential. There is also a risk that trial participants may contract COVID-19, which could affect trial outcomes and increase adverse event counts. Regulatory agencies like the FDA and EMA may experience operational delays, impacting review and approval timelines. Supply chain disruptions from contract manufacturing organizations due to staffing shortages or production issues can further delay the availability of product candidates. Employee resources may be limited due to illness or the need to avoid large gatherings, affecting research and development efforts. Finally, the FDA may refuse to accept data from trials conducted in affected regions, potentially undermining the validity of results.","The COVID-19 pandemic may delay startup of new clinical trial sites, reduce patient enrollment, and disrupt operations of third-party suppliers and manufacturers, leading to delays or disruptions in the supply of product candidates for clinical trials.",5.0,0.794461515475375,1.0,1.0,1.0
"What are the potential consequences of failing to comply with environmental, health, and safety laws and regulations?","Failing to comply with environmental, health, and safety laws and regulations could result in fines or penalties, incur costs, and lead to substantial remediation expenses. It may also result in property damage, personal injury claims, loss of permits, or a cessation of operations. Additionally, liability can be joint and several and without regard to fault or negligence, potentially harming the business and financial condition.","Non-compliance could result in fines, penalties, or increased costs associated with remediation, and could potentially harm our business operations and reputation.",4.5,0.7632567390586223,1.0,1.0,1.0
"How does the company's international operations expose it to additional risks, and what measures does it take to mitigate these risks?","The company's international operations expose it to various risks, including multiple and conflicting laws and regulations related to privacy, taxes, export and import restrictions, employment, and regulatory approvals. It also faces challenges such as the need to obtain and maintain regulatory approvals, potential third-party patent rights, and difficulties in protecting and enforcing intellectual property. Additionally, staffing and managing foreign operations, navigating multiple reimbursement regimes, and financial risks like longer payment cycles, currency exchange fluctuations, and regional financial crises add to the complexity. The company is also exposed to natural disasters, political and economic instability, and compliance risks related to anti-bribery and anti-corruption laws.

To mitigate these risks, the company is likely to implement compliance programs to ensure adherence to applicable laws, including the U.S. Foreign Corrupt Practices Act. It may also invest in legal and regulatory expertise to navigate diverse regulatory environments and establish mechanisms to monitor and manage compliance with local requirements. Furthermore, the company may adopt strategies to protect intellectual property, strengthen financial controls, and manage currency exposure through hedging or other risk management techniques.","The company's international operations expose it to risks such as challenges caused by distance, language, and cultural differences, as well as varying legal, economic, and political conditions in different countries. To mitigate these risks, the company employs various strategies, including compliance with local laws and regulations, careful selection of markets, and diversification of operations across different jurisdictions.",5.0,0.7451083625785864,1.0,0.75,1.0
"What are the potential impacts of data privacy and security laws on the company's operations, and how does it ensure compliance with these regulations?","Data privacy and security laws can significantly affect a company's operations by creating uncertainty in business practices, limiting the ability to collect, store, transfer, and share personal information, and increasing operational costs. Compliance with evolving federal, state, and foreign regulations—such as HIPAA in the U.S. and various state-level privacy laws—requires the acceptance of more stringent contractual obligations and may necessitate changes to data processing practices. Failure to comply, or any perceived failure, can lead to negative publicity, government investigations, enforcement actions, third-party claims, and reputational damage, all of which may adversely impact financial performance and business operations.

To manage these risks, the company must maintain internal policies and procedures aligned with applicable laws and contractually agreed standards, invest in data security infrastructure, and adapt processes to meet the requirements of both domestic and international data protection frameworks. As regulations continue to evolve, the company must remain vigilant to changes in enforcement practices and legal interpretations to ensure ongoing compliance and mitigate potential liabilities.","Data privacy and security laws, such as the GDPR and CCPA, impose stringent requirements on the collection, storage, and use of personal information, which could increase the company's costs and expose it to potential sanctions and lawsuits if not complied with. The company ensures compliance through implementing robust data protection measures, regular audits, and staying updated on regulatory changes to adapt its practices accordingly.",4.5,0.7378811867796736,1.0,0.875,1.0
"What was the total amount of revenue expected to be recognized from remaining performance obligations as of March 31, 2020?",$24.0 billion,"As of March 31, 2020, approximately $24.0 billion of revenue was expected to be recognized from remaining performance obligations.",4.0,0.5230661188676947,1.0,1.0,1.0
What were the major elements contributing to the difference between the U.S. federal statutory tax rate and the effective tax rate in fiscal 2020?,"The major elements contributing to the difference between the U.S. federal statutory tax rate and the effective tax rate in fiscal 2020 included the impact of the national media goodwill impairment charge, which resulted in a significant income tax benefit. This impairment charge, amounting to $252.7 million in the third quarter of fiscal 2020, led to an income tax benefit of $26.9 million, significantly influencing the effective tax rate. Additionally, the Company's effective tax rate was affected by changes in tax law and regulations, including the Tax Cuts and Jobs Act, which reduced the U.S. federal statutory corporate income tax rate to 21%, and subsequent regulations that clarified the allocation of insurance expenses for foreign tax credit limitations, contributing to a one-time income tax benefit of $1.4 billion. These factors collectively resulted in an effective tax rate of 13.3 percent for fiscal 2020.","The major elements contributing to the difference in fiscal 2020 included a non-deductible goodwill impairment charge, a non-taxable gain on an arbitration award, a change in the net valuation allowance on certain deferred tax assets, and an increase in Income Tax and Foreign Tax Credits.",4.0,0.6494039848342817,1.0,0.875,1.0
How did the Company's annual goodwill impairment analysis in fiscal 2020 differ from previous years?,"The Company's annual goodwill impairment analysis in fiscal 2020 differed from previous years primarily due to the adoption of ASU No. 2017-04, which simplified the test for goodwill. This change allowed the Company to perform a single-step impairment test by comparing the fair value of the reporting unit to its carrying value, eliminating the need for a two-step process. Additionally, the analysis in 2020 included specific considerations related to the economic impact of the COVID-19 pandemic, including market capitalization declines and share price fluctuations, which were assessed during the impairment review. The Company conducted these assessments at various points in the year, including the annual test on October 1, 2020, and concluded that goodwill was not impaired. This approach reflected both the updated accounting guidance and the unique circumstances brought about by the pandemic.","In fiscal 2020, the Company performed quantitative goodwill impairment tests during the second and fourth quarters due to a sustained decline in the Company’s stock price and market capitalization, leading to the recognition of total non-cash impairment charges of $6,794 million. This was a departure from previous years where no such impairments were recognized.",2.0,0.668296117714158,1.0,0.0,1.0
How did the Company's approach to managing foreign currency risk through derivative instruments evolve in fiscal 2020?,"The Company's approach to managing foreign currency risk through derivative instruments in fiscal 2020 involved the use of foreign exchange contracts, including forward contracts, to hedge against currency risk arising from non-U.S. subsidiaries' revenue and expenses in currencies other than their functional currency, as well as from forecasted transactions and significant foreign currency asset or liability positions. These derivatives were designated as hedging instruments, with total notional amounts of $340 million at December 31, 2020, and represented net fair value assets of $5 million. Additionally, the Company used foreign currency forward contracts to manage risks associated with customer agreements priced in currencies different from the functional or local currencies of the parties involved and to hedge certain foreign currency-denominated monetary assets and liabilities, including intercompany accounts and forecasted transactions. The total notional amounts of these foreign currency contracts were $3.4 billion as of December 31, 2020. The Company also maintained derivatives not designated for hedge accounting, which were adjusted to fair value through earnings. The longest outstanding maturity of these instruments was 1.7 years as of December 31, 2020. The Company's board of directors reviewed and approved policies for managing this risk.","The Company continued to use foreign currency forward contracts as cash flow hedges to reduce foreign currency risk related to certain intercompany obligations and forecasted transactions. The notional amounts of these contracts designated as cash flow hedges increased to $455 million as of March 31, 2020, from $277 million as of March 31, 2019.",4.0,0.6373505071618727,1.0,0.875,1.0
"How does the company plan to commercialize its product candidates, and what are the associated risks?","The company plans to commercialize its product candidates either by developing its own sales and marketing organization or by outsourcing these functions to third parties. In some cases, the company may choose to build a sales, marketing, and commercial support infrastructure or participate in sales activities with collaborators if and when its product candidates are approved. However, establishing its own commercial capabilities involves significant risks, such as the high cost and time required to recruit and train a sales force or reimbursement specialists, which could delay product launches. If a product launch is delayed or does not occur, the company may incur unnecessary commercialization expenses, and the investment could be lost if it cannot retain or reposition its commercialization personnel. Additionally, risks include challenges in recruiting and retaining effective sales and marketing personnel, difficulties in gaining physician access or market acceptance, issues with pricing or reimbursement negotiations, restricted distribution channels, a lack of complementary products, and unexpected costs associated with building an independent commercialization organization. Furthermore, the company lacks experience in selling, marketing, or distributing pharmaceutical products and may face limitations in its current sales and marketing infrastructure.","The company plans to directly market and commercialize its product candidates by developing its own sales and marketing force. The associated risks include the potential for increased expenses, the inability to hire and retain qualified personnel, and the possibility of failing to build a successful commercial infrastructure.",4.5,0.8293544532401301,1.0,1.0,1.0
What are the potential impacts of the COVID-19 pandemic on the company's business operations?,"The COVID-19 pandemic may disrupt the company's business operations in several ways. It could affect the ability to source necessary equipment, components, and materials due to supply chain disruptions, impacting the production of products and potentially limiting the company’s capacity to meet customer demand. This risk has led the company to maintain higher inventory levels. Additionally, increased global demand for testing has further strained supply chains for materials used in both the company’s products and testing infrastructure.

The company has also faced increased costs due to compliance with governmental measures, and failure to comply could result in restrictions, fines, or penalties. The shift to remote work has heightened cybersecurity risks, including greater exposure to phishing attacks and increased demands on IT systems. Remote work could also affect productivity and collaboration, potentially impacting business performance.

The pandemic may influence customer behavior, reducing demand due to public health concerns, even as economic recovery progresses. Furthermore, the prolonged nature of the pandemic could disrupt financial markets and the company's ability to secure financing under favorable terms. The overall impact depends on evolving factors such as the duration and severity of the pandemic, government responses, and broader economic conditions, all of which remain uncertain.","The COVID-19 pandemic could disrupt the company's preclinical studies, clinical trials, and operations, potentially leading to delays in patient enrollment, difficulties in conducting trials, and interruptions in the supply chain for its product candidates.",4.5,0.6035253599044381,1.0,1.0,1.0
How does the company's reliance on third-party contract manufacturing organizations (CMOs) impact its operations?,"The company's reliance on third-party contract manufacturing organizations (CMOs) introduces several operational risks. Since the company lacks internal infrastructure for manufacturing, it depends on CMOs for the production of product candidates during preclinical and clinical studies, as well as for commercial supply if products are approved. This reliance exposes the company to potential disruptions in the development and commercialization of its products if CMOs fail to supply adequate quantities, meet quality standards, comply with regulations like cGMP, or maintain acceptable pricing. Additionally, replacing CMOs is challenging due to a limited number of qualified providers and the significant time and expertise required to transition, which could delay clinical trials and commercialization. The company also faces competitive risks, as some CMOs may work with competitors. Furthermore, disruptions in supply or inability to find alternative suppliers of acceptable quality and volume could lead to delays in research and commercialization, potentially harming the company's business, financial condition, and results of operations.","The company's reliance on CMOs exposes it to risks such as supply chain disruptions, potential manufacturing defects, and the inability to quickly transition to alternative suppliers if needed, which could delay product development and commercialization.",5.0,0.7896881589657002,1.0,1.0,1.0
What are the potential consequences of the company's failure to comply with healthcare laws and regulations?,"Failure to comply with healthcare laws and regulations may result in civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, and possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs. Additionally, individuals may face imprisonment, and the company could incur reputational harm, diminished profits, and future earnings. There may also be additional reporting requirements or oversight if the company becomes subject to a corporate integrity agreement or similar arrangement. The company might also face curtailment or restructuring of its operations. Defending against such actions can be costly, time-consuming, and require significant personnel resources. If third-party providers or entities fail to comply, they may face similar sanctions, including exclusion from government-funded programs, which could impact the company's ability to operate. Furthermore, actual or perceived non-compliance with data protection, privacy, and security laws could negatively affect the business, results of operations, and financial condition.","Failure to comply with healthcare laws and regulations could result in significant legal, financial, and reputational harm, including the imposition of civil, criminal, and administrative penalties, damages, monetary fines, and potential exclusion from participation in government healthcare programs.",5.0,0.8496007626490297,1.0,1.0,1.0
What are the risks associated with the company's reliance on collaborations and licensing arrangements?,"The risks associated with the company's reliance on collaborations and licensing arrangements include the potential inability to secure necessary collaborative licensing or other arrangements, which could hinder the development and commercialization of product candidates. Negotiating collaboration agreements involves long and complex processes with uncertain outcomes. Even if agreements are reached, collaborations may present greater uncertainty due to reduced control over development and commercialization programs.

Failure by partners to fulfill their obligations or termination of agreements could negatively impact the development, regulatory approval, and commercialization of product candidates. Granting exclusive rights may limit the company's ability to commercialize within specific territories. Termination of agreements could end funding, impairing the ability to finance further development efforts.

Collaborators may develop alternative products or technologies, shift focus away from the company's product candidates, or face financial difficulties, leading to reduced resources or termination of programs. Disagreements over agreement terms may result in delays, litigation, or arbitration, consuming management time and resources. Partners may also pursue competing product candidates, including through collaboration with the company’s competitors, potentially harming the company's business prospects and revenue potential. Additionally, the company may be required to expend significant operational, financial, and management resources, issue equity that dilutes shareholder ownership, or assume substantial actual or contingent liabilities. The company may also lose control over clinical trial design, funding, and marketing efforts, which could compromise the success and commercial viability of its product candidates.","The company's reliance on collaborations and licensing arrangements exposes it to risks such as the potential for partners to shift priorities, terminate agreements, or fail to fulfill their obligations, which could delay or prevent the development and commercialization of its product candidates.",4.5,0.8143045119802501,1.0,1.0,1.0
What are the potential benefits of intrathecal administration of AAV9-based gene therapies?,"Intrathecal administration of AAV9-based gene therapies offers several potential benefits. It allows for a lower dose of the therapy compared to intravenous administration, as the vector is confined to the central nervous system (CNS) with limited uptake into off-target tissues. This targeted delivery reduces exposure to peripheral organs, enabling a higher concentration of the vector to reach the diseased tissue of interest. Additionally, because the CNS is immune-privileged, intrathecal gene therapy can be administered even in the presence of pre-existing antibodies to AAV, which may otherwise limit treatment options. The method also enables more efficient biodistribution and transgene expression within the CNS, with evidence supporting its safety and efficacy in clinical trials. Furthermore, intrathecal delivery may reduce the risk of systemic immune responses and adverse events associated with higher doses, potentially improving the overall safety profile of the therapy.","The potential benefits of intrathecal administration of AAV9-based gene therapies include optimal biodistribution and cell transduction within the CNS, administration even in the presence of pre-existing antibodies to AAV, and limited exposure to peripheral organs.",5.0,0.836198952337563,1.0,0.875,1.0
How does the company plan to finance its cash needs in the future?,"The company plans to finance its future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and other marketing or distribution arrangements.","The company plans to finance its cash needs through a combination of equity offerings, government or private party grants, debt financings, and license and collaboration agreements.",4.5,0.8573715663188907,1.0,1.0,1.0
What are the risks associated with the company's reliance on third-party suppliers for materials used in the manufacture of its product candidates?,"The risks associated with the company's reliance on third-party suppliers include limited control over pricing, availability, quality, and delivery schedules. The company may face challenges in obtaining adequate supplies, especially if the suppliers are disrupted, either within or outside the United States, and may not be able to find alternative sources in a timely or cost-effective manner. There is a risk that suppliers may not meet required specifications or may experience performance failures, leading to delays in development and commercialization. Additionally, the loss of a supplier could result in significant manufacturing delays due to strict licensing requirements and the time needed to qualify new sources. The company also faces risks related to intellectual property rights, such as potentially having to share improvements made by manufacturers in the production process. Contract manufacturers may breach agreements, terminate contracts, or fail to deliver supplies on time, resulting in clinical trial interruptions or lost sales. The possibility of mislabeling, misappropriation of proprietary information, and inconsistent product quality further compounds these risks. If a manufacturer fails to perform, the company may be forced to manufacture materials itself, which it may not have the capabilities or resources for, or face difficulties in securing alternative manufacturers on favorable terms. Moreover, technical skills required for manufacturing may be proprietary to the original manufacturer, making transfer to a backup supplier difficult or impossible. These factors collectively could delay clinical trials, increase costs, and negatively impact the company's ability to commercialize its product candidates on a timely and competitive basis.","Risks include limited control over pricing, availability, and quality of materials, potential supply interruptions, and increased costs if alternative suppliers need to be found, which could delay clinical trials and commercialization efforts.",5.0,0.7434995652969523,1.0,1.0,1.0
How does the company's dependence on collaboration with UT Southwestern affect its research and development programs?,"The company's research and development programs are heavily dependent on its collaboration with UT Southwestern. The company relies exclusively on UT Southwestern for all preclinical research and development activities, including discovery, preclinical development, IND-enabling non-clinical studies, and research-grade manufacturing. UT Southwestern is also responsible for leading interactions with regulatory authorities, such as the FDA, and managing the Health Canada CTA for one of the product candidates, TSHA-101. This reliance means that the company's entire pipeline and discovery programs are tied to the performance and cooperation of UT Southwestern. Any delay, failure, or termination of this collaboration could significantly disrupt the development of product candidates and materially harm the company’s prospects. Additionally, the company does not conduct these activities independently and lacks its own preclinical capabilities, making it vulnerable to the priorities and actions of UT Southwestern, including potential conflicts of interest due to its collaborations with competitors.",The company's dependence on UT Southwestern for preclinical research and development programs could lead to delays or failures in its development efforts if UT Southwestern fails to fulfill its obligations or if there is a breakdown in collaboration.,5.0,0.7866144692221411,1.0,1.0,1.0
"How did the adoption of ASC Topic 842 affect the Company's Consolidated Balance Sheets as of August 3, 2019?","The adoption of ASC Topic 842 resulted in the recognition of operating lease liabilities and corresponding right-of-use assets on the Company's Consolidated Balance Sheets as of August 3, 2019. The amounts recognized were based on the present value of remaining lease payments for existing operating leases. This led to an adjustment in the balance sheet, with the recognition of these new assets and liabilities, while also involving the derecognition of certain property and equipment related to properties that did not qualify for sale-leaseback accounting upon completion of construction. The difference between the right-of-use assets and lease liabilities recognized was primarily related to adjustments to prepaid rent, deferred rent, lease intangible assets/liabilities, and closed property reserves.",The adoption of ASC Topic 842 resulted in the recognition of operating lease liabilities with corresponding right-of-use assets of approximately the same amount based on the present value of the remaining lease payments for existing operating leases.,4.5,0.800281031230558,1.0,0.875,1.0
How did the Company account for the Supervalu acquisition in terms of goodwill and intangible assets?,"The Company recorded the assets and liabilities of Supervalu at their estimated fair values as of the acquisition date. Goodwill was recognized as the future economic benefits arising from synergies expected from combining the operations of the Company and Supervalu, which could not be individually identified or separately recognized. A substantial portion of the goodwill is deductible for income tax purposes. The goodwill was attributed to the Supervalu Wholesale reporting unit and the legacy Company Wholesale reporting unit, which were reorganized into a single U.S. Wholesale reporting unit in the first quarter of fiscal 2020. No goodwill was attributed to the Retail reporting unit or any other reporting units.

Identifiable intangible assets were recorded based on final valuations and are expected to be amortized on a straight-line basis over their estimated useful lives. The fair value of these identifiable intangible assets was determined using income approaches, with significant assumptions based on Company-specific information and projections, making them Level 3 measurements. Acquisition-related costs were also incurred and quantified in Note 5.","In conjunction with the Supervalu acquisition, goodwill resulting from the acquisition was assigned to the previous Supervalu Wholesale reporting unit and the legacy Company Wholesale reporting unit. Identifiable intangible assets were also recorded based on final valuations, with expected useful lives ranging from 5 to 20 years.",4.5,0.8465369052513534,1.0,1.0,1.0
How did the Company's defined benefit pension plans perform in fiscal 2020 in terms of contributions and obligations?,"In fiscal 2020, the Company’s defined benefit pension plans experienced changes in obligations and funded status due to various factors. The aggregate funded status recognized at December 31, 2020, was a net liability of approximately $6.2 billion. The primary U.S. pension plan, which accounted for about 61% of the companywide pension obligation, had a discount rate of 2.4% at year-end, and sensitivity analysis showed that a 0.25% increase in the discount rate would have reduced the plan obligation by approximately $475 million, lowering its underfunded status from $3.2 billion to $2.8 billion.

Pension expense for the primary plan, which accounted for about 67% of the companywide expense, was reduced by approximately $88 million in 2020 due to a 1% increase in the discount rate. A 1% increase in the discount rate would have reduced total pension plan expense by approximately $269 million. 

Actuarial losses in 2020 were primarily driven by a decrease in the discount rate, partially offset by gains from a reduction in interest crediting rates. Additionally, the plan’s assets earned a return of $7.9 million, which exceeded the expected return by $3.8 million. The funded status of the plans decreased by $625,000, and accumulated other comprehensive loss increased by $1.7 million from 2019, influenced by a 90 basis point decrease in the discount rate from 3.2% to 2.3%, which increased the liability by $6.8 million. This was partially offset by a $700,000 reduction due to an update in the mortality projection improvement scale from MP-2019 to MP-2020.

At December 31, 2020, the primary qualified cash balance pension plan was sufficiently funded under ERISA requirements, and the Company was not required to make minimum contributions in 2021. No significant discretionary contributions were expected in 2021. Settlement losses were recognized in conjunction with lump sum payments made under certain pension plans in 2020, consistent with accounting guidance for defined benefit plans.",No minimum pension contributions were required to be made under either the SUPERVALU INC. Retirement Plan or the Unified Grocers pension plan in fiscal 2020. The Company expected to contribute approximately $0.0 million to $5.3 million to its other defined benefit pension plans and postretirement benefit plans in fiscal 2021.,3.0,0.5167343679462157,1.0,0.75,1.0
How did the adoption of the CARES Act affect the Company's deferred tax assets and liabilities?,"The adoption of the CARES Act allowed the Company to carry back net operating losses (NOLs) generated in tax years beginning after December 31, 2017, and before January 1, 2021, for up to five years. This change, which was previously disallowed under the Tax Reform Act, enabled the Company to utilize a 35% federal tax rate for the carryback period, compared to the current 21% rate. As a result, the Company recognized a tax benefit of approximately $39.5 million, which was recorded as a current tax receivable in the Consolidated Balance Sheet as of August 1, 2020. This adjustment increased the deferred tax asset related to the net operating loss carryback. Additionally, the CARES Act modified the deductibility of federal NOLs for tax years beginning on or after January 1, 2021, potentially limiting their future use. The Company continues to assess the full impact of the CARES Act on its consolidated financial statements, including whether state tax systems will conform to the federal changes.","The CARES Act allowed the Company to carry back net operating losses, resulting in a tax benefit of approximately $39.5 million. This was recorded as a current tax receivable in the Consolidated Balance Sheet as of August 1, 2020.",5.0,0.8237456811493297,1.0,1.0,1.0
How did the Company's decision to reclassify Retail operations from discontinued to continuing operations affect the financial statements?,"The Company's decision to reclassify Retail operations from discontinued to continuing operations resulted in the inclusion of Retail’s results of operations, financial position, cash flows, and related disclosures within continuing operations. This change in financial statement presentation required the reclassification of prior periods to conform to the current period presentation, meaning Retail is now presented as part of continuing operations for all periods. Additionally, references to the Consolidated Statements of Operations and the Consolidated Balance Sheets in the Notes to the Consolidated Financial Statements exclude all amounts related to discontinued operations unless otherwise indicated.","The reclassification resulted in the inclusion of Retail’s results of operations, financial position, and cash flows within continuing operations for all periods, affecting the presentation but not the underlying financial performance or position.",4.5,0.8635313401142103,1.0,1.0,1.0
"What was the total net revenue for Quest Diagnostics in 2020, and how did it compare to the previous year?","Quest Diagnostics reported total net revenues of $9.4 billion in 2020, which represented a 22.1% increase compared to the prior year.","The total net revenue for Quest Diagnostics in 2020 was $9.4 billion, which was up 22.1% from the previous year.",5.0,0.9454035866179503,1.0,1.0,1.0
How did the COVID-19 pandemic impact Quest Diagnostics' testing volume and revenues in 2020?,"The COVID-19 pandemic significantly impacted Quest Diagnostics' testing volume and revenues in 2020. While there was a decline in testing volume in the base business, which excludes COVID-19 molecular and antibody testing, this was more than offset by a surge in demand for COVID-19 molecular and antibody testing. This led to an overall increase in volume, measured by the number of requisitions, by 6.6% compared to the prior year, with organic growth driven by the demand for COVID-19 testing. Revenue per requisition increased by 16.2% due to the higher demand for these tests. Despite a 7.0% decrease in DS revenues, the company experienced a 23.4% increase in DIS revenues, primarily driven by the demand for COVID-19 testing. The company also expanded its testing capacity, capable of performing approximately 225,000 molecular and 200,000 antibody tests per day, to meet the increased demand.","The COVID-19 pandemic led to a decline in testing volume in Quest Diagnostics' base business by 11.4% in 2020, but this was more than offset by increased demand for COVID-19 molecular and antibody testing, which drove a 23.4% increase in revenues in the DIS business.",5.0,0.8581772152304928,1.0,0.875,1.0
How did Quest Diagnostics' capital expenditures and investments in technology and infrastructure evolve in 2020?,"Quest Diagnostics planned to invest approximately $350 million to $400 million in capital expenditures during 2021 to support and grow its operations. These investments were primarily focused on information technology, laboratory equipment and facilities—including COVID testing equipment—and the completion of a multi-year laboratory construction project in New Jersey. Additionally, the company continued to invest in advanced diagnostics and consumer growth strategies. As part of a multi-year initiative with the Quest Diagnostics Foundation, over $100 million was allocated to improve access to testing and raise awareness of diagnostic insights, with a significant portion of these efforts expected to occur in 2021. There is no specific information provided about capital expenditures or infrastructure investments in 2020.","Quest Diagnostics invested approximately $350 million to $400 million in capital expenditures in 2020, focusing on investments in information technology, laboratory equipment and facilities, including COVID testing equipment, and completion of a new multi-year laboratory construction in New Jersey.",2.0,0.6352336144776167,1.0,0.375,0.5
"What were the key financial covenants associated with Quest Diagnostics' credit facilities, and how were they amended in 2020?","The key financial covenant associated with Quest Diagnostics' credit facilities was the financial leverage ratio. In April 2020, the company amended its credit facility to provide increased covenant flexibility by raising the leverage ratio covenant. After a specified period, the covenant reverts to a maximum of 3.5 times EBITDA. During the period of the increased covenant, additional limitations and restrictions were imposed, including restrictions on repurchases of common stock, funds used for business acquisitions, incurrence of secured indebtedness, and dividend payments. The company was in compliance with all covenants as of December 31, 2020.","The key financial covenant associated with Quest Diagnostics' credit facilities was the maintenance of a financial leverage ratio. In 2020, the Company amended the Credit Facility to provide increased covenant flexibility, increasing the leverage ratio covenant temporarily to provide more flexibility during the COVID-19 pandemic.",5.0,0.9515867861079467,1.0,1.0,1.0
What are the primary risks related to the company's financial condition and capital requirements?,"The primary risks related to the company's financial condition and capital requirements include the significant risks associated with incurring substantial debt, which can lead to insufficient cash flow to meet debt obligations, potential default, and the inability to borrow under existing financing arrangements. Additionally, high levels of indebtedness increase vulnerability to economic and industry downturns, reduce financial flexibility, and limit the ability to pursue new business opportunities. The company also faces the risk of higher financing costs due to interest rate fluctuations and potential inability to refinance maturing debt on favorable terms. Capital risk is present due to the possibility of failing to meet regulatory capital requirements, which could result from losses or increased risk profiles. Furthermore, liquidity and funding risks arise from mismatches in cash flow timing and the inability to access funding at reasonable costs, especially during market stress, which could impact the company’s ability to meet its financial obligations.","The company faces risks including a limited operating history, significant ongoing losses, and the need for additional funding to expand commercialization and development efforts. Failure to obtain necessary capital could force the company to delay or terminate product commercialization or development efforts.",4.0,0.5366911722516803,1.0,1.0,1.0
How does the company's reliance on a single supplier for key components impact its operations?,"Relying on a single supplier for key components exposes the company to significant operational risks. If the supplier is unable to fulfill orders, fails to meet manufacturing specifications, or becomes unavailable, the company may face interruptions in production. The inability to promptly identify or transition to alternative suppliers could lead to delays, reduced product quality, or even a halt in operations. Additionally, the time and cost associated with qualifying new suppliers and ensuring comparable quality can be substantial, potentially harming the company's financial performance and market reputation. While the company maintains significant inventory of critical components to mitigate this risk, there is no guarantee that this inventory level can be sustained over time.","The company's reliance on a single supplier, TSMC, for manufacturing and supplying wafers used in its probes poses a risk if TSMC fails to fulfill obligations or performs unsatisfactorily. This could negatively affect the company's ability to source its devices and potentially impact cash flows due to minimum purchase obligations.",4.5,0.6065347127811641,1.0,1.0,1.0
What are the cybersecurity risks associated with the company's operations?,"The cybersecurity risks associated with the company's operations include increased opportunities for cyberattacks due to changes in employee work patterns, such as remote work during the COVID-19 pandemic, which expands the attack surface. This environment makes employees more vulnerable to phishing and social engineering attacks. The company relies heavily on technology systems and cloud-based solutions, increasing exposure to risks such as unauthorized access, data breaches, and system disruptions. Despite existing security measures, the company may not be able to anticipate or prevent all threats, which could result in the loss or damage of data, misstated financial information, liability for stolen assets or confidential information, legal actions, and reputational harm. Additionally, disruptions or breaches in the systems of third-party contractors, CROs, and vendors may lead to delays in product development and commercialization, while the costs of addressing such incidents could exceed the coverage provided by cybersecurity insurance. Operational risks are further heightened by the complexity and unpredictability of cloud and mobile technologies and the evolving tactics of cybercriminals.","The company faces risks of cybersecurity incidents that could result in unauthorized access, data breaches, or operational disruptions, potentially leading to harm to customers, business interruptions, legal liabilities, reputational damage, and increased costs for remediation and protection.",4.5,0.6212000781430199,1.0,1.0,1.0
What are the risks associated with the company's reliance on open source software?,"The risks associated with the company's reliance on open source software include the potential for competitors to create similar products more easily, which could lead to a loss of product sales and revenue. There is also a risk of legal claims challenging the company's use of open source software and compliance with applicable licenses, which could result in lawsuits over ownership or licensing terms. Additionally, open source software may introduce security risks due to its public availability, making it easier for hackers to compromise the company's technology platform and systems.

Open source licenses often lack warranties or contractual protections, and some may require the company to make source code for modifications or derivative works publicly available. In certain cases, combining proprietary software with open source software could obligate the company to release its proprietary code, potentially undermining its competitive advantage. The terms of many open source licenses have not been definitively interpreted by U.S. courts, which increases the risk of unanticipated legal conditions or restrictions on commercialization.

Furthermore, the company may be subject to claims of license breaches, which could require seeking licenses from third parties on unfavorable terms, re-engineering products at significant cost and delay, or discontinuing product sales if re-engineering is not feasible. The company's internal processes for monitoring and controlling open source usage may not be effective, and errors or failures in third-party software used in the products could harm customer relationships and damage the company's reputation.","Using open source software may expose the company to risks such as requirements to disclose source code, potential infringement claims, and the possibility that competitors could use the same open source software to create similar products. Failure to comply with open source licenses could restrict the company's ability to sell its products and lead to legal challenges.",5.0,0.8812945126550862,1.0,1.0,1.0
How does Brandywine Realty Trust account for acquisitions of real estate that do not meet the definition of a business?,"Brandywine Realty Trust accounts for acquisitions of real estate and in-substance real estate that do not meet the definition of a business as asset acquisitions. Under this approach, the acquisition consideration, including acquisition costs, is allocated to the individual assets acquired and liabilities assumed based on their relative fair values. This method does not result in the recognition of goodwill or a bargain purchase gain. Additionally, preexisting interests in the acquired assets are not remeasured to fair value but are continued to be accounted for at their historical cost. Direct acquisition costs are capitalized if an asset acquisition is considered probable, and if it is no longer probable, any capitalized costs that are not recoverable are written off.",Acquisitions of real estate that do not meet the definition of a business are accounted for as asset acquisitions. The acquisition consideration (including acquisition costs) is allocated to the individual assets acquired and liabilities assumed on a relative fair value basis.,5.0,0.6998296334098165,1.0,0.875,1.0
What method does Brandywine Realty Trust use to depreciate its buildings and improvements?,"Brandywine Realty Trust uses the straight-line method to depreciate its buildings and improvements over their estimated useful lives, which range from the life of the lease to 55 years.",Brandywine Realty Trust uses the straight-line method to depreciate its buildings and improvements over lives ranging from the life of the lease to 55 years.,5.0,0.9803309714608013,1.0,0.875,1.0
How does Brandywine Realty Trust determine the fair value of its real estate investments for impairment assessments?,"Brandywine Realty Trust determines the fair value of its real estate investments for impairment assessments by evaluating management’s estimated undiscounted future cash flows expected to be generated by the real estate investments. This process includes assessing the reasonableness of significant assumptions such as market rental rates, capitalization rates, and recent sales data for comparable real estate investments. These assumptions are evaluated in the context of the asset’s past performance and compared with evidence obtained in other areas of the audit to ensure consistency and reasonableness. Additionally, the audit process involves testing the completeness and accuracy of data provided by management, as well as evaluating the appropriateness of the methods and model outputs used in the estimation.","Brandywine Realty Trust determines the fair value of its real estate investments for impairment assessments using estimated undiscounted future cash flows expected to be generated from the operations and eventual disposition of the assets over, in most cases, a 10-year hold period. The estimates consider assumptions including market rental rates, capitalization rates, and recent sales data for comparable real estate investments.",4.5,0.7897922102534977,1.0,0.75,1.0
What are the key factors considered by Brandywine Realty Trust in its assessment of whether to consolidate a variable interest entity (VIE)?,"Brandywine Realty Trust considers several key factors in assessing whether to consolidate a variable interest entity (VIE). These include determining whether the entity has variable interests and, if so, whether the Trust is the primary beneficiary of the VIE. The primary beneficiary is defined as the party that has both the power to direct the activities of the VIE that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE.

To assess power, the Trust evaluates all facts and circumstances, including its role in establishing the VIE, ongoing rights and responsibilities, the activities that most significantly impact the VIE’s economic performance, and which party has the power over those activities. This includes analyzing the VIE's purpose and design, risks passed through to investors, voting interests, management and service agreements, involvement in the VIE’s initial design, and the existence of explicit or implicit financial guarantees. The Trust also considers whether it has the right to unilaterally remove decision makers and whether power is shared, assessing if it holds the power over the most significant activities.

In assessing the significance of variable interests, the Trust evaluates the terms, characteristics, and size of its variable interests, the design and characteristics of the VIE, its level of involvement, and any market-making activities related to the interests. The Trust determines whether it has an obligation to absorb losses or the right to receive benefits that could be potentially significant to the VIE.

These assessments are made upon initial involvement with the VIE and are reassessed on an ongoing basis, with periodic evaluations typically conducted quarterly to consider changes in governing documents, circumstances, or events that may affect the VIE's structure or the Trust's role.","Brandywine Realty Trust considers whether it is the primary beneficiary of a VIE, which involves having both the power to direct the activities that most significantly impact the VIE's economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE.",5.0,0.7919521951378005,1.0,1.0,1.0
How has the COVID-19 pandemic impacted the company's underwriting results in 2020?,"The COVID-19 pandemic had a significant impact on the company's underwriting results in 2020, primarily through increased catastrophe losses. These losses were evident across multiple segments, including property and casualty, contributing to a higher underwriting loss in 2020 compared to 2019. The pandemic-related catastrophe losses were a key factor in the shift from underwriting profit in 2019 to underwriting loss in 2020, particularly affecting the reinsurance segment and, to a lesser extent, RSUI. Additionally, the pandemic led to reduced travel and entertainment costs, which influenced the cost structure, although this partially offset the negative impact of higher losses.","The COVID-19 pandemic significantly impacted the company's underwriting results in 2020 by causing an underwriting loss due to pandemic-related catastrophe losses, which included event cancellation coverage for conferences and sporting events, business interruption claims, and related estimated legal expenses.",4.5,0.8271504424862444,1.0,1.0,1.0
What measures has the company taken to mitigate the impact of catastrophe events?,"The company has implemented disaster recovery and business continuity plans to mitigate the impact of catastrophe events. Additionally, as part of its risk management policy, the company maintains insurance coverage at levels it believes are appropriate for its business.","The company has taken several measures to mitigate the impact of catastrophe events, including considering catastrophe risks in underwriting and pricing decisions, purchasing reinsurance, monitoring and modeling accumulated exposures, and managing exposure in key geographic zones and product lines prone to catastrophe events.",3.0,0.7217278752270554,1.0,0.75,1.0
"How does the company account for prior accident year loss reserve development, and what impact does it have on financial results?","The company accounts for prior accident year loss reserve development by including it in net loss and LAE, reflecting both favorable and unfavorable movements in loss reserves from prior periods. These adjustments are primarily driven by changes in loss emergence compared to previously assumed patterns. 

In certain cases, such as medical malpractice treaties, favorable prior accident year loss reserve development is largely offset by an increase in profit commission expense, as the cedants retain most of the underwriting profits generated by these favorable developments. This results in a net neutral impact on the company's financial results, despite the favorable loss emergence.

Additionally, the impact varies by line of business and accident year. Favorable developments often stem from better-than-expected claims experience in longer-tailed casualty lines and shorter-tailed lines like ocean marine, automobile liability, and accident & health, particularly in earlier accident years. Conversely, unfavorable developments may arise from significant events such as natural disasters or catastrophic losses, including hurricanes, typhoons, and wildfires, which can affect specific accident years.

Overall, these developments affect the company’s net loss and LAE, with the net effect depending on the balance between favorable and unfavorable adjustments across different lines and years.","The company accounts for prior accident year loss reserve development by periodically analyzing and adjusting the expected ultimate cost of liabilities to reflect favorable or unfavorable development in loss experience and new information. Adjustments to these reserves, both favorable and unfavorable, are reflected in the financial results of the periods in which these adjustments are made.",4.5,0.6621820010820737,1.0,0.875,1.0
"What is the role of non-GAAP financial measures in the company's financial analysis, and how are they reconciled with GAAP measures?","Non-GAAP financial measures, such as underwriting profit and adjusted earnings before income taxes, are used in the company's financial analysis to provide a presentation that is considered more meaningful and useful to investors, analysts, rating agencies, and others evaluating performance. These measures are not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. The company acknowledges that these non-GAAP measures may differ from those used by other companies, which limits their usefulness for comparison purposes. However, the specific reconciliation of these non-GAAP measures with GAAP measures is not detailed in the provided context.","Non-GAAP financial measures, such as underwriting profit and adjusted earnings before income taxes, provide additional information to investors and analysts by highlighting specific aspects of performance that management believes are meaningful. These measures are not a substitute for GAAP measures and are reconciled with the most comparable GAAP financial measures in the financial statements.",4.0,0.6921325161030989,1.0,0.75,1.0
How has the company's capital structure and liquidity position been managed to support its operations during the financial year 2020?,"During the financial year 2020, the company managed its capital structure and liquidity position by actively monitoring and controlling liquidity and funding risk in accordance with HSBC policy. Despite disruptions caused by the COVID-19 pandemic, the company did not experience significant impacts on its liquidity or funding capabilities. To address increased commercial loan demand in March, the company raised deposits, utilized short-term borrowings through securities sold under repurchase agreements, and borrowed from the Federal Home Loan Bank (FHLB) to maintain adequate liquidity while supporting client needs. Substantially all of the drawn commercial lines of credit were repaid. The company did not utilize any of the Federal Reserve's liquidity facilities established to stabilize markets. Interest-bearing deposits with banks totaled $14.35 billion at the end of 2020, with $13.89 billion held at the Federal Reserve Bank. The company continues to monitor market events and adapt its framework as necessary to manage liquidity effectively.","The company has managed its capital structure and liquidity position by maintaining a relatively liquid financial position at its unrestricted holding companies, issuing new senior notes, and utilizing credit facilities. These measures have ensured adequate funds for operational needs, including acquisitions and share repurchases, despite challenges posed by the COVID-19 pandemic.",4.0,0.6574807846731736,1.0,0.875,1.0
What are the key assumptions used in the valuation of Huntington Bancshares Incorporated's mortgage servicing rights (MSRs)?,"The key assumptions used in the valuation of Huntington Bancshares Incorporated's mortgage servicing rights (MSRs) are derived from a discounted future cash flow model. Since MSRs do not trade in an active, open market with readily observable prices, their fair value is estimated using this model. The valuation is highly sensitive to movements in interest rates, as expected future net servicing income depends on the projected outstanding principal balances of the underlying loans. These balances are significantly influenced by the level of prepayments. Changes in the assumptions used in the model can have a significant impact on the valuation of MSRs. The sensitivity of the MSR value to changes in these assumptions is monitored and reported as part of the company's financial disclosures.","The key assumptions used in the valuation of Huntington Bancshares Incorporated's MSRs include the discount rate, prepayment speed, and the servicing fee. These assumptions are used in a discounted future cash flow model to estimate the fair value of MSRs.",4.0,0.8340100868477666,1.0,0.875,1.0
What is the significance of the allowance for credit losses (ACL) in the context of Huntington Bancshares Incorporated's financial reporting?,"The allowance for credit losses (ACL) is a critical component of Huntington Bancshares Incorporated's financial reporting as it represents the estimated amount of credit losses expected in the loan and lease portfolio. This measure is essential for providing a realistic assessment of the bank's financial health by accounting for potential losses due to defaults. The ACL is determined using the current expected credit loss (CECL) model under ASC Topic 326, which requires forecasting credit losses over the life of the financial assets. 

Prior to the implementation of ASU 2016-13 (CECL), the bank utilized an incurred loss methodology, which only recognized losses once they were probable and estimable. With the adoption of CECL, the bank made a significant adjustment to its ACL at implementation, resulting in an increase of $393 million, reflecting a more forward-looking approach to credit risk management.

The ACL is segmented into commercial and consumer categories, as well as covering off-balance sheet exposures through the AULC (Allowance for Unfunded Loan Commitments). These measures ensure that the financial statements reflect the risks inherent in the loan portfolio, including economic uncertainties and changes in macroeconomic conditions, such as the impact of the COVID-19 pandemic. The changes in the assumed unemployment rate, for instance, significantly influenced the ACL estimates, highlighting its sensitivity to economic factors.

Overall, the ACL plays a pivotal role in the transparency and accuracy of Huntington's financial statements, ensuring that the potential credit losses are adequately reserved and disclosed, thereby allowing stakeholders to make informed decisions.","The allowance for credit losses (ACL) is significant in Huntington Bancshares Incorporated's financial reporting as it represents the amount set aside to cover potential credit losses on financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. The ACL is deducted from the amortized cost basis of a financial asset or a group of financial assets so that the balance sheet reflects the net amount Huntington expects to collect.",5.0,0.8353369835353363,1.0,1.0,1.0
How does Huntington Bancshares Incorporated manage its interest rate risk through derivative financial instruments?,"Huntington Bancshares Incorporated manages its interest rate risk through the use of interest rate swaps, which are employed to hedge the interest rate risk associated with certain fixed-rate debt by converting it to a variable rate. These derivative instruments are part of balance sheet hedging activities, primarily aimed at asset and liability management. The company utilizes both fair value hedges, which protect against changes in the fair value of fixed-rate debt and investment securities due to interest rate fluctuations, and cash flow hedges, which modify the interest rate characteristics of designated commercial loans to mitigate the impact of future cash flow changes resulting from market interest rate movements. The net amounts receivable or payable on these derivative contracts are accrued as adjustments to interest income or interest expense. Additionally, certain amounts related to amortization of floor premiums, changes in the fair value of economic hedges, and terminated hedges reclassified from accumulated other comprehensive income (AOCI) are also recorded as adjustments to interest income.","Huntington Bancshares Incorporated manages its interest rate risk through the use of derivative financial instruments, principally interest rate swaps, caps, floors, and collars. These instruments provide flexibility in adjusting Huntington’s sensitivity to changes in interest rates without exposure to loss of principal and higher funding requirements. They are used in asset and liability management activities to protect against the risk of adverse price or interest rate movements.",4.5,0.876360551063849,1.0,1.0,1.0
What was the total acquisition-date fair value of consideration transferred in the Sprint Merger?,The total acquisition-date fair value of consideration transferred in the Sprint Merger was $40.8 billion.,The total acquisition-date fair value of consideration transferred in the Sprint Merger was $40.8 billion.,5.0,1.0,1.0,1.0,1.0
How much did T-Mobile pay in Commitment Letter fees to certain financial institutions in connection with the Merger?,T-Mobile paid $355 million in Commitment Letter fees to certain financial institutions in connection with the Merger.,T-Mobile paid $355 million in Commitment Letter fees to certain financial institutions in connection with the Merger.,5.0,1.0,1.0,1.0,1.0
"What was the impact of the new credit loss standard on the allowance for credit losses as of January 1, 2020?","On January 1, 2020, the adoption of the new credit loss standard resulted in a $10.4 million increase to the allowance for credit losses.","The new credit loss standard resulted in an increase to the allowance for credit losses of $91 million as of January 1, 2020.",3.0,0.9059212568579039,1.0,1.0,1.0
"What was the total principal amount of Senior Secured Notes issued by T-Mobile USA on April 9, 2020?",$19.0 billion,"The total principal amount of Senior Secured Notes issued by T-Mobile USA on April 9, 2020 was $19.0 billion.",5.0,0.566750373288547,1.0,1.0,1.0
What are the primary risks associated with investing in the shares of the company as outlined in the financial report?,"Investing in the company's shares carries significant risks primarily due to its focus on technology-related companies. These companies are subject to volatility, intense competition, shortened product life cycles, changes in regulatory and governmental programs, and periodic downturns, which could result in the loss of all or part of an investment. Many of these companies have narrow product lines and small market shares, making them more vulnerable to competitive actions, market conditions, and economic downturns. Revenues, income, and valuations of such companies often fluctuate suddenly and dramatically, and the industries are characterized by abrupt business cycles and intense competition. Overcapacity and economic downturns may lead to substantial decreases in market capitalization, which could be significant and not temporary. Additionally, rapid technological change leads to a historical trend of decreasing average selling prices for products and services, which could negatively impact operating results, debt obligations, and equity values. The company’s investments in sustainable and renewable technology companies also involve operational risks, including underestimated cost projections, unanticipated operation and maintenance expenses, loss of government subsidies, and challenges in delivering cost-effective energy solutions compared to traditional products. Furthermore, the business faces potential risks from cyber security threats, especially as the reliance on technology systems and cloud-based operations increases due to remote work practices, which could compromise sensitive information and disrupt operations.","The primary risks include the company's lack of an operating history, potential for significant fluctuations in quarterly results, and the risk of not achieving investment objectives due to market conditions and competition.",4.5,0.5306893257269628,1.0,0.875,1.0
How does the company's status as a non-diversified investment company under the 1940 Act affect its investment strategy?,"The company's status as a non-diversified investment company under the 1940 Act allows it to invest a larger proportion of its assets in securities of a single issuer compared to a diversified fund. This means the company is not limited by the 1940 Act regarding the percentage of assets that can be invested in any one issuer, except for restrictions on investments in other investment companies. As a result, the company may concentrate its investments in relatively few portfolio companies or industries, which increases the potential for greater fluctuations in its net asset value due to changes in the financial condition or market perception of those issuers. It also makes the company more vulnerable to individual economic or regulatory events affecting specific issuers or sectors. While the company has the flexibility to operate as a diversified investment company, its non-diversified status supports a strategy that may involve larger positions in fewer investments.","As a non-diversified investment company, the company is not limited in the proportion of assets it may invest in securities of a single issuer, which may increase the volatility of its NAV and make it more susceptible to economic or regulatory occurrences.",5.0,0.6800011288895459,1.0,1.0,1.0
What measures does the company take to mitigate the risk of unrealized losses on its portfolio?,"The company employs several measures to mitigate the risk of unrealized losses on its portfolio. These include utilizing investment securities to manage interest rate exposure within established guidelines and limits, using natural and offsetting economic hedges to reduce the need for off-balance sheet derivative instruments, and considering expected interest rate movements in managing interest rate risk. Additionally, the company uses simulation analyses to formulate strategies that achieve a desired risk profile within capital and liquidity parameters. For market risk, the company manages and controls exposures through approved limits set by the Risk Committee of the Board of Directors and the Risk Management Meeting, and these limits are monitored daily by an independent market risk management function. The company also employs stress testing to evaluate the impact of extreme but plausible events on portfolio values, using a variety of scenarios such as single risk factor stress, technical, hypothetical, and historical scenarios. To further assess potential risks, the company conducts reverse stress tests to identify scenarios that could lead to significant losses, thereby understanding systemic implications. Additionally, the company applies similar risk management policies and measurement techniques to both trading and non-trading portfolios, aiming to optimize return on risk while maintaining a risk profile consistent with its risk appetite. The company also uses a credit risk management framework that includes credit data warehouses to centralize reporting, support risk analysis, and calculate credit loss reserves. These measures collectively help to monitor and control market and credit risks, ensuring that portfolio losses are minimized.","The company values its investments at market value or fair value as determined in good faith by its Board of Trustees, considering various factors such as the estimated enterprise value of a portfolio company, the nature and realizable value of collateral, and the portfolio company’s ability to make payments based on its earnings and cash flow.",5.0,0.27755537958547255,1.0,0.875,1.0
How does the company plan to address the risk of fluctuations in interest rates affecting its cost of capital and net investment income?,"The company plans to address the risk of fluctuations in interest rates by using interest rate risk management techniques, including various interest rate hedging activities, to the extent permitted by the 1940 Act. These hedging activities are intended to limit exposure to interest rate fluctuations. However, such hedging may also limit the ability to benefit from lower interest rates in the hedged portfolio. The company acknowledges it has limited experience with these techniques and will need to acquire or develop expertise in this area.","The company may use interest rate risk management techniques, including various interest rate hedging activities to the extent permitted by the 1940 Act, to limit its exposure to interest rate fluctuations.",4.5,0.9055659231629369,1.0,1.0,1.0
What are the potential consequences if the company fails to maintain its status as a Business Development Company (BDC)?,"If the company fails to maintain its status as a Business Development Company (BDC), it could face several significant consequences. It might be subject to regulation as a registered closed-end investment company under the 1940 Act, which would significantly decrease its operating flexibility. This could lead to the need to restrict borrowings, reduce leverage, sell securities, and engage in other activities that are permitted under BDC regulations but not as a closed-end investment company. Additionally, failure to comply with the requirements imposed on BDCs by the 1940 Act could result in enforcement actions by the SEC or expose the company to claims from private litigants. The company's overall operating flexibility would be reduced, and compliance with more stringent regulations could increase the costs of doing business.","If the company fails to maintain its BDC status, it could be regulated as a registered closed-end investment company under the 1940 Act, subjecting it to more regulatory restrictions and potentially decreasing its operating flexibility.",5.0,0.86372278961864,1.0,1.0,1.0
How does the company manage the risk of default by portfolio companies on their debt obligations?,"The company manages the risk of default by portfolio companies on their debt obligations through several measures. It monitors financial and operating covenants to ensure compliance, as failure to meet these could lead to default, loan termination, and foreclosure on secured assets. In the event of a default, the company may incur expenses to seek recovery or negotiate new terms, which could include restructuring loans. Additionally, the company relies on the secured nature of its debt and may provide managerial assistance, which could influence a bankruptcy court's treatment of its claims, potentially protecting its position in the event of bankruptcy.",The company may incur expenses to seek recovery upon default or to negotiate new terms with defaulting portfolio companies. It also relies on the investment expertise and network of business contacts of the Adviser and its affiliates to monitor and service its investments.,4.5,0.6705893768437073,1.0,0.875,1.0
What are the implications of Intec Israel being characterized as a passive foreign investment company (PFIC) for U.S. shareholders?,"If Intec Israel is classified as a passive foreign investment company (PFIC) for any taxable year during which a U.S. shareholder holds its ordinary shares or American depositary shares (ADSs), certain adverse U.S. federal income tax consequences may apply. These consequences include the treatment of all or a portion of any gain on disposition as ordinary income, the application of a deferred interest charge on such gain and the receipt of certain dividends, and the obligation to comply with specific reporting requirements under U.S. federal income tax laws and regulations. Additionally, U.S. shareholders may be ineligible for preferential tax rates on capital gains or on actual or deemed dividends, and may face interest charges on certain taxes treated as deferred.","U.S. shareholders of a PFIC may face adverse tax consequences, including having gains classified as ordinary income, loss of preferential tax rates on dividends, and application of interest charges to distributions and share sales.",5.0,0.7706299384910195,1.0,1.0,1.0
How did the adoption of the Current Expected Credit Loss (CECL) model affect the Company's financial statements in 2020?,"The adoption of the Current Expected Credit Loss (CECL) model in 2020 resulted in a cumulative-effect adjustment to retained earnings, with corresponding increases in the allowance for credit losses on loans and unfunded commitments. The Company recorded a cumulative effective adjustment to decrease retained earnings by $25,018, reflecting the adoption of the new model under a modified retrospective approach. This adjustment was accompanied by the establishment of a deferred tax asset on the consolidated balance sheet. Additionally, the adoption led to the inclusion of expected credit losses over the life of the loan portfolio, which approximated four years, and the inclusion of an allowance for all purchased loans that were previously excluded. The CECL model also required the establishment of a reserve for potential losses from unfunded commitments, which was recorded separately in other liabilities. The implementation of CECL did not have a material impact on the Company's consolidated financial statements, as the changes were accounted for retrospectively and did not affect prior period comparative financial statements.","Upon adoption of CECL on January 1, 2020, the Company recorded a cumulative effect adjustment to decrease retained earnings by $25,018, with corresponding adjustments to the allowance for credit losses on loans and unfunded commitments.",4.5,0.8274134086537361,1.0,1.0,1.0
What significant mergers and acquisitions did FB Financial Corporation complete in 2020?,"In 2020, FB Financial Corporation completed a merger with Franklin Financial Network, Inc. and its wholly owned subsidiaries. The merger became effective on August 15, 2020, with FB Financial Corporation continuing as the surviving entity. As part of the transaction, the company acquired total assets of $3.63 billion, loans of $2.79 billion, and assumed total deposits of $3.12 billion. The merger added 10 branches and expanded the company's presence in middle Tennessee and the Nashville metropolitan statistical area. The merger consideration included 15,058,181 shares of FB Financial Corporation's common stock, $31,330 in cash, and the issuance of replacement restricted stock units with a total fair value of $674 attributed to pre-combination service. The closing price of the common stock on August 15, 2020, was $29.52, resulting in aggregate consideration of approximately $477,830. Additionally, goodwill of $67,191 was recorded, and measurement period adjustments of $6,546 were recorded in the fourth quarter of 2020 related to finalizing valuations of commercial loans held for sale, deposits, and premises and equipment.","FB Financial Corporation completed mergers with Franklin Financial Network, Inc. on August 15, 2020, and FNB Financial Corp. on February 14, 2020.",4.0,0.8485421701938808,1.0,1.0,1.0
How did the Company's allowance for credit losses change in 2020 due to the acquisitions of Franklin and FNB Financial Corp.?,"The Company's allowance for credit losses increased by $77,653 as a result of the acquisition of Franklin, effective as of the August 15, 2020 acquisition date, and by $4,494 due to the acquisition of Farmers National, effective as of the February 14, 2020 acquisition date.","The acquisitions of Franklin and FNB Financial Corp. increased the allowance for credit losses by $77,653 and $4,494, respectively, as of their acquisition dates.",4.0,0.8557843336301878,1.0,0.875,1.0
"What was the impact of the PPP loans on the Company's loan portfolio as of December 31, 2020?","As of December 31, 2020, the PPP loans had a significant impact on the Company's loan portfolio. The Bank had over 4,400 PPP loans, totaling $667.1 million, primarily in the commercial and industrial loan class. These loans were net of $12.5 million in deferred processing fee income and costs. The PPP loans were fully guaranteed by the SBA, and the Bank anticipated that most would be forgiven in whole or in part. The loans earned interest at a fixed rate of 1 percent and were primarily structured with a two-year term, with the possibility of extending to five years under the Paycheck Protection Program Flexibility Act. Additionally, the Bank recognized $6.2 million in interest income and $16.2 million in deferred processing fee income as a yield adjustment during the year ended December 31, 2020.","As of December 31, 2020, the Company had $212,645 of loans originated as part of the PPP, which are federally guaranteed and have minimal credit risk associated with them.",4.0,0.7181675417365851,1.0,1.0,1.0
How did the Company's investment in Federal Home Loan Bank (FHLB) stock affect its financial position?,"The Company's investment in Federal Home Loan Bank (FHLB) stock affected its financial position by being classified as a long-term investment accounted for under the cost method, with the ultimate recoverability of its par value considered rather than temporary declines in value. This investment was included in other assets on the consolidated balance sheets and amounted to $18.1 million as of December 31, 2020, and $34.1 million as of December 31, 2019. The stock was held to meet regulatory requirements, and excess stock could be sold to the FHLB subject to a five-year redemption notice period and at the sole discretion of the FHLB. This provided a mechanism for managing the investment while ensuring compliance with regulatory capital requirements.","The Bank accounts for its investments in FHLB stock at cost and evaluates them for impairment. As of December 31, 2020, the investment in FHLB stock was carried at cost and evaluated for impairment.",4.0,0.7438282240392396,1.0,0.875,1.0
What were the quarterly earnings per share (EPS) for FB Financial Corporation in 2020?,The provided context does not contain information about the quarterly earnings per share (EPS) for FB Financial Corporation in 2020.,"The quarterly EPS for FB Financial Corporation in 2020 were as follows: Q1 - $0.71, Q2 - $0.95, Q3 - $1.00, and Q4 - $1.11.",1.0,0.7909793487333123,1.0,0.25,1.0
How does the ongoing COVID-19 pandemic potentially affect the company's operations?,"The ongoing COVID-19 pandemic poses several risks to the company's operations. Disruptions in supply chains due to factory closures, port restrictions, and increased demand for testing equipment can limit the availability of essential components and materials needed to manufacture products. This has led to higher inventory levels as a precautionary measure. Additionally, compliance with governmental measures such as shelter-in-place orders and work-from-home policies may negatively impact productivity, delay preclinical and clinical programs, and restrict access to laboratory facilities. These operational disruptions can affect research and development activities, reduce the ability to engage with medical and investor communities, and limit field team interactions with healthcare providers and payors. The pandemic has also increased cyber security risks due to the rise in remote work, along with potential data accessibility and communication issues. Furthermore, workforce availability may be compromised by illness, quarantine, or travel restrictions, which could hinder the company's ability to deliver products efficiently. The situation remains uncertain, and ongoing health and safety measures may continue to impact demand, increase operating costs, and affect the distribution and shipping of products.","The COVID-19 pandemic could materially affect the company's operations, including clinical development, sales and marketing efforts, supply chain operations, research and development activities, and fundraising activities, potentially leading to delays or disruptions.",5.0,0.6239970884555955,1.0,1.0,1.0
How does the company's reliance on third-party manufacturers for the production of its product candidates pose risks?,"The company's reliance on third-party manufacturers for the production of its product candidates poses several risks. These include dependence on the third party for regulatory compliance and quality assurance, the potential for breaches of manufacturing agreements due to factors beyond the company's control—such as failure to synthesize or manufacture products according to specifications—and the possibility that the third party may terminate or choose not to renew the agreement based on their own business priorities, which could result in significant costs or damage to the company. Additionally, the FDA and other regulatory authorities require that products be manufactured according to cGMP and similar foreign standards, which involve registration, periodic inspections, and strict controls over manufacturing process changes. Any deviations from these standards may require investigation, correction, and reporting, increasing the operational burden on both the company and its manufacturers.

Further risks include the inability to secure alternative suppliers if the current manufacturer cannot meet demand or encounters issues, or the inability to find a third party capable of replicating the existing manufacturing method on commercially reasonable terms or in a timely manner. This could delay or prevent the completion of product development or the ability to market or distribute products. There are also risks related to supply chain vulnerabilities, such as disruption from a limited number of suppliers or single sources for essential components, which could lead to insufficient product supply. Additionally, scaling up production may introduce quality issues, require costly equipment and facility validation, and necessitate additional regulatory filings. Carrier disruptions or increased costs beyond the company’s control may also impact production and distribution. Finally, the failure of third-party manufacturers to comply with cGMP regulations or other requirements could result in regulatory actions such as clinical holds, fines, recalls, or suspension of production, significantly affecting the company's ability to commercialize its products.","Reliance on third-party manufacturers carries risks such as potential breaches of manufacturing agreements, termination of agreements, reliance on the third party for regulatory compliance, quality assurance, and potential supply disruptions.",5.0,0.8169181838734059,1.0,1.0,1.0
What are the potential impacts of the company's limited operating history as a pharmaceutical company?,"The company's limited operating history as a pharmaceutical company may make it difficult to evaluate its future viability. This is because the company has not yet demonstrated the ability to successfully complete large-scale clinical trials, obtain marketing approval, manufacture commercial-scale products, or conduct sales and marketing activities necessary for product commercialization. As a result, predictions about its future success or viability may be less accurate than they would be if the company had a longer operating history or a track record of successfully developing and commercializing pharmaceutical products. 

Additionally, the company may face unforeseen expenses, difficulties, complications, delays, and other challenges due to its limited experience. For example, interim Phase 2a trial results did not meet expectations, highlighting the risks associated with early-stage development. The company also needs to transition from a research-focused entity to one capable of supporting commercial activities, a shift that may not be successfully achieved. These factors, along with financial and operational fluctuations, could adversely affect the company's business and future performance.","The company's limited operating history makes it difficult to evaluate its future success and viability, and it may encounter risks and difficulties frequently experienced by early-stage pharmaceutical companies, which could adversely affect its business, operating results, and financial condition.",4.5,0.754455818271123,1.0,1.0,1.0
How does the company's status as an emerging growth company and a smaller reporting company affect its disclosure requirements?,"The company's status as an emerging growth company and a smaller reporting company allows it to take advantage of reduced disclosure requirements. As an emerging growth company, it is not required to comply with auditor attestation requirements under Section 404 of the Sarbanes-Oxley Act, has reduced disclosure obligations regarding executive compensation, and is exempt from holding nonbinding advisory stockholder votes on executive compensation or requiring stockholder approval of golden parachute payments not previously approved. Additionally, it is only required to provide two years of audited financial statements and two years of selected financial data in its annual report. 

As a smaller reporting company, it continues to benefit from exemptions such as reduced disclosure about executive compensation and market risk, which are typically required of larger public companies. These exemptions result in less detailed information being provided to stockholders compared to other public companies. Furthermore, the company may continue to benefit from certain exemptions even after ceasing to qualify as an emerging growth company, as long as it remains a smaller reporting company.","As an emerging growth company and a smaller reporting company, the company is permitted to rely on exemptions from certain disclosure requirements, which may make its common stock less attractive to investors and could affect the trading price of its stock.",5.0,0.7377108657831023,1.0,1.0,1.0
How did the COVID-19 pandemic impact VF's financial position as of March 2020?,"The financial statements for VF as of March 2020 reflect estimates and assumptions related to the impact of the COVID-19 pandemic. Management included these estimates based on available information at the time, acknowledging that the actual results could differ from the estimates due to the uncertainty surrounding the duration and severity of the pandemic's effects on the business. However, no specific financial figures or impacts were provided in the context regarding the direct influence of COVID-19 on VF's financial position.",The COVID-19 pandemic led VF to draw down $1.0 billion from its Global Credit Facility to strengthen its cash position and support general working capital needs.,3.0,0.40449697992780653,1.0,0.0,1.0
"What was the total amount of cash flow hedges used by VF as of March 2020, and how much was expected to be reclassified to earnings within the next 12 months?","The total amount of cash flow hedges used by VF as of March 2020 was not explicitly stated in the provided context. However, the context indicates that VF uses derivative contracts primarily to hedge a portion of the exchange risk for forecasted sales, purchases, production costs, operating costs, and intercompany royalties. Additionally, at March 2020, accumulated OCI included $60.2 million of pre-tax net deferred gains for foreign currency exchange contracts expected to be reclassified to earnings within the next 12 months.","VF had $60.2 million of pre-tax net deferred gains for foreign currency exchange contracts in accumulated OCI as of March 2020, of which $60.2 million was expected to be reclassified to earnings within the next 12 months.",4.0,0.6394528710798482,1.0,1.0,1.0
How does the COVID-19 pandemic impact the company's commercial launch of TAZVERIK?,"The COVID-19 pandemic has impacted the commercial launch of TAZVERIK in follicular lymphoma (FL) and epithelioid sarcoma (ES), potentially affecting the ability to initiate and complete preclinical studies and ongoing and planned clinical trials, disrupting regulatory activities, and further disrupting the commercialization of TAZVERIK. It may also have other adverse effects on the company's business and operations.","The COVID-19 pandemic has limited the company's ability to access accounts and healthcare professionals, negatively impacted patient visits to physicians, and continued to disrupt commercialization efforts, which could result in adverse effects on the business and operations.",4.0,0.6823190503363357,1.0,1.0,1.0
What are the financial implications of the company's reliance on third-party manufacturers for the production of tazemetostat?,"The financial implications of the company's reliance on third-party manufacturers for the production of tazemetostat include the risk of not having sufficient quantities of the product at an acceptable cost or quality, which could delay, prevent, or impair development or commercialization efforts. Additionally, any performance failure by a distributor or manufacturer could lead to delays in clinical development or marketing approval, resulting in additional losses and depriving the company of potential product revenue. If the company is unable to establish agreements with third-party manufacturers on a timely basis or on acceptable terms, or if existing agreements are breached, terminated, or nonrenewed at inconvenient times, this could lead to increased costs and delays in securing production, further impacting financial performance.","Reliance on third-party manufacturers increases the risk of not having sufficient quantities of tazemetostat or such quantities at an acceptable cost or quality, which could delay, prevent, or impair development or commercialization efforts.",4.5,0.8148255702924339,1.0,1.0,1.0
How does the company's intellectual property portfolio affect its competitive position?,"The company's intellectual property portfolio plays a crucial role in maintaining its competitive position, as the ability of its portfolio companies to obtain and maintain proprietary technology is essential. This technology often constitutes a significant portion of the collateral securing investments. The portfolio companies depend on patent, trade secret, and trademark protections to safeguard their innovations. However, risks such as misappropriation by competitors or disputes over ownership can undermine these protections. Litigation to enforce intellectual property rights or defend against infringement claims may lead to substantial costs and resource diversion, potentially impacting the ability of the portfolio companies to service debt and the value of related investments. Additionally, the company's competitive advantage could be weakened if trade secrets are disclosed or independently developed by others, particularly since enforcing trade secret protection can be challenging and uncertain. The uncertainty arising from intellectual property disputes and the varying effectiveness of protection in different jurisdictions further affect the company's ability to maintain a strong market position.","The company's ability to protect its intellectual property rights is crucial for maintaining a competitive edge. Failure to obtain, maintain, and enforce patent protection could allow competitors to develop and commercialize similar products, adversely affecting the company's business.",4.0,0.47764462866688545,1.0,0.0,1.0
What are the risks associated with the company's reliance on collaborations for product development and commercialization?,"Collaborations involving the company's product candidates pose several risks, including limited control over the efforts and resources collaborators allocate, potential delays or abandonment of clinical trials, insufficient funding, or the need for new formulations. Collaborators may also choose not to pursue development or commercialization based on clinical trial results, changes in strategic focus, funding availability, or external factors such as business combinations. There is a risk that collaborators could independently develop competing products or fail to properly maintain or defend the company’s intellectual property, potentially leading to litigation or loss of rights. Disputes with collaborators may cause delays or termination of projects, resulting in costly legal proceedings. Collaborations may be terminated, which could eliminate rights to commercialize certain product candidates and require additional capital. Additionally, the company may face challenges entering new markets without prior experience, experience disruption in ongoing operations, and potential failure of due diligence to uncover significant issues with acquired or licensed products or companies.","Risks include collaborators' discretion in determining resource allocation, potential de-emphasis or termination of development programs, and the possibility of disagreements over proprietary rights or contract interpretation, which could adversely affect the company's business.",4.5,0.7158227489750058,1.0,1.0,1.0
What are the four reportable operating segments of Willis Towers Watson?,"Human Capital and Benefits (HCB), Corporate Risk and Broking (CRB), Investment, Risk and Reinsurance (IRR), Benefits Delivery and Administration (BDA)","The four reportable operating segments are Human Capital and Benefits (HCB), Corporate Risk and Broking (CRB), Investment, Risk and Reinsurance (IRR), and Benefits Delivery and Administration (BDA).",5.0,0.7677864015646483,1.0,1.0,1.0
What are the key assumptions used in the valuation of Willis Towers Watson's defined benefit pension plans?,"The key assumptions used in the valuation of Willis Towers Watson's defined benefit pension plans include the discount rate, expected long-term return on plan assets, rates of participant mortality, and the expected long-term rate of compensation and pension increases. These assumptions are reviewed annually by senior management and are based on factors such as economic forecasts, relevant benchmarks, historical trends, portfolio composition, and peer company comparisons. The discount rate is determined using a granular approach for service and interest costs, while the expected return on plan assets is based on the weighted-average yield expected from the target asset allocations.","The key assumptions include discount rates, expected long-term rates of return on plan assets, rates of participant mortality, expected long-term rates of compensation and pension increases.",5.0,0.7107933886715289,1.0,0.875,1.0
How does Willis Towers Watson recognize revenue from broking services?,"Willis Towers Watson recognizes revenue from broking services at a point in time, typically at the later of the policy inception date or when the policy placement is complete, as this is viewed as the date when control is transferred to the client. For most broking arrangements, revenue is recognized at this point because the primary performance obligation is the placement of an effective insurance policy. However, for employer-sponsored Medicare broking, revenue is recognized over time since the company is standing ready to place retiree Medicare coverage under its agreements. In situations where fees are variable, the company estimates the likely commission per policy, considering factors such as cancellation likelihood, and applies judgment to determine the transaction price, which may be adjusted over time as more information becomes available.","Revenue from broking services is recognized at the later of the policy inception date or when the policy placement is complete, as this is viewed as the date when control is transferred to the client.",4.5,0.7090035001290149,1.0,0.875,1.0
What are the key risks and uncertainties related to the COVID-19 pandemic that Willis Towers Watson has considered in its financial statements?,"The key risks and uncertainties related to the COVID-19 pandemic that Willis Towers Watson has considered in its financial statements include the potential for extended remote work arrangements to increase operational risks such as cybersecurity threats and strain technological resources and business continuity plans. The company also faces risks related to third-party vendors potentially being unable to perform due to force majeure or operational failures caused by the pandemic. Additionally, the spread of the virus could impact the availability of executive officers and key employees essential to conducting business. The overall impact on the business, financial condition, and results of operations depends on uncertain future developments, including the widespread distribution, acceptance, and effectiveness of vaccines, as well as the global economic response and the success of measures to control the virus. Furthermore, the pandemic could lead to a prolonged economic downturn, affecting revenues related to data products and IPOs, and could impact customers' businesses and their risk management needs and ability to trade. Regulatory uncertainty resulting from governmental actions or delays in regulatory measures may also affect the business.","The key risks and uncertainties include the collectability of billed and unbilled receivables, the estimation of revenue, and the fair value of reporting units, tangible and intangible assets, and contingent consideration.",3.0,0.3470222328535813,1.0,1.0,1.0
"What is the total amount of remaining performance obligations as of December 31, 2020, and how is it expected to be recognized in future periods?","As of December 31, 2020, the total amount of remaining performance obligations is approximately $8.4 billion, which includes deferred installation revenues. The majority of this amount is expected to be recognized over the next 24 months.","As of December 31, 2020, approximately $8.4 billion of total revenues, including deferred installation revenues, are expected to be recognized in future periods, the majority of which will be recognized over the next 24 months.",5.0,0.8056208091552899,1.0,0.875,1.0
"How did the adoption of Topic 842 (Leases) impact the Company's financial results on January 1, 2019?","The adoption of Topic 842 on January 1, 2019, resulted in the recognition of new right-of-use (ROU) assets and lease liabilities on the Company's balance sheet for all operating leases. This change was implemented using the alternative transition method, which required the Company to record a ROU asset and lease liability of $82.2 million at the commencement date. The cumulative effect of initially applying the standard was not material to the opening balance of retained earnings, and no cumulative-effect adjustment was recorded. As a result, the adoption did not have a material impact on the consolidated income statement. The Company also applied practical expedients permitted under the transition guidance, which allowed it to avoid reassessing existing contracts for lease classification and other related matters, and elected not to apply the standard to short-term leases. The primary impact was increased transparency and comparability in financial reporting by recognizing lease assets and liabilities that were previously off-balance-sheet under the prior guidance.","On January 1, 2019, the adoption of Topic 842 resulted in the recognition of new ROU assets and liabilities on the balance sheet for all operating leases, and the de-recognition of existing build-to-suit assets and liabilities with a cumulative effect adjustment to retained earnings.",5.0,0.7971572517660039,1.0,1.0,1.0
"What are the key risks and uncertainties that may have a material adverse effect on the company's business, financial condition, or results of operations?","The key risks and uncertainties that may have a material adverse effect on the company's business, financial condition, or results of operations include unfavorable global economic conditions, which could lead to financial market volatility, difficulties in raising capital, and supply chain disruptions. The company is also exposed to cyber security threats due to its reliance on information technology systems, particularly as remote work has increased since the COVID-19 pandemic, potentially creating more vulnerabilities. Additionally, the company may face new regulatory costs and challenges as a result of Brexit, including increased trade barriers and the loss of benefits from global trade agreements negotiated by the European Union. The ongoing impact of the COVID-19 pandemic could contribute to a severe or prolonged economic downturn, which may disrupt financial markets and hinder the company's ability to raise capital. Furthermore, any failure, inadequacy, interruption, or security lapse in the company's information technology infrastructure, including cyber incidents, could compromise sensitive data—such as intellectual property, proprietary business information, and personal identifiable information—and impair the company’s ability to operate effectively. The company also faces risks related to operating in multiple international jurisdictions, including differing regulatory and compliance requirements, currency exchange rate fluctuations, trade barriers, changes in tax laws, workforce challenges abroad, production shortages due to supply chain disruptions, and business interruptions caused by geo-political actions or natural disasters.","The key risks include uncertainty regarding future revenue and access to funding, potential failure to develop or commercialize drug or biologic product candidates, clinical trial delays, reliance on third parties for management of clinical programs and manufacturing, extensive regulation by government and regulatory agencies, and reliance on intellectual property.",4.0,0.4555630964042702,1.0,1.0,1.0
How does the company plan to address the risk of failing to obtain regulatory approval for its product candidates?,"The company does not have a specific plan to address the risk of failing to obtain regulatory approval, as it acknowledges the significant uncertainty and challenges involved. It recognizes that failure to obtain regulatory approval could result in delays or discontinuation of development for its product candidates, and that the regulatory approval process is lengthy, complex, and expensive. The company relies on consultants and third-party contract research organizations to assist in navigating the approval process, but it does not provide a detailed strategy for overcoming the risks associated with regulatory failure.","The company plans to navigate the regulatory approval process by ensuring compliance with all necessary clinical trial designs, data submissions, and regulatory requirements. It also aims to maintain open communication with regulatory authorities to address any issues promptly.",3.0,0.6081593188611851,1.0,0.875,1.0
What are the potential impacts of clinical trial delays on the company's business?,"Clinical trial delays can significantly impact the company's business by harming the commercial prospects of its product candidates and delaying or preventing the generation of product revenues. Such delays increase costs, slow down the development and approval process, and jeopardize the ability to start future product sales and generate income. Additionally, delays may allow competitors to bring similar products to market earlier, potentially reducing the company's exclusive commercialization period and impairing its ability to commercialize the product candidates. These factors collectively may harm the company’s business, reputation, financial condition, and results of operations. Delays may also lead to the denial of regulatory approval or the cessation of development, further affecting the company’s long-term viability.","Clinical trial delays could result in increased costs, delays in advancing product candidates, and potential loss of market opportunities, which could harm the company's competitive position and financial performance.",5.0,0.7899522166378109,1.0,1.0,1.0
How does the company plan to manage the financial risk associated with the need for substantial additional funding?,"The company plans to manage the financial risk associated with the need for substantial additional funding by seeking capital through various means such as equity or debt financings, government or third-party funding, marketing and distribution arrangements, collaborations, strategic alliances, and licensing arrangements. They may pursue these financing options either through a single method or a combination of approaches depending on the situation. The company acknowledges that raising funds in the current economic environment may present additional challenges and that future financing may not be available in sufficient amounts or on acceptable terms. They also recognize that any additional fundraising efforts could divert management attention from day-to-day operations, potentially affecting their ability to develop and commercialize product candidates. To mitigate these risks, the company may seek additional capital if market conditions are favorable or if there are specific strategic considerations, even if they believe they have sufficient funds for their current or future operating plans.","The company plans to manage this risk through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, and other marketing or distribution arrangements to secure the necessary capital on acceptable terms.",4.5,0.5831007166620731,1.0,1.0,1.0
What are the potential consequences of material weaknesses in the company's internal control over financial reporting?,"Material weaknesses in the company's internal control over financial reporting could result in a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. This could lead to inaccurate financial reporting, which may harm the company's business and reduce investor confidence. Additionally, undetected material weaknesses might require financial statement restatements and incur remediation expenses. Failure to maintain compliance with Section 404 of the Sarbanes-Oxley Act and related rules could also negatively impact the market price of the company's common stock.","Material weaknesses could lead to a failure to maintain compliance with securities law requirements, loss of investor confidence, and a decline in the company's share price. It could also result in investigations by regulatory authorities.",4.5,0.7282510496742804,1.0,1.0,1.0
"What was the total purchase price for the acquisition of eNett and Optal by WEX Inc., and how was this amount allocated?","The total purchase price for the acquisition of eNett and Optal by WEX Inc. was $577.5 million, which was the revised amount after the Amended Purchase Agreement. This amount was subject to certain working capital and other adjustments as described in the Amended Purchase Agreement, resulting in a total cash payment of $615.4 million. Initially, the purchase agreement had set the aggregate purchase price at $1.3 billion in cash and 2.0 million shares of the Company’s common stock.","The total purchase price for the acquisition of eNett and Optal by WEX Inc. was $577.5 million. This amount was allocated to the acquired businesses based on their estimated fair value of $415 million, with the residual value of $162.5 million allocated to the legal settlement.",3.0,0.937098609398361,1.0,1.0,1.0
What measures did WEX Inc. take in response to the COVID-19 pandemic to safeguard its business and employees?,"WEX Inc. took several precautionary measures in response to the COVID-19 pandemic to safeguard its business and employees. These included restricting business travel, temporarily closing offices, and canceling participation in various industry events. Additionally, the company implemented measures to rescale its operations by permanently reducing headcount and furloughing employees across its worldwide offices where necessary. The furloughs ended during the third quarter of 2020, and the precautionary steps such as travel restrictions and office closures largely remained in place as the company continued to monitor the evolving situation.","WEX Inc. took several precautionary measures in response to the COVID-19 pandemic, including restricting business travel, temporarily closing offices, canceling participation in industry events, permanently reducing headcount, and furloughing employees across worldwide offices where necessary.",5.0,0.8837660938518526,1.0,1.0,1.0
What is the primary focus of the company's business?,"The primary focus of the company's business is investing in non-regulated renewable energy and sustainable infrastructure in the State of Hawaii to help achieve the state’s sustainability goals. This is carried out through its subsidiaries, Hamakua Energy, LLC and Mauo, which are involved in projects such as the acquisition and operation of a 60-MW combined cycle power plant and a solar-plus-storage project with a capacity of 8.6 MW of solar and 42.3 MWh of storage.",The company is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer by offering better and more durable benefits than currently available immuno-oncology treatments.,1.0,0.2905257339862704,1.0,0.875,1.0
What are the main product candidates currently under development by the company?,"The company is currently developing six distinct programs in its pipeline, which span methyltransferases, kinases, protein-protein interactions, and targeted protein degraders. These programs are part of a target class agnostic approach, allowing for broad applicability across various indications, including potential uses beyond oncology. Since the company's inception in 2016, four of these programs have received IND clearance, with three already advanced into clinical development and the fourth expected to begin clinical development in the first half of 2021. Additionally, three programs are in various stages of preclinical development and are planned to be advanced into clinical development starting in 2021. The company has structured its R&D organization to deliver a new IND every 12 to 18 months.","The main product candidates are FS118, a tetravalent mAb2 bispecific antibody targeting PD-L1 and LAG-3; FS120, a dual agonist bispecific antibody stimulating CD137 and OX40; FS222, a bispecific antibody targeting CD137 and PD-L1; and SB 11285, a next-generation cyclic dinucleotide-based STING agonist.",1.0,0.36571127686086263,1.0,0.875,1.0
What are the key challenges and competitive landscape for the company's immuno-oncology therapies?,"The company operates in a highly competitive biotechnology and pharmaceutical sector focused on immuno-oncology therapies. Key challenges include competing with established pharmaceutical and biotechnology companies, as well as universities and research institutions, many of which possess greater financial, research, and development resources. Large pharmaceutical companies have significant experience in clinical testing, patient recruitment, regulatory approvals, manufacturing, and marketing, giving them a competitive advantage. Smaller and early-stage companies can also pose challenges, especially through partnerships with larger entities. These competitors vie for access to qualified scientific and management personnel, clinical trial sites, patient enrollment, and complementary technologies necessary for product development.

The competitive landscape includes major players such as AstraZeneca, BMS, Eli Lilly, MSD, EMD Serono, Novartis, Pfizer, Genentech, Roche, and Sanofi, all of which are actively developing or have commercialized immuno-oncology therapies. Additionally, numerous companies are exploring advanced therapeutic strategies, such as combining immuno-oncology antibody therapies to target two cancer pathways simultaneously, or developing bispecific antibodies and fusion proteins to enhance the therapeutic effects of traditional monoclonal antibodies in a single molecule. The field is marked by rapid technological innovation, increasing the intensity of competition.","The company faces potential competition from many sources, including large biotechnology and pharmaceutical companies, academic institutions, government agencies, and other public and private research organizations. The immuno-oncology field is characterized by rapidly advancing technologies and innovation, intense competition, and a strong emphasis on intellectual property.",5.0,0.7073270791256403,1.0,0.75,1.0
What are the regulatory requirements for marketing approval of the company's product candidates in the United States?,"In the United States, marketing approval for the company's product candidates requires compliance with the Federal Food, Drug, and Cosmetic Act and related regulations enforced by the FDA. The process includes completing preclinical laboratory and animal studies in accordance with Good Laboratory Practices, submitting an investigational new drug application (IND) that becomes effective before clinical trials can begin, and conducting adequate and well-controlled human clinical trials to establish safety and efficacy. After completing pivotal clinical trials, the company must prepare and submit a new drug application (NDA) containing substantial evidence of safety and efficacy. The FDA reviews the NDA within 60 days to determine if it will be filed for review. Prior to approval, the FDA conducts a pre-approval inspection of manufacturing facilities to ensure compliance with good manufacturing practices (GMP) and of clinical investigation sites to confirm adherence to good clinical practices (GCP). An FDA Advisory Committee review may also be required. Finally, the FDA must review and approve the NDA to permit commercial marketing of the product for specific indications.","The regulatory requirements include completing nonclinical laboratory tests and animal studies, submitting an Investigational New Drug (IND) application, conducting adequate and well-controlled human clinical trials, submitting a Biologics License Application (BLA) or New Drug Application (NDA), undergoing FDA pre-approval inspections of manufacturing facilities, and potential FDA audits of clinical trial sites.",5.0,0.7768729246645294,1.0,1.0,1.0
What are the potential environmental risks associated with the Partnership’s operations?,"The Partnership’s operations are subject to risks related to environmental damage or pollution, which could result in losses exceeding insurance coverage. A catastrophic release of natural gas, marine disaster, or natural disasters could lead to significant financial harm. Additionally, environmental regulations may increase costs and limit the availability of insurance. The operations also face risks from contamination or damage to the environment, as well as potential disruptions due to pandemics such as COVID-19, which can affect supply chains and financial markets. There is also the possibility of operational hazards like fire, explosion, or structural collapse that may cause environmental contamination. These factors, combined with the need for extensive remediation at current and former facilities, contribute to the environmental risks faced by the Partnership.","The Partnership’s operations involve the generation, handling, and disposal of hazardous substances, hydrocarbons, and wastes, which are subject to stringent environmental laws and regulations. Non-compliance with these laws could result in significant penalties, remediation costs, and other liabilities.",4.0,0.5808519396210675,1.0,0.875,1.0
How does the Partnership’s reliance on key customers impact its financial results?,"The Partnership’s reliance on key customers significantly impacts its financial results, as a substantial majority of its revenue comes from a limited number of clients. The loss of any significant customer could have a material adverse effect on its business, financial condition, and results of operations. This concentration exposes the Partnership to risk, as the loss of key clients, failure to renew or expand contracts, or disruptions due to mergers and acquisitions involving those clients, could lead to reduced revenue and negatively affect its ability to attract new customers. Additionally, the Partnership’s revenue is derived from contracts entered into in prior periods, meaning declines in new or renewed contracts may not immediately impact current revenue but will negatively affect future periods. This reliance on a concentrated customer base, combined with the long-term nature of its subscription model, makes it difficult to quickly recover from revenue downturns or scale revenue rapidly, potentially leading to inconsistent financial performance and increased vulnerability to market changes.",The Partnership’s intrastate and interstate transportation and storage operations depend on key customers to transport natural gas through its pipelines. The failure of these major shippers to fulfill their contractual obligations could have a material adverse effect on the Partnership’s cash flow and results of operations.,4.0,0.47683553935993805,1.0,1.0,1.0
What are the major types of revenue within the Partnership's reportable segments?,"The major types of revenue within the Partnership's reportable segments include intrastate transportation and storage, interstate transportation and storage, midstream, NGL and refined products transportation and services, crude oil transportation and services, investment in Sunoco LP, fuel distribution and marketing, all other, investment in USAC, contract operations, and retail parts and services.","The major types of revenue within the Partnership's reportable segments include intrastate transportation and storage, interstate transportation and storage, midstream, NGL and refined products transportation and services, crude oil transportation and services, investment in Sunoco LP, investment in USAC, and all other.",4.0,0.9876920583783105,1.0,1.0,1.0
"What is the total amount of long-term debt as of December 31, 2020?","$42,767 million","The total amount of long-term debt as of December 31, 2020 was $51.37 billion.",3.0,0.5757280217311371,1.0,1.0,1.0
How does the Partnership determine the fair value of its financial assets and liabilities?,"The Partnership determines the fair value of its financial assets and liabilities by adhering to the framework established in ASC 820, Fair Value Measurements. This framework requires the Partnership to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Partnership considers the principal or most advantageous market and assumes the market participants’ perspective, including relevant risks such as transfer restrictions and nonperformance risk.

To measure fair value, the Partnership categorizes inputs into a three-level hierarchy:

- **Level 1**: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Partnership can access.
- **Level 2**: Inputs are observable for the asset or liability, either directly or indirectly, and include quoted prices for similar assets or liabilities in active markets, or inputs such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals.
- **Level 3**: Inputs are unobservable and reflect significant management judgment, typically based on the entity’s own assumptions when there is little or no market activity. These inputs are used in models or valuation techniques such as discounted cash flow methodologies.

In cases where multiple levels of inputs are used, the fair value measurement is categorized based on the lowest level input that is significant to the entire measurement. The Partnership assesses the significance of each input based on the specific asset or liability, using judgment to determine which inputs are material. The Partnership also provides disclosure of the estimated fair values for certain financial instruments as required by ASC 820.","The Partnership determines the fair value of its financial assets and liabilities by using the highest possible “level” of inputs, including observable quotes in an active market for identical assets and liabilities (Level 1), inputs observable for similar assets and liabilities (Level 2), and unobservable inputs (Level 3).",5.0,0.7946341894185377,1.0,1.0,1.0
What are the key risks related to the company's financial position as outlined in the financial report?,"The key risks related to the company's financial position include the substantial level of indebtedness, which increases the risk of being unable to generate sufficient cash to meet debt obligations. This high leverage exposes the company to greater vulnerability during economic downturns and limits flexibility in managing its business operations and responding to market changes. The company may be required to allocate a significant portion of its cash flow to debt payments, reducing funds available for operations, growth initiatives, or shareholder distributions.

Additionally, there are risks associated with variable interest rates on certain borrowings, and the potential inability to fully mitigate interest rate exposure through hedging instruments. The company's credit agreements contain restrictive covenants that may limit strategic decisions and the ability to capitalize on business opportunities. Failure to comply with these covenants could result in default and acceleration of debt.

The company faces challenges in refinancing debt, especially if it matures before the underlying investments generate returns, and there is a risk of being unable to secure additional financing on favorable terms or at all. The ability to service debt and manage interest rate fluctuations may be constrained by adverse credit market conditions and macroeconomic trends.

Furthermore, the company's financial position is complicated by the need to repay convertible senior notes in the aggregate amount of $985 million, with no guarantee of sufficient financial resources or access to favorable financing to meet these obligations. Restrictive debt covenants may limit operational freedom, and any failure to comply with these agreements could trigger cross-defaults or other consequences across the company's broader indebtedness. The uncertainty surrounding capital availability is heightened by external factors such as the COVID-19 pandemic, which impacts financial markets and liquidity.","The key risks related to the company's financial position include a history of losses, reliance on a limited number of significant clients, and the need for additional capital to support business growth.",4.5,0.5543374409110532,1.0,1.0,1.0
How does the company's dependence on a few large clients impact its financial stability?,"The company's dependence on a few large clients impacts its financial stability by making it vulnerable to the loss or non-renewal of contracts with these key clients. A significant portion of revenue comes from a limited number of clients, with the largest client, Anthem, accounting for 22%, 23%, and 21% of revenue in 2020, 2019, and 2018, respectively. The top ten clients collectively contributed 42% to 48% of total revenue over those years. This reliance increases the risk of material adverse effects on business performance, financial condition, and results of operations if any major client discontinues services or if mergers or acquisitions lead to contract cancellations. Additionally, the company’s ability to obtain new clients is tied to its reputation and recommendations from these key clients, further amplifying the financial risks associated with losing such relationships.","The company's dependence on a few large clients, such as Anthem, exposes it to significant financial risk if any of these clients were to reduce their business or terminate their contracts, which could materially affect revenue and financial stability.",5.0,0.8053330488119709,1.0,1.0,1.0
What are the potential impacts of rapid technological changes on the company's business?,"Rapid technological changes can significantly impact the company's business in several ways. The company may face challenges in developing new products and enhancing existing ones to keep pace with evolving technology and customer demands, which could adversely affect its business and operating results. Competitors may adapt more quickly to emerging technologies or business models, creating products that are technologically superior or more appealing to consumers. This could result in a loss of market share or reduced competitiveness.

In addition, new technologies, techniques, or products could offer better combinations of price and performance, potentially displacing the company's offerings. The company must make assumptions about future market needs and technologies when developing new products, and there is a risk that these assumptions may be incorrect or outdated by the time the product is launched. This could lead to products that are not competitive or meet less market demand than anticipated.

Moreover, technological innovation can disrupt traditional industry practices, leading to new businesses and approaches that compete with the company or its investments. Such disruptions can damage investments, increase competition, and materially and adversely affect the company’s business, financial condition, and investment returns. The company may also be affected if platform providers develop competitive offerings, further impacting its growth prospects and market position.","Rapid technological changes pose a risk of obsolescence for the company's current technology and services, requiring continuous investment in research and development to stay competitive and relevant in the market.",4.5,0.6490707567642511,1.0,0.875,1.0
What is the primary risk factor mentioned in the financial report regarding the legality of cannabis under U.S. federal law?,"The primary risk factor mentioned in the financial report is that cannabis remains illegal under U.S. federal law, classified as a Schedule I controlled substance under the Controlled Substances Act. This creates a significant risk because federal enforcement of cannabis laws could change, potentially leading to actions against the company for producing, cultivating, or dispensing cannabis, even in states where it is legal. Since federal law pre-empts state laws, enforcement by federal authorities could severely impact the business, financial condition, and operations.","The primary risk factor is that cannabis remains illegal under U.S. federal law, which could lead to enforcement actions by federal authorities and potentially harm the company's business operations and financial condition.",5.0,0.8958773061643807,1.0,1.0,1.0
What are the potential consequences if the company fails to comply with state regulations in the jurisdictions where it operates?,"Failure to comply with state regulations in the jurisdictions where the company operates could result in a range of consequences. These may include fines, penalties, or other enforcement actions, as well as the imposition of injunctions, civil or criminal penalties, and the suspension or withdrawal of marketing approvals. The company may also face restrictions on its operations, such as limitations on product distribution, labeling, or marketing, and could be required to conduct post-marketing studies or clinical trials. Additionally, there could be impacts on product distribution or use, including product recalls, seizures, or detention. Regulatory authorities may issue warning letters or impose additional restrictions on business activities, potentially leading to the closure of contract manufacturers’ facilities. Such noncompliance could damage the company’s reputation, generate negative publicity, and affect relationships with collaborators. In some cases, if the regulatory requirements are deemed overly burdensome, the company might decide to discontinue operations in certain jurisdictions, which could lead to a decline in revenue. Ultimately, these outcomes could materially and adversely affect the company's business, financial condition, and results of operations.","If the company fails to comply with state regulations, it could face sanctions including revocation or additional conditions on licenses, suspension or expulsion from markets, imposition of fines and censures, and potential material liabilities or revocation of licenses and permits.",5.0,0.7250941042165414,1.0,1.0,1.0
What measures does the company take to mitigate the risk of security breaches and theft in its operations?,"The company implements multiple layers of security measures to protect the confidentiality, integrity, and availability of customer data and systems. These include the use of current security technologies such as encryption and data depersonalization. The company also monitors and routinely tests its defenses to ensure their effectiveness. To further mitigate risks, the company operates regionally diverse primary and backup data centers and maintains comprehensive business continuity and disaster recovery plans. These plans are designed to ensure nearly continuous availability of services even during disruptions or disasters. Additionally, the company has incident and crisis management plans in place to respond to disruptive events at any of its global locations. 

The company also employs a Cybersecurity Strategy (CSS) that guides its security program, focusing on the nature of its business, ongoing threat intelligence, and specific risk areas. This strategy is ratified by the Risk Committee of the Board of Directors and relevant corporate governance committees. Risk management activities are framed around thematic threats such as sabotage, fraud, and theft of assets or customer data, and are evaluated by key executives including the Board of Directors, Chief Risk Officer, and Chief Information Security Officers. The CSS provides a framework for assessing risk, prioritizing testing, identifying remedial actions, and validating improvements. Despite these measures, the company acknowledges that threats such as cyberattacks, unauthorized access, data corruption, and operational disruption remain significant risks due to evolving techniques and potential vulnerabilities in both internal and third-party systems.","The company has implemented security measures at its facilities and engages a security firm for the transport and movement of large amounts of cash and products, including escorting employees by armed guards when necessary.",4.0,0.38439477223604573,1.0,1.0,1.0
What are the potential impacts of a global economic slowdown or financial market disruptions on the company's business?,"A global economic slowdown or financial market disruptions could lead to significant adverse effects on the company's business. These include disruptions and extreme volatility in global financial markets, increased rates of default and bankruptcy, and declining consumer and business confidence. Such conditions can result in decreased consumer spending, which may negatively impact the company, as its performance depends on the general economic environment and levels of consumer spending. This could make it difficult to maintain existing customers or attract new ones, potentially forcing the company to reduce product prices. Additionally, the company may face challenges in maintaining its financial condition, results of operations, and cash flow. The uncertainty surrounding the occurrence, duration, and severity of such disruptions makes it difficult to predict their impact. Furthermore, trade-related factors such as tariffs and trade restrictions could increase costs, delay time to market, and reduce sales, while also contributing to higher volatility in financial markets.","A global economic slowdown or financial market disruptions could lead to decreased consumer spending, reduced demand for the company's products, increased competition, and potentially lower revenues and profitability.",4.5,0.7834169919603806,1.0,1.0,1.0
"What critical audit matter was identified in the audit of Evergy, Inc.'s financial statements?","The critical audit matter identified in the audit of Evergy, Inc.'s financial statements was the impact of rate regulation on the financial statements, specifically related to rate matters and regulation. This involved evaluating how the Company's rates are determined and approved by regulatory commissions in Kansas and Missouri, and the effect of these regulatory processes on the financial statements.","The critical audit matter identified was the impact of rate regulation on the financial statements, particularly related to the accounting for the economics of rate regulation which impacts multiple financial statement line items and disclosures. This matter involved especially challenging, subjective, or complex judgments due to the high degree of subjectivity involved in assessing the impact of future regulatory orders on the financial statements.",4.5,0.7756229410081152,1.0,0.875,1.0
"What are the key components of Evergy, Inc.'s property, plant, and equipment accounting?","Evergy, Inc.'s property, plant, and equipment accounting includes several key components. Depreciation and amortization of utility plant, excluding nuclear fuel, are computed using the straight-line method over the estimated lives of depreciable property, based on rates approved by state regulatory authorities, with an average annual depreciation rate of approximately 3%. Nuclear fuel is amortized to fuel expense based on the quantity of heat produced during electricity generation.

When utility plant is retired, the original cost, net of salvage, is charged to accumulated depreciation. If an asset is expected to be retired significantly earlier than its original useful life and in the near term, the asset's cost and related accumulated depreciation are recognized as a separate asset and a probable abandonment. If the asset remains in service, it is classified as ""plant to be retired, net"" on the consolidated balance sheets; if no longer in service, it is classified as a regulatory asset. The net book value retained for abandonment depends on the probability of recovery through regulated rates, including return, and any difference between the remaining net book value and the present value of future revenues may result in an impairment charge.

Additionally, Evergy's property, plant, and equipment include investments in jointly-owned electric utility plants, where each owner funds its own portion of operating expenses and capital expenditures. The company also consolidates certain variable interest entities (VIEs), such as its 50% leasehold interest in La Cygne Unit 2, which are reflected in the property, plant, and equipment figures.

Regulatory assets and liabilities are also integral to the accounting, as they represent costs probable of future recovery or future reductions in revenues, and are assessed regularly for recovery based on regulatory decisions from entities such as the MPSC, KCC, and FERC. These regulatory considerations influence the recognition and amortization of various costs, including pension and post-retirement benefits, which are included in regulatory assets and amortized over specific periods.","The key components of Evergy, Inc.'s property, plant, and equipment accounting include recording the value at cost, which includes contracted services, direct labor and materials, indirect charges for engineering and supervision, and an allowance for funds used during construction (AFUDC). Depreciation and amortization are computed using the straight-line method over the estimated lives of depreciable property based on rates approved by state regulatory authorities.",4.5,0.6570024098988454,1.0,0.9375,1.0
"How does Evergy, Inc. account for nuclear plant decommissioning costs?","Evergy, Inc. accounts for nuclear plant decommissioning costs by estimating the costs associated with decontamination, dismantlement, and site restoration using either the immediate or deferred dismantling method as determined by the State Corporation Commission of the State of Kansas (KCC) and the Missouri Public Service Commission (MPSC). These cost estimates are used to fund a tax-qualified trust fund, with contributions made by Evergy Kansas Central and Evergy Metro to support the decommissioning of the Wolf Creek nuclear plant. The related liabilities are recorded on the consolidated balance sheets as asset retirement obligations (AROs). Differences between the decommissioning trust fund asset and the related ARO are recognized as regulatory assets or liabilities due to authorized regulatory treatment and related regulatory accounting.","Evergy, Inc. accounts for nuclear plant decommissioning costs by contributing to a tax-qualified trust fund to be used to decommission Wolf Creek. Related liabilities for decommissioning are included in asset retirement obligations (AROs) on the consolidated balance sheets. Differences between the decommissioning trust fund asset and the related ARO are recorded as a regulatory asset or liability, reflecting the authorized regulatory treatment and related regulatory accounting.",5.0,0.9269257508190324,1.0,1.0,1.0
How does reliance on third-party manufacturers impact our business?,"Reliance on third-party manufacturers impacts our business by introducing several risks that could affect our ability to manufacture products and product candidates in sufficient quality and quantity. If these third parties cease providing services or if we cannot find suitable replacements in a timely manner, our commercial, pre-clinical, clinical, and EAP activities may be adversely affected. Any issues with manufacturing processes or facilities can reduce our attractiveness to potential partners, limit access to development programs, and hinder our ability to meet market demand. Additionally, due to the limited number of specialized manufacturers, establishing or maintaining adequate manufacturing arrangements on commercially reasonable terms may be challenging. We may also face difficulties in securing necessary financial capital and ensuring compliance with agreed-upon timelines, which can delay business plans and commercialization efforts. Long-term agreements with exclusivity or termination penalties can further limit operational flexibility. A significant outbreak of COVID-19 at a partner site could also cause delays in manufacturing. Furthermore, reliance on third parties involves risks such as regulatory non-compliance, potential misappropriation of proprietary information, disruption from changing suppliers, and the inability to scale production efficiently. These factors collectively could lead to clinical trial delays, failure to obtain regulatory approvals, or difficulties in successfully commercializing our products.","Reliance on third-party manufacturers increases the risk of supply disruptions, quality control issues, and potential delays in product development and commercialization, which could adversely affect our ability to generate revenue.",5.0,0.7882671145385228,1.0,1.0,1.0
"How does KemPharm, Inc. recognize revenue from contracts with customers?","KemPharm, Inc. recognizes revenue in accordance with ASC 606, “Revenue Recognition.” The company recognizes revenue as, or when, it satisfies performance obligations under a contract. A contract is accounted for when the parties have approved it and are committed to perform, the rights and payment terms are identified, the contract has commercial substance, and it is probable that the company will collect substantially all of the consideration. A performance obligation is a promise to transfer a distinct good or service or a series of distinct goods or services to a customer. The transaction price is allocated to each performance obligation based on its relative standalone selling price, and revenue is recognized when control of the promised goods or services is transferred to the customer. For contracts with multiple performance obligations, each obligation is evaluated to determine if it is distinct based on whether the customer can benefit from the good or service on its own or with readily available resources and whether it is separately identifiable. In development contracts, revenue is recognized based on progress toward completion, typically using the input method to measure progress. Consideration related to at-risk substantive performance milestones is recognized when it is probable that a significant reversal of recognized revenue will not occur. For royalties, the company uses the sales and usage-based royalty exception, recognizing revenue as underlying sales occur.","KemPharm recognizes revenue in accordance with ASC 606, which involves identifying performance obligations, determining the transaction price, allocating the transaction price to each performance obligation, and recognizing revenue when (or as) each performance obligation is satisfied.",5.0,0.8444790142632279,1.0,1.0,1.0
"How has KemPharm, Inc. addressed its liquidity concerns?","KemPharm, Inc. addressed its liquidity concerns through a Purchase Agreement dated February 17, 2020, between the company and Lincoln Park Capital Fund, LLC.","After taking into account the underwritten public offering, debt restructuring with subsequent payoff, and warrant inducement transactions discussed in Note R, the Company's cash and cash equivalents as of the filing date are sufficient to fund the Company's operating expenses and capital expenditure requirements for at least one year from the date the financial statements are issued.",3.0,0.3657132157615753,1.0,0.25,1.0
What are the terms of the KP415 License Agreement with Commave Therapeutics SA?,"The KP415 License Agreement with Commave Therapeutics SA includes the following terms:

The Company granted Commave an exclusive, worldwide license to develop, manufacture, and commercialize product candidates containing serdexmethylphenidate (SDX) and d-methylphenidate (d-MPH), including AZSTARYS, KP484, and, at Commave's option, KP879, KP922, or other future SDX-based product candidates for the treatment of ADHD or other central nervous system disorders.

Commave paid an upfront payment of $10.0 million. Additionally, the agreement includes milestone payments of up to $63.0 million upon achievement of specified regulatory milestones related to AZSTARYS and KP484, and up to $420.0 million in U.S. sales milestones.

Commave is obligated to pay quarterly, tiered royalty payments on a product-by-product basis. In the United States, royalties range from a percentage in the high single digits to the mid-twenties of Net Sales, while outside the United States, royalties are in the low to mid-single digits of Net Sales, with both subject to specified reductions under certain conditions. These royalty payments continue until the expiration of the Royalty Term for the applicable product.

Commave is also responsible for reimbursing the Company for all development, commercialization, and regulatory expenses related to the Licensed Product Candidates, subject to limitations outlined in the agreement.

A joint steering committee was established to oversee the development of AZSTARYS and KP484. While Commave is the sponsor of any clinical trials conducted by the Company on its behalf, the Company retains responsibility for conducting all regulatory activities required to obtain NDA approval for these products.

Additionally, pursuant to the March 20, 2012 Termination Agreement with Aquestive Therapeutics, Aquestive Therapeutics has the right to receive 10% of any royalty or milestone payments made to the Company under the KP415 License Agreement related to AZSTARYS, KP484, or KP879.","Under the KP415 License Agreement, KemPharm granted Commave an exclusive, worldwide license to develop, manufacture, and commercialize the Company’s product candidates containing serdexmethylphenidate (SDX) and d-methylphenidate (d-MPH), including AZSTARYS, KP484, and optionally KP879, KP922, or any other product candidate developed by the Company containing SDX and developed to treat ADHD or any other central nervous system disorder. Commave paid an upfront payment of $10.0 million and agreed to pay milestone payments, sales milestones, and tiered royalty payments on net sales.",4.5,0.837021013491495,1.0,1.0,1.0
What was the outcome of the debt restructuring mentioned in the financial report?,"The debt restructuring resulted in no gain on restructuring because the total cash outflows required under the amended Deerfield Facility Agreement exceeded the carrying value of the original agreement. The Deerfield Facility Agreement and the associated convertible note will continue to be carried net of the associated discount and debt issuance costs, which will be amortized as interest expense using a modified effective interest rate based on the amendments. Additionally, the changes to the 2021 Notes were treated as a debt modification, with a $2.3 million change in fair value of the embedded conversion feature recorded as an increase to additional paid-in capital and as a debt discount to be amortized to interest expense over the remaining term of the 2021 Notes.","In anticipation of the Public Offering, the Company restructured the December 2019 Notes and the January 2020 Note in the aggregate principal amount of $60.8 million and the Deerfield Note in the principal amount of $7.5 million. The Company exchanged $31.5 million of the outstanding principal and accrued interest on the Facility Notes for Series B-2 Preferred Stock and Exchange Warrants and made a payment of $30.3 million in partial repayment of the remaining outstanding principal and accrued interest on the Facility Notes.",2.5,0.5629441426230014,1.0,0.875,1.0
What is the role of the Dividend Retention Fund in Chubb's operations?,"The Dividend Retention Fund serves as a financial safeguard within Chubb's operations, primarily tied to the restructuring of its insurance subsidiaries. It was established by INA Financial Corporation with an initial principal of $50 million, intended to support the financial stability of Century, a run-off company, following the restructuring. The fund is replenished through withholding a portion of dividends paid from INA Holdings Corporation to its parent companies, ensuring its balance is maintained at $50 million. This obligation remains in effect until the restructuring order is lifted. Capital contributions from the fund to Century are triggered only when the XOL Agreement—another key reinsurance contract—has less than $200 million of remaining capacity on an incurred basis for statutory reporting. The fund may not be terminated without prior written approval from the Pennsylvania Insurance Commissioner, underscoring its regulatory significance. In practice, it plays a crucial role in maintaining capital levels at Century, especially when reinsurance capacity is constrained, thereby supporting the broader financial resilience of Chubb's consolidated structure.","The Dividend Retention Fund is used to maintain the statutory capital and surplus of Century Indemnity Company, a subsidiary of Chubb, by replenishing the principal to $50 million from dividends withheld from Chubb Group Holdings.",4.5,0.8060762633786764,1.0,1.0,1.0
How does Chubb manage its foreign currency exposure?,"Chubb manages its foreign currency exposure by using foreign currency forward contracts to minimize the impact of fluctuating foreign currencies. As a global company, Chubb entities transact business in multiple currencies, and their policy is to generally match assets, liabilities, and required capital for each individual jurisdiction in local currency, which includes the use of derivatives. Chubb does not hedge its net asset non-U.S. dollar capital positions but considers economic hedging for planned cross-border transactions.","Chubb manages its foreign currency exposure by using foreign currency forward contracts to exchange specific currencies at a future date, aiming to minimize the effect of fluctuating foreign currencies.",4.5,0.9283864810694437,1.0,1.0,1.0
What is the impact of the COVID-19 pandemic on Chubb's unpaid losses and loss expenses in 2020?,"The COVID-19 pandemic significantly impacted Chubb's unpaid losses and loss expenses in 2020, primarily driving the increase in both gross and net unpaid losses and loss expenses due to catastrophe losses incurred.","The COVID-19 pandemic led to an increase in Chubb's unpaid losses and loss expenses in 2020, primarily due to catastrophe losses incurred.",5.0,0.9741505666110463,1.0,0.875,1.0
What is the policy for dividend distributions from Chubb Limited?,"Dividend distributions from Chubb Limited are approved annually by shareholders at general meetings and are paid in four quarterly installments. The Board of Directors determines the record and payment dates for these dividends, which are distributed from capital contribution reserves transferred to free reserves. Dividends are stated in Swiss francs under Swiss corporate law but are paid in U.S. dollars without withholding tax. Shareholders have approved dividends for previous years, with specific amounts per share for each year, and the Board retains discretion to abstain from paying dividends if deemed necessary.","Chubb Limited issues dividends without subjecting them to withholding tax by way of distributions from capital contribution reserves and payment out of free reserves, with dividends stated in Swiss francs but paid in U.S. dollars.",5.0,0.8423478988762882,1.0,1.0,1.0
What are the principal risk factors associated with investing in the company's securities?,"The principal risk factors associated with investing in the company's securities include the uncertainty in valuing portfolio investments, as they are recorded at fair value with the Board having final responsibility for estimating their value, particularly when there is no readily available market for the securities. Additionally, the market price of the common stock may fluctuate significantly due to factors such as overall market conditions, investor demand, regulatory changes, and perceptions of portfolio value. The company also faces risks related to securities litigation or stockholder activism, which could lead to significant expenses and impact stock price and investment strategy. Furthermore, the failure to maintain certain tax statuses, such as RIC qualification, and operational performance issues could negatively affect the business, financial condition, and the value of the securities. Lastly, there is a risk that investments in portfolio companies may not succeed due to competition from larger, more established firms with greater resources.","Investing in the company's securities involves a high degree of risk, including speculative and leveraged investments, potential loss of capital, regulatory restrictions, and exposure to market volatility.",4.5,0.5338749931289406,1.0,1.0,1.0
How does the company's business model depend on referral relationships with venture capital and private equity fund sponsors?,"The company's business model depends on referral relationships with venture capital and private equity fund sponsors because these relationships are a primary source of deal flow. The company relies on its management team's existing connections with such firms to identify potential investment opportunities. These relationships are critical for sourcing debt and other investments, as individuals affiliated with these sponsors are not obligated to provide opportunities, and there is no guarantee that such relationships will result in investments. Without maintaining or developing strong relationships with these sponsors, the company may struggle to grow its investment portfolio. Additionally, in a competitive market for investment opportunities, the ability to source deals through these networks may influence the company's effectiveness and performance relative to competitors.",The company's business model significantly relies on strong referral relationships with venture capital and private equity fund sponsors to generate investment opportunities. The inability to maintain or develop these relationships could adversely affect the company's business.,4.5,0.809621278972864,1.0,0.875,1.0
What are the regulatory risks the company faces as a Business Development Company (BDC)?,"The company faces several regulatory risks as a Business Development Company (BDC). Under the 1940 Act, BDCs must invest at least 70% of their gross assets in specified securities, including private companies, thinly-traded U.S. public companies, cash, cash equivalents, U.S. government securities, and high-quality debt investments maturing in one year or less. Failure to comply with these requirements could lead to enforcement actions by the SEC or private litigant claims. Additionally, if the company fails to maintain its BDC status—either through withdrawal or loss of qualification—it may become subject to significantly greater regulation as a closed-end investment company, which would reduce operating flexibility and increase costs. The regulations also affect the company’s ability to raise capital and how it does so, potentially exposing it to typical risks associated with leverage.","As a BDC, the company is subject to regulatory constraints that may affect its ability to raise additional capital, incur debt, and make certain investments. Non-compliance with BDC regulations could lead to loss of status or enforcement actions.",5.0,0.7782676633902256,1.0,1.0,1.0
How does the company's exposure to changes in interest rates affect its profitability?,"The company's profitability is affected by changes in interest rates due to its exposure to interest rate risk, primarily arising from its core activities of extending loans and accepting deposits. When interest rates change, the timing, basis, or amount at which loans and deposits mature or reprice can lead to losses in net interest income or net interest margin. This occurs because the income earned on interest-earning assets and the cost of interest-bearing liabilities may not align with changes in the general level of interest rates.

A significant increase in interest rates can adversely affect the company’s ability to attract new portfolio companies and originate new loans, while also increasing the cost of borrowing and potentially increasing credit risk for borrowers. This may result in higher loan defaults and lower investment performance. In addition, changes in interest rates can impact loan demand, prepayment speeds, and credit losses, all of which affect earnings.

The company’s net investment income depends on the difference between the rates at which it borrows funds and the interest rates earned on its investments. If interest expense exceeds interest income—especially during periods of rising interest rates or when assets are not fully match-funded—this can lead to operating losses. Furthermore, fluctuations in interest rates can reduce the yield on existing floating-rate assets, affect the performance of hedging instruments, and impact the value of investments, all of which influence overall profitability.","Changes in interest rates can impact the company's net investment income, as higher rates may increase borrowing costs and reduce the demand for loans, while lower rates may decrease yields on new investments.",5.0,0.7140733341971233,1.0,1.0,1.0
What is the nature of the Company's business and what types of companies does it primarily lend to?,"The Company operates as a holding entity within the financial services sector, primarily focused on providing a range of business finance and related services through its portfolio companies. It is involved in credit and debit card processing, check approval services, and the provision of processing equipment and software via Newtek Merchant Solutions, LLC. It also provides third-party loan servicing for SBA and non-SBA loans through Small Business Lending, LLC, including comprehensive support for the entire SBA lending process such as credit analysis, structuring, packaging, and compliance. Additionally, it offers retail and wholesale brokerage insurance services through Newtek Insurance Agency, LLC, specializing in commercial and health/benefits lines for small and medium-sized businesses.

The Company primarily lends to small and medium-sized businesses, providing outsourced loan and servicing solutions to lending institutions and supporting them through various aspects of the lending lifecycle.","The Company is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries.",3.0,0.49478192205947463,1.0,0.625,1.0
"What is the Company's policy regarding the declaration and payment of dividends, and how does it affect its tax status?","The company is subject to taxation in both Canada and the United States. It is treated as a Canadian resident company for Canadian income tax purposes and as a U.S. corporation for U.S. federal income tax purposes under Section 7874 of the Internal Revenue Code. This dual tax treatment means the company is taxed on its worldwide income in both jurisdictions, which could materially affect its financial condition and results of operations.

The company is unlikely to pay dividends on its Subordinate Voting Shares in the foreseeable future. However, if dividends are paid, they are subject to different tax treatments depending on the shareholder's residency. Dividends received by Canadian residents may be subject to U.S. withholding tax and may not qualify for a reduced rate under the Canada-U.S. tax treaty. Additionally, a foreign tax credit or deduction for foreign taxes may not be available. Dividends paid to U.S. shareholders are not subject to U.S. withholding tax but are subject to Canadian withholding tax. These dividends are considered U.S. source income for foreign tax credit purposes, but U.S. shareholders may only claim a credit for Canadian tax withheld if they have an excess foreign tax credit limitation due to other low or zero-rate foreign income.

If a significant number of shareholders elect to receive cash, the available cash is allocated among those shareholders, with the remainder of the distribution paid in stock. Shareholders electing to receive cash will not receive less than the lesser of the amount they elected to receive in cash or a percentage of their total distribution based on the available cash. For U.S. federal income tax purposes, the amount of the dividend paid in stock is deemed equal to the cash that could have been received. Taxable U.S. shareholders must include the full dividend amount as ordinary income (or long-term capital gain, if properly reported) up to the company's current and accumulated earnings and profits. This may result in tax liability exceeding the cash received, potentially requiring the sale of stock to cover the tax, which could lead to a loss if stock prices fall. Non-U.S. shareholders may also face U.S. tax withholding on dividends, including those paid in stock. A large number of shareholders selling stock to pay taxes could put downward pressure on the stock price.","The Company's policy is to declare and pay dividends on a quarterly basis, ensuring that it distributes at least 90% of its investment company taxable income to maintain its RIC tax status. This avoids federal income tax on the distributed portion of its taxable income.",1.0,0.484427881078409,1.0,0.875,1.0
"How does the Company manage its credit risk, and what measures are in place to mitigate potential losses?","The Company manages its credit risk through a combination of strategies aimed at reducing exposure and ensuring timely collection of receivables. Concentration of credit risk is mitigated by the diversity of payers and their geographic dispersion, with particular attention given to large buyers of the Company’s services. The Company regularly assesses the financial strength of these payers to limit credit risk exposure.

To further reduce risk, receivables are categorized into pools based on customer types: healthcare insurers, government payers, client payers, and patients. The Company applies assumptions and judgments, including historical collection experience and the period receivables have been outstanding, to assess collectability and determine net revenues and accounts receivable, especially for patient-related receivables, which represent the largest portion of credit risk.

The Company does not consider receivables due from federal and state governmental agencies to pose a significant credit risk because the related healthcare programs are funded by government sources, and payment depends on timely submission of proper documentation. As of December 31, 2020 and 2019, government payer receivables under Medicare and Medicaid accounted for approximately 6% and 11% of consolidated net accounts receivable, respectively.

In addition, the Company employs a methodology for estimating its allowance for credit losses, incorporating historical loss rates, probable losses from economic or qualitative factors, and impairment assessments based on expected cash flows or fair value of collateral. Loan losses are charged to the allowance when uncollectability is confirmed, and subsequent recoveries are credited to the allowance.

The Company also emphasizes risk mitigation through a strong culture of responsible lending, robust risk policies, and independent risk management oversight. The credit risk associated with various portfolios, including commercial, consumer, and wholesale credit, is managed by designated officers who report directly to the Chief Risk Officer. Stress testing and early warning indicators are utilized to monitor risk across economic and financial cycles.","The Company manages its credit risk through rigorous credit assessment processes, including obtaining first priority security interests in portfolio companies' assets, which may include intellectual property. It also monitors portfolio companies' financial performance and market conditions to mitigate potential losses.",4.5,0.464936908063951,1.0,0.875,1.0
What was the impact of the adoption of ASC 606 on the company's revenue recognition?,"The adoption of ASC 606 resulted in changes to the timing of revenue recognition for certain contracts. Specifically, it accelerated the recognition of a portion of original listing fees related to the New York Stock Exchange businesses and, to a lesser extent, decelerated the recognition of a portion of clearing fee revenues. However, the impact on performance obligations in the clearing business was minimal, and revenue recognition for all other businesses remained unchanged. The company adopted ASC 606 using the modified retrospective approach, and the changes were reflected in its consolidated financial statements starting from the adoption date.",The adoption of ASC 606 accelerated the timing of recognition of a portion of original listing fees related to the New York Stock Exchange businesses and decelerated the timing of recognition of a portion of clearing fee revenues.,4.5,0.9045576808721608,1.0,0.875,1.0
How does the company account for stock-based compensation?,"The company accounts for stock-based compensation by recognizing compensation expense over the service period required to earn the award, which is the shorter of the vesting period or the time period in which an employee becomes eligible to retain the award at retirement. For equity awards such as stock options, the total compensation cost is based on the grant date fair value, while for liability awards like stock appreciation rights, it is based on the settlement value. Compensation expense is recorded net of estimated forfeitures and recognized over each award’s requisite service period. The company uses the straight-line method for service-based stock options and restricted stock units, while graded-vesting methodologies are applied for market performance-based stock options and performance-based restricted stock units. Stock options typically become exercisable at a rate of 25% per year, beginning one year after the grant date, and expire no later than 10 years after the grant date. Compensation cost for awards expected to vest is recognized over the service period, with accelerated recognition for retirement-eligible employees.","The company measures and recognizes compensation expense for share-based payment awards, including employee stock options, restricted stock, and shares purchased under the Employee Stock Purchase Plan, based on estimated fair values on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as stock-based compensation expense over the requisite service period.",4.5,0.6886088290121634,1.0,1.0,1.0
What is the primary function of the Exchanges segment?,"The primary function of the Exchanges segment is to operate regulated marketplaces for the listing, trading, and clearing of a broad array of derivatives contracts and financial securities, including commodities, interest rates, foreign exchange, equities, and corporate and exchange-traded funds. This segment also includes services related to trading and listings revenue, data, and connectivity for these platforms.","The Exchanges segment operates regulated marketplaces for the listing, trading, and clearing of a broad array of derivatives contracts and financial securities.",5.0,0.8939528751634361,1.0,1.0,1.0
What services does the Fixed Income and Data Services segment provide?,"The Fixed Income and Data Services segment provides evaluated end-of-day and real-time pricing services for approximately three million fixed income securities across 151 countries and 73 currencies, including sovereign, corporate, and municipal bonds, mortgage and asset-backed securities, and leveraged loans. It offers reference data with descriptive information on millions of financial instruments, supporting its fixed income index complex, ICE Data Indices. The segment also delivers fixed income analytics and workflow solutions such as best execution services, liquidity indicators, fixed income portfolio analytics, and an ETF Hub. Additionally, it provides electronic trading platforms through ICE Bonds, supporting multiple trading protocols including click-to-trade, request for quotation (RFQ), and auctions. The segment offers clearing services for credit default swaps (CDS), handling over 90% of the global CDS market by gross notional cleared, with support for more than 520 single-name reference entities and 160 index CDS instruments. Revenues from the segment include interest income on clearing margin deposits.","This segment provides fixed income pricing, reference data, indices, execution services, global credit default swaps clearing, and multi-asset class data delivery solutions.",5.0,0.8295579335389844,1.0,1.0,1.0
What is the significance of the NYSE in the company's Exchanges segment?,"The NYSE is a key component of the company's Exchanges segment, which includes the New York Stock Exchange and other registered securities exchanges collectively referred to as the NYSE. It contributes to the segment's operations by providing regulated marketplaces for the listing, trading, and clearing of financial securities, including equities and exchange-traded funds (ETFs). As part of the broader ICE Exchanges segment, the NYSE generates revenue through trading and listings, and supports the company's global futures network and data and connectivity services. Its inclusion reflects the segment's focus on diversified transaction revenues and recurring data and listings revenues, and underscores the strategic importance of the NYSE within the company's global marketplace infrastructure.","The NYSE is the global leader in listings, having been the venue of choice for innovators, visionaries, and leaders for over 225 years, and it is the leading listing venue across a range of sectors.",5.0,0.6390349366211404,1.0,0.875,1.0
What measures have been taken to protect the company from clearing member defaults?,"The company has implemented several measures to protect against clearing member defaults. These include contributing its own capital to the front of the guaranty fund of the clearing houses, which can be used in the event of a default. Additionally, in 2019, a layer of default insurance was added to the clearing member default protection. This insurance layer is positioned after the ‘Skin In The Game’ contributions from ICE Clear Credit, ICE Clear Europe, and ICE Clear U.S., and before the guaranty fund contributions from non-defaulting clearing members. The default insurance has a three-year term and is subject to renewal. Furthermore, the company's clearing houses hold substantial assets, including $67.3 billion in non-cash margin or guaranty fund contributions as of December 31, 2020, which consist primarily of U.S. and other sovereign treasury securities. Despite these safeguards, there is no assurance that these measures will fully protect against significant defaults or their adverse effects.",The company has contributed its own cash to the guaranty funds and added a layer of insurance to its clearing member default protection.,5.0,0.8147995175976069,1.0,1.0,1.0
How does the company's data services offerings aim to address market demands?,"The company's data services offerings aim to address market demands by providing real-time industry and peer benchmarking tools that give originators a granular view of trends in nearly half of the U.S. residential mortgage market. Additionally, the company offers a Data as a Service (DaaS) solution through private data clouds, enabling lenders to access their own data and origination information. These services are primarily subscription-based and recurring, ensuring sustained value and alignment with customer needs. The company also continues to invest in enhancing its technology infrastructure and software services to reduce latency, improve security, and deliver relevant data, thereby improving trading and connectivity experiences. Furthermore, the company focuses on developing new products through internal development and strategic partnerships, aiming to expand its offerings in exchanges, fixed income, and mortgage technology to meet evolving global market demands.","The company's data services offerings aim to address the rising demand for independent, real-time information, which is being driven by regulation, market fragmentation, increasing technology and data demands, and passive investing and indexation.",4.5,0.5808478655036968,1.0,0.75,1.0
How does the company manage cybersecurity risks?,"The company manages cybersecurity risks through a comprehensive approach that includes a Cybersecurity Strategy (CSS) and risk management practices. The CSS outlines key priorities for the cybersecurity program and is ratified by the Risk Committee of the Board of Directors and relevant corporate governance committees. It emphasizes understanding the business nature, gathering intelligence on threats, and focusing on major risk areas. Risk management is structured around thematic threats such as sabotage, fraud, and asset or data theft, which are evaluated by senior leadership including the Board of Directors, Risk Committee, Chief Risk Officer, and Chief Information Security Officers (CISOs). This framework supports risk assessment, prioritization of testing, identification of remedial actions, and validation of improvements. Additionally, the company implements multiple layers of security measures, uses current technologies like encryption and data depersonalization, and monitors and tests defenses regularly. Despite these efforts, the company acknowledges the evolving nature of cyber threats and the challenges in detecting and preventing sophisticated attacks.","The company employs a Cybersecurity Strategy (CSS) that emphasizes ongoing intelligence collection regarding cybersecurity threats and initiatives to address prominent areas of cybersecurity risk, including the deployment of external and internal teams of ethical hackers.",4.5,0.6014516741804116,1.0,0.875,1.0
How does the fair value determination of our portfolio investments impact our financial condition?,"Fair value determinations of portfolio investments can significantly impact our financial condition because these valuations may differ materially from actual market values, especially in the absence of a ready market. This uncertainty can lead to our net asset value either understating or overstating the true value of our investments on a given date. If the net asset value is overstated, investors buying common stock may pay more than the underlying investment value, while investors selling during a period of understated net asset value may receive less than the true value of their holdings. 

Additionally, any unrealized depreciation in the portfolio may indicate that portfolio companies are struggling to meet repayment obligations or that the value of equity investments is impaired, which could lead to future realized losses. These losses, in turn, reduce the income and gains available for distribution. As a result, the fair value determinations directly affect our reported financial position, investor perceptions, and the ability to generate returns for shareholders.","The fair value determination of our portfolio investments is subjective and dependent on a valuation process approved by our Board. Fair value fluctuations may cause our net asset value to materially understate or overstate the value we may ultimately realize on our investments, impacting our financial condition.",4.5,0.7005142700713773,1.0,0.875,1.0
How does the highly competitive market for investment opportunities affect our business?,"The highly competitive market for investment opportunities can delay the deployment of capital, reduce returns, and lead to losses. Competing with other BDCs, investment funds, traditional financial services companies, and alternative investment vehicles such as hedge funds may result in losing investment opportunities if the terms or pricing cannot match those of competitors. This competition may also force the business to accept less favorable terms, potentially leading to lower returns or substantial capital loss. Despite these challenges, the business maintains a competitive advantage due to the underserved nature of the market for investments in middle market private U.S. companies.","The highly competitive market for investment opportunities could reduce returns and result in losses as we may lose investment opportunities to competitors with greater financial, technical, and marketing resources. Competitors may also offer better pricing and more flexible structuring, forcing us to match their terms or forego opportunities.",4.5,0.8081304854905357,1.0,1.0,1.0
What measures are in place to manage the risk of material non-public information limiting our investment discretion in portfolio companies?,"We will not enter into any agreements unless and until we are satisfied that doing so will not raise concerns under the 1940 Act or, if such concerns exist, we have taken appropriate actions to seek review and approval by our Board or exemptive relief for such transaction. Our Board will review these procedures on an annual basis. The investment committee and other investment professionals of Capitala Investment Advisors may, from time to time, possess material non-public information about or related to our portfolio companies, limiting our investment discretion. Members of our Investment Advisor’s investment committee and other investment professionals of the Investment Advisor may serve as directors of, or in a similar capacity to, portfolio companies in which we invest. In the event that material nonpublic information is obtained with respect to such companies, or we become subject to trading restrictions under the internal trading policies of those companies or as a result of applicable law or regulations, we could be prohibited for a period of time from purchasing or selling the securities of such companies, and this prohibition may have an adverse effect on us.","Members of our Investment Advisor’s investment committee and other investment professionals may serve as directors or in similar capacities in portfolio companies. If material non-public information is obtained, we could be prohibited from purchasing or selling securities of such companies, limiting our investment discretion.",4.5,0.7863247828115157,1.0,0.875,1.0
How does the involvement of interested directors in the valuation process create potential conflicts of interest?,"The involvement of interested directors in the valuation process creates potential conflicts of interest because the Investment Advisor’s management fee is based, in part, on the value of the company's gross assets, and its incentive fees are based, in part, on realized and unrealized gains and depreciation. This alignment of interests may influence the valuation decisions made by the Board, including these directors, potentially leading to outcomes that favor the Investment Advisor rather than the company's overall best interests.","The involvement of interested directors in the valuation process could result in conflicts of interest as the Investment Advisor’s management fee is based on the value of our gross assets, and its incentive fees are based on realized and unrealized gains. This participation could influence the valuation process in a way that may not be in the best interest of all stockholders.",4.5,0.9058340809241376,1.0,1.0,1.0
What are the implications of the terms of the Investment Advisory Agreement and the Administration Agreement not being negotiated on an arm’s length basis?,"The terms of the Investment Advisory Agreement and the Administration Agreement not being negotiated on an arm’s length basis may result in terms that are less favorable to the entity compared to what might have been achieved through negotiation with an unaffiliated third-party. This includes an incentive fee structure that could encourage the Investment Advisor to pursue riskier or more speculative investments, as well as to use leverage in situations where it may not be prudent. Such arrangements may not be as advantageous as they would be if negotiated independently.","The non-arm’s length negotiation of these agreements may result in terms that are not as favorable to us as if they had been negotiated with an unaffiliated third-party. This could include higher fees and less favorable incentive fee structures, which may induce the Investment Advisor to pursue speculative investments or use leverage when it may not be advisable.",5.0,0.8960293164563947,1.0,1.0,1.0
How does the potential for PIK interest payments affect our assets under management and the fees payable to Capitala Investment Advisors?,"PIK interest payments increase the size of the loan balance for the underlying debt investments, which in turn increases the assets under management. This increase in assets under management leads to higher base management fees and incentive fees payable to Capitala Investment Advisors. Additionally, the higher loan balance resulting from PIK interest causes the loan to accrue interest on a larger amount, increasing pre-incentive fee net investment income and further increasing the incentive fees payable to the Investment Advisor.","PIK interest payments increase the size of the loan balance, thereby increasing our assets under management. This results in an increase in the base management fee payable to the Investment Advisor. Additionally, the accrual of interest on the higher loan balance increases our pre-incentive fee net investment income, leading to an increase in incentive fees.",5.0,0.9324875504049202,1.0,1.0,1.0
What are the primary risks associated with the commercial success of our products in the U.S.?,"The provided context does not contain information about the primary risks associated with the commercial success of products in the U.S. The context focuses on risks related to commercializing product candidates outside the United States, including international regulatory, economic, legal, and operational challenges. There is no mention of specific risks within the U.S. market.","The primary risks include the inability to meet sales expectations, attain profitability and positive cash-flow from operations, and the dependency on the effectiveness of sales, managed markets, marketing efforts, and support for our products.",1.0,0.36555095423763295,1.0,0.6875,1.0
What are the potential consequences of failing to comply with cGMP regulations in our manufacturing processes?,"Failure to comply with cGMP regulations in manufacturing processes may lead to a range of consequences, including the issuance of warning letters, requests for modifications to promotional materials, or the need to provide corrective information to healthcare practitioners. The FDA may require entering into a consent decree, which could involve fines, reimbursement for inspection costs, penalties for noncompliance, and specific action deadlines. Additionally, the FDA may seek an injunction, impose civil or criminal penalties, or levy monetary fines. Regulatory approval could be suspended or withdrawn, ongoing clinical trials may be halted, and pending or supplemental applications could be refused for approval. Operations might be suspended or restricted, potentially requiring costly new manufacturing requirements. Products could be seized or detained, imports or exports may be denied, or a product recall may be required. These events could inhibit commercialization efforts and reduce revenue potential. Furthermore, even after marketing approval, products may face ongoing regulatory scrutiny, including requirements for post-marketing safety data, continued compliance with cGMP standards, and other post-approval obligations, with possible limitations on usage or conditions of approval.","Failure to comply with cGMP regulations could result in product seizures, recalls, or withdrawals, suspension or withdrawal of marketing approvals, fines, and criminal prosecutions, which could significantly harm our business.",5.0,0.7587750525079147,1.0,1.0,1.0
What are the key provisions in our loan agreement that could restrict our operations?,"The loan agreement includes several key provisions that could restrict operations. These include restrictions on selling, transferring, or disposing of business or property, making changes to the organizational structure, consolidating or merging with other entities, acquiring other entities, incurring additional debt or creating liens on assets, paying dividends (other than in shares of common stock), making distributions or repurchasing stock, repaying subordinated debt, and making certain investments. Additionally, the agreement requires compliance with various operating and financial covenants, which may limit the ability to finance operations, engage in business activities, or expand strategies. Breach of these covenants could result in a default, potentially triggering immediate repayment of all outstanding debt.","The loan agreement contains negative covenants that restrict our ability to sell or dispose of assets, amend certain material agreements, consolidate or merge, incur additional indebtedness, incur additional liens, pay dividends or make certain payments, and make payments of certain subordinated indebtedness.",5.0,0.773491839789512,1.0,1.0,1.0
How does the classification of our board of directors into two classes affect our corporate governance?,"The context provided does not mention the classification of the board of directors into two classes. Instead, it consistently refers to the classification of the board into three classes—Class I, Class II, and Class III—with each class serving staggered three-year terms. This structure may delay the ability of stockholders to change the majority of the board of directors, as only a portion of the board is up for election each year. There is no information available about a two-class board structure or its implications for corporate governance.","The classification of our board of directors into two classes, with one class elected each year, may make it more difficult for a third party to acquire control of us or effect a change in our board of directors and management, potentially deterring hostile takeovers or changes in control.",2.0,0.45651839205157857,1.0,1.0,1.0
What are the potential impacts of Brexit on our international operations?,"Brexit may lead to significant political and economic uncertainty, which could negatively impact global economic conditions and financial markets. This uncertainty may affect our international operations by disrupting the movement of goods between the United Kingdom and members of the European Union and the United States, potentially causing delays or interruptions in imports and exports. Additionally, the UK's withdrawal from the EU could result in changes to trade, economic arrangements, and regulatory frameworks, which may increase trade protection measures, import or export licensing requirements, or other restrictive actions by governments. These developments could also affect our ability to operate efficiently in international markets, impact access to capital, and disrupt business activities, ultimately having a material adverse effect on our business, financial condition, and results of operations.","Brexit could lead to legal uncertainty and divergent national laws and regulations, new regulatory costs and challenges, potential restrictions on direct investments by foreign entities and trade restrictions, and changes in tax laws and tariffs, which could adversely affect our operations.",4.5,0.6793145815080697,1.0,1.0,1.0
How does the company plan to manage the transition from a research and development focus to commercial activities?,"The company acknowledges that it will eventually need to transition from a research and development focus to a company capable of supporting commercial activities, but there is no detailed plan outlined for how this transition will be managed. The context indicates uncertainty about the success of such a transition, emphasizing that unforeseen expenses, difficulties, complications, and delays may arise, and many factors influencing this process are beyond the company's control. Additionally, the company has not yet demonstrated an ability to manufacture products on a commercial scale or conduct sales and marketing activities necessary for successful commercialization. The transition may involve engaging third parties for clinical trials and potentially relying on partners like Commave and KVK for commercialization efforts under license agreements, but specific strategies or steps for the transition are not provided.","The company may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown obstacles during this transition. It may not be successful in this transition, which could adversely affect its business.",4.0,0.5524990968903373,1.0,0.75,1.0
What are the potential consequences if the company is unable to raise additional funding when needed?,"If the company is unable to raise additional funding when needed, it may be forced to significantly delay, scale back, or discontinue research and development efforts, as well as the development or commercialization of product candidates. In extreme cases, it may be compelled to cease all operations. Additionally, the company might need to seek strategic alliances earlier than desired or on less favorable terms, or enter into product collaborations that could require it to relinquish or license its rights to intellectual property, product candidates, or products under potentially unfavorable conditions. This lack of capital could also limit the company's ability to use net operating loss carryforwards to offset taxable income, further impacting its financial position.","If the company is unable to raise capital when needed, it could be forced to delay, reduce, or eliminate its product development programs or commercialization efforts, which would significantly impact its ability to develop and market its products.",5.0,0.7635880436289405,1.0,1.0,1.0
How does the company's reliance on third-party manufacturers impact its operations?,"The company's reliance on third-party manufacturers impacts its operations in several significant ways. First, it creates dependence on these partners for regulatory compliance, quality assurance, and the protection of proprietary information, increasing the risk of misappropriation of trade secrets. The company also faces potential disruptions and costs when changing suppliers, including the need for additional regulatory filings and the risk of delays or inability to expand manufacturing capacity. Manufacturing issues related to scaling up production, such as quality problems and the need for costly equipment and facility validation, further add to operational challenges. Additionally, the company may face difficulties in securing favorable manufacturing agreements, as well as risks associated with the breach, termination, or nonrenewal of contracts, which could be costly or damaging. The reliance on limited or single-source suppliers for critical product components can lead to supply shortages, hindering the timely production and sale of products. Furthermore, disruptions such as a significant outbreak of COVID-19 at a partner site can delay manufacturing. These issues collectively threaten the company’s ability to manufacture products in sufficient quality and quantity, meet market demand, attract partners, and execute its business plans on schedule. The use of long-term agreements with exclusivity or termination penalties also reduces operational flexibility.","The company's reliance on third-party manufacturers for the manufacture of its product candidates and related raw materials may expose it to risks such as unforeseen expenses, difficulties, complications, delays, and other known and unknown obstacles. If these third-party manufacturers fail to comply with regulatory requirements or meet contractual obligations, it could delay or prevent the company's ability to develop or commercialize its product candidates.",5.0,0.7068573450903528,1.0,1.0,1.0
What are the key risks related to the company's intellectual property?,"The key risks related to the company's intellectual property include the inability to fully protect its technology and product candidates, which could allow competitors to develop and commercialize similar products. The company relies on a combination of trade secrets, patents, copyrights, and trademark laws, along with confidentiality agreements, all of which offer only limited protection. There is uncertainty regarding the future scope and effectiveness of intellectual property rights, as patents may not cover all relevant technologies or may be invalidated or deemed unenforceable due to legal challenges. Additionally, the company may face challenges in identifying patentable aspects of inventions in a timely manner, and the patent prosecution process can be costly and time-consuming. The company may not control the filing or enforcement of patents licensed to third parties, potentially undermining their value. Furthermore, the company may choose not to patent certain innovations to preserve trade secrets, increasing the risk that competitors could later patent the same technology. Finally, the company may not develop additional patentable technologies, and it could be exposed to infringement claims from others' patents, all of which could harm its competitive position and financial performance.","The key risks include the inability to obtain, maintain, or adequately protect intellectual property rights, potential infringement claims from third parties, and the uncertainty of patent litigation outcomes. Additionally, the company may face challenges in enforcing its patents and may not be able to prevent competitors from using similar technologies.",5.0,0.7847415565426273,1.0,1.0,1.0
What is the primary risk associated with investing in the company's common stock?,"The primary risk associated with investing in the company's common stock is that the investments in portfolio companies may be highly speculative and aggressive, making the investment unsuitable for investors with lower risk tolerance. Additionally, the market price of the common stock may decline, and there is no assurance of a sustained public trading market. The stock has also traded below its net asset value at times, which could limit the company's ability to issue additional shares without stockholder approval. Furthermore, common stockholders bear the expenses of borrowings, and debt security holders have senior rights to repayment, which may not align with the interests of common stockholders. Sales of substantial amounts of common stock in the public market could also negatively impact the stock price.","Investing in the company's common stock involves a high degree of risk, including the potential for significant losses if the market price of the stock declines.",4.0,0.7309220124118233,1.0,0.875,1.0
What is the potential impact of the COVID-19 pandemic on the company's business?,"The COVID-19 pandemic has adversely impacted and is likely to further adversely impact the company's operations, as well as those of its borrowers, customers, portfolio companies, and business partners. The extent of this impact depends on various uncertain factors, including the duration and scope of the pandemic, government actions to manage its financial and economic effects, travel advisories and restrictions, disruptions to supply and demand, investor liquidity, consumer confidence, economic activity, and global, regional, and local supply chains. Additionally, operations may be significantly disrupted or halted due to quarantine measures, travel restrictions, and potential health risks to personnel, which could lead to widespread business continuity issues.","The COVID-19 pandemic has adversely impacted and may continue to adversely impact the company's business, including its preclinical studies and clinical trials, and finances, by causing disruptions in operations, delays in clinical trials, and financial market volatility.",4.5,0.7001668071635043,1.0,0.875,1.0
What are the risks related to the company's reliance on third-party manufacturers?,"The risks related to the company's reliance on third-party manufacturers include the potential for these manufacturers to fail to comply with regulatory requirements such as cGMP, which could lead to sanctions, clinical holds, fines, injunctions, delays, or withdrawal of approvals. There is also a risk of breach or termination of manufacturing agreements by third parties at inconvenient or costly times. The company may face challenges in replacing manufacturers due to added costs and delays in identifying and qualifying alternatives. Additionally, third-party manufacturers may misappropriate proprietary information, including trade secrets and know-how, or fail to produce materials according to specifications or on schedule. The company has limited control over quality assurance, safety, and pharmacovigilance processes managed by these manufacturers. Furthermore, reliance on a limited number of manufacturers, some of which may lack experience with approved therapies, could result in competition for manufacturing capacity and delays in clinical development or commercialization. Catastrophic events at a third-party facility could also disrupt supply, and the company currently lacks redundant supply arrangements.","Risks include the potential for not having sufficient quantities of product candidates, failure of third-party manufacturers to comply with regulatory requirements, and the inability to control the quality and timeliness of manufacturing processes.",5.0,0.7760347725215544,1.0,1.0,1.0
What are the potential consequences of the company's inability to protect its intellectual property rights?,"The company's inability to protect its intellectual property rights could lead to several significant consequences. Competitors may develop similar products, which could undermine the company's ability to develop, manufacture, and market its own products on a commercially viable basis. This could result in reduced sales, decreased revenue, and a material adverse effect on the company's financial condition and results of operations. Additionally, the failure to protect trade secrets, know-how, and unpatented technology could allow competitors to access or independently develop these proprietary assets, further eroding the company's competitive advantage. Misappropriation or unauthorized use of intellectual property may also harm the company's reputation and diminish its ability to compete effectively.

Moreover, the company may face allegations of infringing third-party intellectual property rights, which could lead to costly litigation, mandatory cessation of product development or marketing, the need to obtain licenses, or redesigns to avoid infringement. The company could also be required to pay damages, all of which could negatively impact its business, financial condition, and operating results. Litigation itself may consume substantial financial and managerial resources, distract key personnel, and result in public announcements that may adversely affect the company's stock price. Even if the company successfully defends its intellectual property rights, the legal process may be unpredictable and could lead to the invalidation or unenforceability of its own intellectual property.","Inability to protect intellectual property rights could lead to competitors developing and commercializing similar products, which could harm the company's business, financial condition, and competitive position.",5.0,0.7907407609287347,1.0,1.0,1.0
How does the company's reliance on third-party manufacturers impact its business operations?,"The company's reliance on third-party manufacturers impacts its business operations in several significant ways. If these third parties cease providing quality manufacturing and related services, and suitable replacements cannot be found promptly, the company’s ability to produce its products or product candidates in the required quality and quantity for commercial, pre-clinical, clinical, or EAP activities could be adversely affected. This reliance also poses challenges in establishing or maintaining sufficient manufacturing arrangements due to the limited number of qualified manufacturers, long lead times, and availability of raw materials. Additionally, the company may face difficulties in securing the financial capital needed for such arrangements.

Even when agreements are in place, third-party manufacturers may fail to meet agreed-upon terms and timelines, which can disrupt business plans related to product commercialization and development. Long-term agreements with exclusivity provisions or termination penalties further limit operational flexibility. Problems in manufacturing processes or facilities can diminish the company’s attractiveness to potential partners, including larger pharmaceutical companies and academic institutions, potentially restricting access to valuable development programs and limiting the ability to meet market demand.

Furthermore, the company is exposed to risks such as regulatory non-compliance, misappropriation of proprietary information, and supply chain disruptions, including delays caused by events like the COVID-19 pandemic. These risks may result in clinical trial delays, regulatory actions, or failure to commercialize products successfully. Disruptions in securing essential product components or dealing with carrier issues could also hinder production and sales.","The company's reliance on third-party manufacturers for the production of its product candidates increases the risk of supply chain disruptions, quality control issues, and potential delays in the development and commercialization of its products.",5.0,0.739521844841827,1.0,1.0,1.0
How does the company's financial position and need for capital affect its ability to pursue its business objectives?,"The company's financial position and capital needs significantly influence its ability to pursue business objectives. While the company is currently well capitalized, it may use its available resources sooner than expected or need to seek additional funds earlier than planned due to changes in its operating plan or unexpected demands. Raising additional capital is essential to expand development efforts, obtain regulatory approval, and commercialize product candidates. However, the process of securing funding can divert management attention from day-to-day operations, potentially affecting progress. Additionally, the company cannot guarantee that future financing will be available on favorable terms, or at all. Negative outcomes in clinical programs or regulatory setbacks may further complicate fundraising by reducing stock value, making financing more difficult. Furthermore, the issuance of additional securities could dilute stockholders' ownership and impact their rights, potentially affecting investor confidence. As a result, the ability to secure sufficient capital on acceptable terms is critical to maintaining momentum in achieving business objectives.","The company's need for substantial additional funding to pursue its business objectives may limit its ability to conduct research and development, initiate clinical trials, and seek marketing approval for its product candidates, potentially delaying or preventing the achievement of its goals.",4.5,0.5377054160194071,1.0,1.0,1.0
What are the implications of the company's dual-class stock structure for minority shareholders?,"The company's dual-class stock structure results in a concentration of voting power among a small group of shareholders, specifically the chairman and founder, Dr. Rothberg, who holds all of the Class B shares. These shares carry 20 votes per share, compared to one vote per share for Class A shares. As a result, Dr. Rothberg controls approximately 76.2% of the voting power, enabling him to significantly influence key corporate decisions such as the election of directors, amendments to organizational documents, and major transactions like mergers or asset sales. This structure limits the ability of minority shareholders to affect the outcome of important matters, potentially leading to delays or prevention of changes in control, even if such changes might be in the best interest of other stockholders. Additionally, this concentrated control may reduce the likelihood of a premium being offered for the company in a sale, as well as affect the market price of Class A common stock. Minority shareholders may also face reduced influence over corporate governance and may experience limited visibility regarding certain transactions. Furthermore, certain index providers may exclude companies with such structures from their indexes, which could impact investment demand and market perception.","The dual-class stock structure may limit the ability of minority shareholders to influence corporate matters and could result in decisions that are not aligned with their best interests, as the majority of voting power is concentrated among a few significant stockholders.",5.0,0.7666137575541468,1.0,1.0,1.0
How does Prelude Therapeutics design its clinical trials?,"Prelude Therapeutics designs its clinical trials to leverage the broad utility of its compounds, with a focus on efficient regulatory pathways. This approach is intended to enable potentially transformative medicines to quickly reach patients with high unmet medical need. The trials are designed to take advantage of validated cancer signaling pathways and early clinical proof-of-concept, which supports advancement through expedited approval processes.",Prelude Therapeutics designs its clinical trials to leverage the broad utility of its compounds with a focus on efficient regulatory pathways to enable potentially transformative medicines to quickly reach patients with high unmet medical need.,5.0,0.9315460654392566,1.0,0.875,1.0
How does Prelude Therapeutics protect its intellectual property?,"Prelude Therapeutics protects its intellectual property through a combination of patent, trademark, and trade secret laws, as well as license and access agreements and other contractual provisions. The company files domestic and international patent applications for its commercially valuable inventions, including compositions and methods of treatment developed from its product candidates. It also relies on trade secrets to safeguard aspects of its business that are not suitable for patent protection. To further protect its proprietary information, Prelude requires employees, consultants, and certain contractors to sign confidentiality and assignment of inventions agreements. Despite these efforts, the company acknowledges that its intellectual property protections are limited and may be challenged, invalidated, circumvented, infringed, diluted, or misappropriated.","Prelude Therapeutics protects its intellectual property by seeking and maintaining patent protection for compositions of matter, methods of use, and other inventions important to its business. It also relies on know-how and continuing technological innovation to maintain its proprietary position.",4.5,0.7757920713072877,1.0,1.0,1.0
What was the primary reason for the decrease in income tax expense in 2020?,"The primary reason for the decrease in income tax expense in 2020 was the decrease in total income before tax for the company, which amounted to $12.99 billion. This reduction was primarily driven by lower crude oil prices, partially offset by lower impairments and project write-off charges.","The decrease in income tax expense in 2020 was primarily due to the decrease in total income before tax, which was mainly caused by lower crude oil prices, partially offset by lower impairment and write-off charges.",5.0,0.932838859496205,1.0,1.0,1.0
How did Chevron respond to market conditions and the COVID-19 pandemic during 2020?,"Chevron responded to market conditions and the COVID-19 pandemic during 2020 by taking swift action to protect its long-term health and value. The company adjusted factors it could control, reducing capital expenditures by 35 percent and lowering operating expenses—excluding non-recurring severance costs—by $1.4 billion compared to 2019. Chevron also completed an enterprise-wide transformation to capture additional cost efficiencies and suspended its stock repurchase program in March 2020. The company entered the crisis well-positioned with a strong balance sheet, a flexible capital program, and a low cash flow breakeven price.","Chevron responded to market conditions and the COVID-19 pandemic by swiftly adjusting controllable items, such as lowering capital expenditures by 35% and reducing operating expenses by $1.4 billion compared to 2019. Additionally, the company suspended its stock repurchase program in March 2020 to protect the dividend and maintain a strong balance sheet.",5.0,0.9336480820351516,1.0,1.0,1.0
What were the key factors affecting Chevron's upstream segment earnings in 2020?,"Chevron's upstream segment earnings in 2020 were impacted by several key factors. Lower refined product, crude oil, and natural gas prices, along with reduced refined product volumes, contributed to a decline in sales and other operating revenues. Additionally, income from equity affiliates decreased due to the full impairment of Petropiar and Petroboscan in Venezuela and lower upstream-related earnings from Tengizchevroil in Kazakhstan. Other factors included a $4.58 billion reduction in income tax expense, driven by a $12.99 billion decrease in total income before tax, and after-tax charges of approximately $4.8 billion for impairments and other asset write-offs related to upstream operations. These charges were higher than the $10.4 billion in 2019 and $2 billion in 2018, indicating continued pressure on upstream assets. Exploratory expenses also increased, primarily due to higher charges for well write-offs. Lastly, while depreciation, depletion, and amortization expenses decreased due to lower impairments, this was partially offset by higher severance costs linked to restructuring efforts.","The key factors affecting Chevron's upstream segment earnings in 2020 included lower crude oil and natural gas realizations, higher impairment and write-off charges, and lower crude oil sales volumes. These factors were influenced by external market conditions, including the impact of the COVID-19 pandemic and lower commodity prices.",4.5,0.8591771821399232,1.0,0.875,1.0
What were the major impairments and write-offs recorded by Chevron in 2020?,"In 2020, Chevron recorded after-tax charges of approximately $4,800 for impairments and other asset write-offs related to the upstream segment. These charges were part of the earnings for that year. Additionally, there were after-tax gains of approximately $765 from the sale of certain properties, which included $30 related to downstream and $735 related to upstream assets.","In 2020, Chevron recorded major impairments and write-offs primarily due to downward revisions to its oil and gas price outlook. The company fully impaired its investments in Petropiar and Petroboscan in Venezuela, resulting in a total impairment of $2.6 billion.",3.0,0.7522023033128976,1.0,0.875,1.0
What was the impact of the Noble Energy acquisition on Chevron's financial position?,"The acquisition of Noble Energy, Inc. had a significant impact on Chevron's financial position. The aggregate purchase price was $4,109, with approximately 58 million shares of Chevron common stock issued as consideration, representing about 3% of shares outstanding. As part of the transaction, Chevron recognized long-term debt and finance leases with a fair value of $9,231. The acquisition added low-cost proved reserves, attractive undeveloped resources, and cash-generating assets to Chevron's portfolio. Additionally, the company assumed debt from Noble, including senior notes with an aggregate principal amount of $5,800, which were later exchanged for new senior notes issued by Chevron. The acquisition was accounted for as a business combination under ASC 805, with assets and liabilities measured at their acquisition date fair values. The transaction also resulted in provisional fair value measurements for acquired assets and liabilities, with potential adjustments made up to one year after the acquisition date. The cash received from the acquisition is reflected in the Consolidated Statement of Cash Flows as ""Cash acquired from Noble Energy, Inc."" Other balance sheet changes not affecting cash were not included in the cash flow statement.","The acquisition of Noble Energy added $7.7 billion in assets sales proceeds and increased Chevron's debt by assuming total debt, including finance lease obligations, with a fair value of approximately $9.4 billion. This acquisition provided Chevron with low-cost proved reserves and attractive undeveloped resources.",4.5,0.7439858300467205,1.0,0.875,1.0
What are the potential impacts of changes in tax laws or regulations on the company's financial condition?,"Changes in tax laws or regulations could have a material adverse effect on the company's business, cash flow, financial condition, and results of operations. New tax laws or modifications to existing ones could adversely affect the tax treatment of domestic or foreign earnings, increase tax expenses, or impact the realization of net deferred tax assets. For instance, changes in corporate tax rates, the deductibility of expenses, or the taxation of foreign earnings under legislation such as the Tax Cuts and Jobs Act or future reform measures could result in significant one-time charges and increase future U.S. tax expenses. Additionally, retroactive application of tax law changes or guidance from tax authorities could increase the company's or its stockholders’ tax liability. Such changes may also require adjustments in business operations to minimize tax burdens, potentially affecting financial performance.","Changes in tax laws or regulations, such as the Tax Cuts and Jobs Act of 2017 and the California Consumer Privacy Act (CCPA), could increase the company's compliance burdens and costs, potentially impacting its financial condition and results of operations.",5.0,0.6738731083672871,1.0,1.0,1.0
"What is the current status of the Company's investment in Oak Therapeutics, Inc.?","The Company's investment in Oak Therapeutics, Inc. has been terminated. On April 15, 2019, the Company entered into a Termination and Release Agreement with Oak, surrendering all of its Oak shares and terminating all contractual relationships, including any rights to acquire additional shares or interest in Oak. As a result, the investment was deconsolidated, and the Company’s investment in Oak was written off, reflected at a value of zero in its consolidated financial statements for the year ended December 31, 2019.","On April 15, 2019, the Company entered into a Termination and Release Agreement with Oak Therapeutics to surrender all of its Oak shares to Oak and terminate any rights the Company might have to acquire additional shares or interest in Oak. The parties terminated all contractual relationships between them. As of the date of deconsolidation, Oak had a negative net asset, which resulted in a gain of $0.08 million.",5.0,0.8902289442029857,1.0,1.0,1.0
How does the Company assess the recoverability of its long-lived assets?,"The Company assesses the recoverability of its long-lived assets by reviewing them for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. This assessment involves estimating the undiscounted future cash flows expected to be generated by the asset or asset group and comparing it to the carrying value. If the carrying amount exceeds the undiscounted cash flows, an impairment loss is recognized, and the asset is written down to its fair value. The fair value is typically determined using a discounted cash flow analysis, and the asset group is defined as the lowest level for which identifiable cash flows are available and largely independent of other asset groups. Factors such as significant underperformance, changes in business strategy, economic conditions, and regulatory actions may trigger such assessments.","The Company assesses the carrying value of its long-lived asset groups when indicators of impairment exist and recognizes an impairment loss when the carrying amount of a long-lived asset is not recoverable when compared to undiscounted cash flows expected to result from the use and eventual disposition of the asset. Indicators of impairment include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the assets or in its business strategy, loss of or changes in customer relationships, and significant negative industry or economic trends.",5.0,0.7648459120414649,1.0,1.0,1.0
How does our dependence on Merck for collaboration affect our business and financial condition?,"Our dependence on Merck for collaboration significantly impacts our business and financial condition. All of our recent revenue has been derived from this single partnership, and we currently have no other agreements that could provide material, ongoing future revenue. This reliance creates financial vulnerability, as any changes in Merck’s strategic direction, funding, or decisions regarding the collaboration could disrupt our income.

Under the collaboration agreement, Merck provides research and development funding up to specified caps during the research phase. When expenses exceed these caps—such as occurred in the fiscal year ended December 31, 2020—we are required to use our own financial resources to continue development or risk pausing or suspending projects. The potential for reduced or discontinued funding under any modified collaboration, particularly after the current research phase ends, increases the risk of financial strain and limits our ability to advance certain product candidates.

Additionally, our ability to influence Merck’s efforts is limited after proof-of-concept data is generated and Merck exercises its option to acquire an exclusive license. Even with the potential to participate in a cost and profit-sharing arrangement later, our control remains constrained. Moreover, Merck has unilateral discretion over extending the research phase, which may be reduced or terminated, and we cannot guarantee agreement on modified terms. This uncertainty could result in the termination of support for certain product candidates and disrupt our development pipeline.

The lack of alternative collaborations and the potential for Merck to opt out of continuing development or commercialization based on clinical results, acquisition activity, or other external factors further heighten the risks. In the absence of successful collaborations, we may be unable to capitalize on the market potential of our product candidates, which could materially and adversely affect our business and financial condition.","Our dependence on Merck involves risks such as Merck potentially not extending the research phase of the collaboration, deciding not to proceed with certain product candidates, or terminating the collaboration, which could delay or preclude our ability to complete research and development programs and materially adversely affect our business and financial condition.",5.0,0.7800469607304842,1.0,0.875,1.0
"What are the potential impacts of disease outbreaks, epidemics, and pandemics, such as COVID-19, on our business operations?","Disease outbreaks, epidemics, and pandemics such as COVID-19 can significantly disrupt business operations by affecting the health and productivity of employees, impacting third-party partners and regulatory agencies, and hindering the timely delivery of content or execution of business strategies. The implementation of remote work arrangements may lead to inefficiencies in collaboration and pose challenges in recruiting and hiring qualified personnel. Additionally, these events can negatively impact consumer health, potentially reducing sales of virtual items and leading to the cancellation or lower attendance at events. Economic downturns, including recessions and high unemployment, resulting from such crises can further adversely affect business performance. Moreover, public health emergencies can disrupt supply chains, reduce consumer confidence, impact investor liquidity, and result in widespread business continuity issues due to government-imposed restrictions or precautionary measures.","Disease outbreaks like COVID-19 can disrupt our operations, delay clinical trials, impact patient enrollment, and increase costs. They can also affect our ability to obtain regulatory approvals and commercialize our product candidates, thereby harming our business, financial condition, and results of operations.",4.5,0.5412812868360177,1.0,1.0,1.0
What are the risks associated with our international operations and expansion plans?,"Operating internationally involves several risks that could materially adversely affect the business. These include navigating multiple, conflicting, and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, and regulatory requirements. There is also the risk of failing to obtain or maintain regulatory approvals for product use in various countries, as well as encountering additional third-party patent rights and difficulties in protecting and enforcing intellectual property.

Managing foreign operations can present staffing and management challenges, along with complexities related to multiple payor reimbursement regimes, government payors, or patient self-pay systems. The ability to penetrate international markets may be limited, and financial risks such as longer payment cycles, difficulties collecting accounts receivable, and exposure to foreign currency exchange rate fluctuations are present. Additionally, there are risks related to natural disasters, political and economic instability, wars, terrorism, political unrest, disease outbreaks, boycotts, and trade restrictions.

Other considerations include additional expenses for travel, translation, and insurance, as well as regulatory and compliance risks associated with the U.S. Foreign Corrupt Practices Act and other anti-bribery and anti-corruption laws. The United Kingdom’s withdrawal from the European Union could also negatively impact global economic conditions, financial markets, and the business. Any of these factors could significantly harm international expansion and operations, potentially affecting overall results of operations.","Risks include compliance with varying regulatory requirements, potential difficulties in obtaining and maintaining regulatory approvals, challenges in managing foreign operations, and exposure to financial risks such as currency exchange rate fluctuations and longer payment cycles.",5.0,0.7729930476643422,1.0,1.0,1.0
What is the potential impact if the company fails to complete its initial business combination by the deadline?,"If the company fails to complete its initial business combination by the deadline, it will cease all operations except for winding up, redeem all outstanding public shares at a per-share price based on the funds in the trust account (including interest, less dissolution expenses), and then dissolve and liquidate after obtaining necessary approvals. The redemption price will be paid in cash, and this process will extinguish public stockholders' rights as stockholders. In such case, public stockholders may receive $10 per share or less, and the company's warrants will expire worthless. Additionally, stockholders could be liable for claims made against the company to the extent of the distributions they received, with potential liability extending beyond the third anniversary of the distribution date.","If the company fails to complete its initial business combination by the deadline, it will cease all operations except for winding up, redeem public shares, and dissolve, resulting in shareholders receiving only their pro rata portion of the funds in the trust account, which may be less than $10.10 per share, and the warrants will expire worthless.",4.5,0.8827361756617518,1.0,1.0,1.0
What are the key components of the decoupling mechanism for the Utilities?,"The key components of the decoupling mechanism for the Utilities include:

1. Monthly revenue balancing account (RBA) revenues or refunds, which address the difference between PUC-approved target revenues and recorded adjusted revenues, thereby separating revenues from kWh sales.
2. Rate adjustment mechanism (RAM) revenues, which account for increases in certain operation and maintenance expenses and changes in rate base.
3. Major Project Interim Recovery (MPIR) component, now part of the Exceptional Project Recovery Mechanism (EPRM), used for recovery of extraordinary projects or programs.
4. Performance incentive mechanisms (PIMs), which provide financial rewards for exemplary performance.
5. An earnings sharing mechanism that reduces revenues between rate cases if the utility exceeds the allowed return on average common equity (ROACE) in its most recent rate case.","The key components of the decoupling mechanism for the Utilities include monthly revenue balancing account (RBA) revenues or refunds, rate adjustment mechanism (RAM) revenues, major project interim recovery (MPIR), performance incentive mechanisms (PIMs), and an earnings sharing mechanism (ESM).",5.0,0.947068680315615,1.0,1.0,1.0
How does HEI manage its investment securities portfolio?,"HEI manages its investment securities portfolio by classifying debt securities as held-to-maturity (HTM), trading, or available-for-sale (AFS) at the time of purchase. Securities intended to be held to maturity are classified as HTM and reported at amortized cost. Trading securities, which are bought for short-term resale, are reported at fair value with unrealized gains and losses included in earnings. Securities not classified as HTM or trading are classified as AFS and reported at fair value, with unrealized gains and losses excluded from earnings and recorded in accumulated other comprehensive income until realized.

Interest income is recognized on an accrual basis, with discounts and premiums on securities accreted or amortized using the interest method over the remaining contractual or estimated lives, adjusted for anticipated prepayments. For mortgage-backed securities, the accretion or amortization is done on a retrospective basis, adjusting the effective yield each time prepayment estimates change to reflect the revised expectations as if they had been known from the time of acquisition.

The portfolio is structured to allow management to respond to investment opportunities arising from changes in interest rates, prepayments, tax and credit considerations, or other factors, including mismatches between the desired duration of debt securities and the duration of liabilities. This strategic flexibility supports the management of interest rate risk and portfolio responsiveness to market conditions.","HEI manages its investment securities portfolio by classifying investments as held-to-maturity (HTM), trading, or available-for-sale (AFS), and by using fair value estimates obtained from independent third-party pricing services or brokers.",5.0,0.7215845310800464,1.0,1.0,1.0
What is the significance of the performance-based regulation (PBR) framework approved by the PUC?,"The performance-based regulation (PBR) framework approved by the PUC is significant because it supports financial stability for utilities while aligning their operations with Hawaii’s goals for a clean energy economy and renewable portfolio standards. It builds on the existing decoupling model with modifications, allowing utilities to continue using current cost recovery mechanisms while introducing new tools to incentivize performance. These include the Exceptional Project Recovery Mechanism (EPRM) for extraordinary projects, Performance Incentive Mechanisms (PIMs), and Shared Savings Mechanisms (SSMs) to reward exemplary performance. The framework also incorporates safeguards such as a symmetric Earnings Sharing Mechanism (ESM) to protect both utilities and customers from excessive earnings or losses, as well as a Re-Opener mechanism for potential adjustments. Additionally, it integrates performance evaluation through Scorecards, Reported Metrics, and an expedited Pilot Process, ensuring transparency and responsiveness in regulatory oversight.","The PBR framework approved by the PUC provides a new regulatory model that aims to provide financial stability to the Utilities and facilitate the transition to a clean energy economy. It includes mechanisms such as the annual revenue adjustment (ARA), earnings sharing mechanism (ESM), and performance incentive mechanisms (PIMs) to ensure efficient and effective operations.",5.0,0.7973332070515939,1.0,1.0,1.0
How does HEI manage its short-term borrowings?,"HEI manages its short-term borrowings through a combination of commercial paper and a term loan. As of December 31, 2020, HEI had $65 million in commercial paper outstanding, which decreased from $97 million in 2019. On April 20, 2020, HEI closed on a $65 million 364-day term loan from a syndicate of two banks. This term loan was used to pay down the balance on the HEI Facility, thereby increasing the available borrowing capacity by $65 million. The term loan bears interest at a floating rate, with options for either an alternate base rate or an adjusted London interbank offered rate plus an applicable margin, and matures on April 19, 2021. The term loan allows for prepayment without penalty at any time, although proceeds from debt capital market transactions over $50 million must first be used to pay down the loan. On December 29, 2020, HEI drew $50 million in unsecured senior notes, which were used to pay down the term loan on December 30, 2020. The remaining $15 million of the term loan was repaid on January 29, 2021.","HEI manages its short-term borrowings through commercial paper and bank term loans. As of December 31, 2020, HEI had $65 million of commercial paper outstanding and a $65 million 364-day term loan from a syndicate of two banks. HEI also maintains credit facilities to support its short-term commercial paper program and working capital needs.",5.0,0.8994929535359013,1.0,1.0,1.0
How does HEI manage its long-term debt?,"HEI manages its long-term debt through a combination of term loans and senior notes, which are structured with specific financial covenants and conditions. The company utilized a $65 million 364-day term loan that was used to reduce the balance on the HEI Facility, thereby increasing available borrowing capacity. This loan was fully repaid by January 29, 2021, with $50 million drawn on unsecured senior notes on December 29, 2020, and the remaining $15 million paid off shortly thereafter.

Additionally, HEI issued unsecured senior notes through private placement agreements, including a $50 million agreement on September 11, 2020, and a $75 million agreement on November 17, 2020, which was to be drawn in two tranches. These senior notes and term loans include customary representations, warranties, affirmative and negative covenants, and events of default. The agreements require HEI to maintain certain financial ratios consistent with those in its revolving unsecured credit agreement. Furthermore, under certain conditions such as a change of control or specific asset disposals, HEI is obligated to offer to prepay the senior notes. This structure ensures debt management aligns with financial stability and compliance standards.",HEI manages its long-term debt by issuing unsecured senior notes through private placements and maintaining credit facilities to support its short-term commercial paper program and working capital needs. HEI also ensures compliance with financial covenants and customary conditions in its debt agreements.,4.5,0.8026887853801338,1.0,0.875,1.0
What are the unique properties of CSN therapeutics?,"CSN therapeutics are distinguished by their ability to act through multiple mechanisms to enhance the cellular bioenergetic state, reduce oxidative stress, and stimulate protein homeostasis within central nervous system cells. Unlike the traditional ""one drug-one target"" approach, these therapeutics utilize faceted clean-surfaced nanocrystals that exchange thousands of electrons per second, addressing cellular energy deficits without depleting existing energy reserves. This multifunctional action supports cellular function and replenishes bioenergetic deficiencies, offering a novel approach to treating neurodegenerative diseases.","CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystalline form, possess unusually high, unique catalytic activities not present in those same elements in bulk form. These nanocatalytic activities drive, support, and maintain beneficial metabolic and energetic intercellular reactions within diseased, stressed, and damaged cells.",4.0,0.6849729175959955,1.0,0.875,1.0
What is the patent-protected position of Clene?,"Clene's patent-protected position involves the development of a broad and deep pipeline of novel clean-surfaced nanotechnology (CSN) therapeutics. These therapeutics are composed of transition metal atoms assembled in nanocrystalline form, which exhibit unusually high and unique catalytic activities not present in the bulk form of these elements. The company has developed a proprietary electrochemistry drug development platform that enables the synthesis of stable, clean-surfaced nanocrystals without toxic organic residues or stabilizing surfactants, allowing for the therapeutic use of transition metal catalytic activity.",Clene's patent-protected position affords it the potential to develop a broad and deep pipeline of novel CSN therapeutics to address a range of diseases with high impact on human health.,4.5,0.7372969582367866,1.0,0.875,1.0
What is the Clene Approach to drug development?,"The Clene Approach to drug development is innovation focused and scientifically driven. It involves the innovation of highly active therapeutic nanocatalysts with novel mechanisms of action derived from proprietary advances in nanotechnology, plasma and quantum physics, biochemistry, and materials science. This platform enables the creation of new drug modalities targeting diseases that have been difficult to treat using traditional small molecule or monoclonal antibody approaches. The approach is also scientifically driven, emphasizing clear scientific rationale and sound experimental design from basic science to clinical trials. Clene has deep expertise in the chemical properties, safety profiles, and catalytic abilities of transitional metal nanocrystals, and has developed methods to produce stable, highly active, clean-surfaced nanocrystal suspensions using efficient, scalable, and environmentally friendly processes.","The Clene approach to drug development is innovation-focused and scientifically driven, involving the creation of highly active therapeutic nanocatalysts with novel mechanisms of action resulting from proprietary advances in nanotechnology, plasma and quantum physics, biochemistry, and materials science.",5.0,0.8922916202533275,1.0,1.0,1.0
What is the market opportunity for CSN therapeutics in neurodegenerative diseases?,"The market opportunity for CSN therapeutics in neurodegenerative diseases is significant due to the urgent demand for effective treatments and the limited availability of disease-modifying therapies. Currently, there are no therapies that promote remyelination or improve function in people with non-active, progressive multiple sclerosis (MS), which accounts for about one-third of all MS cases. Additionally, existing FDA-approved treatments for amyotrophic lateral sclerosis (ALS) have limited disease-modifying effects, and there are no disease-modifying therapies for Parkinson's disease (PD), with current options only providing symptomatic relief. 

CSN therapeutics, particularly the candidate CNM-Au8, offer a unique first-mover advantage by addressing unmet medical needs through mechanisms such as enhancing cellular bioenergetics, reducing oxidative stress, and stimulating protein homeostasis. If clinical studies confirm remyelination or improved neurological function, CSN therapeutics could have substantial commercial potential for treating MS, PD, and ALS, driven by the global need for safe and effective treatments for these conditions.","Despite the urgent demand for treatments and the tremendous market opportunities for neurodegenerative disease therapeutics, effective treatments are limited. If the clinical studies underway provide evidence of remyelination or demonstrate improved neurological function, CSN therapeutics will have significant commercial sales potential in treating MS, PD, or ALS.",4.5,0.7958736347044052,1.0,1.0,1.0
What is the primary responsibility of the management of the Federal Home Loan Bank of Boston regarding internal control over financial reporting?,The primary responsibility of the management of the Federal Home Loan Bank of Boston regarding internal control over financial reporting is to establish and maintain adequate internal control over financial reporting.,The management of the Federal Home Loan Bank of Boston is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America.,4.0,0.9134015260734892,1.0,1.0,1.0
How does the Federal Home Loan Bank of Boston manage its credit risk exposure from advances?,"The Federal Home Loan Bank of Boston manages its credit risk exposure from advances through an integrated approach that includes establishing credit limits for each borrower and conducting ongoing reviews of their financial condition. Credit quality is primarily assessed based on the types and levels of collateral provided. The Bank requires sufficient collateral to fully secure credit products, including first-mortgage loans, government securities, cash, and other real-estate-related assets with readily ascertainable value. For community financial institutions, eligible collateral also includes secured loans for small business and agriculture. Collateral may be retained by the borrower under a control agreement or physically possessed by the Bank or a third-party custodian. The Bank has the right to call for additional or substitute collateral to safeguard its security interest. Additionally, the Bank perfects its security interests in collateral through UCC filings, possession, or other appropriate methods. The Bank also benefits from Section 10(e) of the FHLBank Act, which grants priority to its security interests, though this may not apply to insurance company members due to state law exceptions. Management believes these policies and procedures effectively mitigate credit risk.","The Federal Home Loan Bank of Boston manages its credit risk exposure from advances through an integrated approach that includes establishing credit limits for each borrower, ongoing review of each borrower's financial condition, and collateral and lending policies that limit risk of loss while balancing borrowers' needs for a reliable source of funding.",5.0,0.7300496757825945,1.0,1.0,1.0
What are the key features of the Mortgage Partnership Finance® (MPF®) program through which the Federal Home Loan Bank of Boston invests in mortgage loans?,"The Mortgage Partnership Finance® (MPF®) program allows the Federal Home Loan Bank of Boston to invest in mortgage loans, primarily single-family loans, through partnerships with participating financial institutions. These loans are either guaranteed or insured by federal agencies (government loans) or are credit-enhanced by the originating financial institution (conventional loans). The loans are typically originated and credit-enhanced by the participating institution and are often serviced by the originating institution or a third-party servicer. The program includes various products such as MPF Xtra®, which facilitates third-party investment in loans. Key features include credit-enhancement mechanisms such as primary and supplemental mortgage insurance, performance-based credit-enhancement fees, and structured risk-sharing models where losses are allocated in layers between the Bank and the participating institution. The credit risk is analyzed at the individual master commitment level using third-party models to determine the required credit-enhancement amounts, ensuring the loans meet a single-A-minus rating equivalent. Additionally, the program includes nonorigination fees such as delivery-commitment-extension, pair-off, price-adjustment, and counterparty fees, which are recorded in income or as adjustments to the carrying value of the loans.",The MPF program allows the Federal Home Loan Bank of Boston to invest in conventional and government-insured or -guaranteed residential fixed-rate mortgage loans purchased from participating financial institutions. These loans are either guaranteed or insured by federal agencies or credit-enhanced by the related entity that sold the loan.,4.5,0.7678013993422077,1.0,0.875,1.0
How does the company's significant indebtedness affect its financial flexibility?,"The company's significant indebtedness reduces its financial flexibility by requiring a substantial portion of cash flow from operations to be used for debt payments, which limits the funds available for working capital, capital expenditures, and other general corporate purposes. This can restrict the company's ability to respond to changing business conditions, pursue new opportunities, or invest in growth initiatives. Additionally, the debt agreements include restrictive covenants that limit certain business activities, and failure to comply could lead to defaults, accelerating debt repayment obligations. The substantial leverage also makes the company more vulnerable to economic downturns and interest rate fluctuations, further constraining its ability to manage financial risks effectively.","Significant indebtedness increases the risk of loss, reduces cash available for distributions, and may limit the company's ability to refinance debt or pursue new investments, potentially affecting its financial condition and results of operations.",5.0,0.6609383835118781,1.0,1.0,1.0
How does the lack of liquidity in the company's investments affect its business?,"The lack of liquidity in the company's investments may adversely affect its business by making it difficult to sell these investments when desired. Since the company generally invests in privately held companies with securities that are not publicly traded, there is no established trading market for these securities. As a result, if the company needs to liquidate all or a portion of its portfolio quickly, it may realize significantly less than the recorded value of the investments. Additionally, the company does not expect to achieve liquidity in its investments in the near-term, and it may face further restrictions on liquidation if it possesses material non-public information about a portfolio company.","The lack of liquidity in the company's investments makes it difficult to sell assets quickly if needed, which could limit its ability to respond to changes in economic conditions or meet financial obligations.",5.0,0.8120792295723127,1.0,1.0,1.0
"What was the outcome of Rayonier Inc.'s management assessment of internal control over financial reporting as of December 31, 2020?","Rayonier Inc.'s management concluded that its internal control over financial reporting was effective as of December 31, 2020.","Based on their evaluation under the criteria set forth in the Internal Control - Integrated Framework, management concluded that their internal control over financial reporting was effective as of December 31, 2020.",5.0,0.6857610488573372,1.0,1.0,1.0
What are the inherent limitations of internal control over financial reporting?,"Internal control over financial reporting may not prevent or detect misstatements due to its inherent limitations. Additionally, projections of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.","The inherent limitations of internal control over financial reporting include the possibility of misstatements due to error or fraud not being prevented or detected on a timely basis. Additionally, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.",5.0,0.9539514869079757,1.0,1.0,1.0
What are the reportable business segments of Rayonier Inc. after the merger with Pope Resources?,"The reportable business segments of Rayonier Inc. after the merger with Pope Resources include timberlands, private equity timber funds, and real estate development.","After the merger with Pope Resources, Rayonier Inc. operates in six reportable segments: Southern Timber, Pacific Northwest Timber, New Zealand Timber, Timber Funds, Real Estate, and Trading.",3.0,0.9219077026373701,1.0,0.5,1.0
What is the nature of the environmental remediation liabilities assumed by Rayonier Inc. in the merger with Pope Resources?,"Rayonier Inc. assumed environmental and natural resource damage (NRD) liabilities in connection with the merger with Pope Resources, related to certain real estate in Port Gamble, Washington. These liabilities stem from past operations of Pope & Talbot Inc., which operated a sawmill from 1853 to 1995 and conducted shipping, log storage, and log transfer activities in the Port Gamble Bay area from 1974 to 2004. These operations resulted in the release of contaminated materials to the townsite, millsite, and adjacent bay. The liabilities arise under federal and state environmental laws that impose strict liability on current and former property owners for cleanup or restoration, regardless of fault. The in-water portion of the cleanup was completed prior to the merger, and a consent decree with a cleanup action plan was entered in November 2020. Negotiations with Trustees regarding NRD liabilities are ongoing, with expected outcomes involving agreed-upon mitigation activities.","In the merger with Pope Resources, Rayonier Inc. assumed environmental remediation liabilities related to potential liability associated with environmental contamination and Natural Resource Damages (NRD) in Port Gamble, Washington.",5.0,0.8801495453222214,1.0,1.0,1.0
How does Rayonier Inc. account for its investments in marketable equity securities?,"Rayonier Inc. accounts for its investments in marketable equity securities by classifying them in ""Other Assets"" based on the nature of the securities and their availability for use in current operations.","Rayonier Inc. accounts for its investments in marketable equity securities at fair value based on quoted prices in their active market, with both the realized and unrealized gains and losses reported in “Interest and other miscellaneous income, net.”",2.0,0.8121073487305595,1.0,0.75,1.0
"What is the primary focus of Starwood Property Trust, Inc.?","Starwood Property Trust, Inc. is primarily focused on originating, acquiring, financing, and managing mortgage loans and other real estate investments in both the United States and Europe.","Starwood Property Trust, Inc. is primarily focused on originating, acquiring, financing, and managing mortgage loans and other real estate investments in both the United States and Europe.",5.0,1.0,1.0,1.0,1.0
How has the adoption of Accounting Standards Codification Topic 326 affected the Company's accounting for expected credit losses?,"The adoption of Accounting Standards Codification Topic 326 has changed the Company's accounting for expected credit losses by implementing a forward-looking approach based on expected losses rather than incurred losses. This change requires the Company to estimate lifetime expected credit losses on financial instruments measured at amortized cost, such as trade receivables, loans, and held-to-maturity debt securities. As a result, the allowance for credit losses is now recognized earlier, improving the timeliness of loss recognition. The adoption also introduced a qualitative component to the reserve calculation, assessing the impact of recent economic trends and forecasts on loss rates, in addition to the quantitative analysis based on historical loss experience. For available-for-sale debt securities with unrealized losses, credit losses due to credit-related factors are now recognized as an allowance on the balance sheet with a corresponding adjustment to earnings in the income statement. The Company applied the modified retrospective method of adoption, which did not require adjustments to prior period financial statements, and this change did not have a material impact on its consolidated financial statements.","The adoption of ASC 326, effective January 1, 2020, changed the Company's method of accounting for expected credit losses to a current expected credit loss model (CECL), which requires the consideration of possible credit losses over the life of an instrument, as opposed to only upon the occurrence of a discrete loss event.",5.0,0.6143367792550879,1.0,1.0,1.0
How does the Company manage its exposure to interest rate risk?,"The Company manages its exposure to interest rate risk through a combination of strategies, including the use of derivatives such as interest rate swaps and interest rate caps to hedge variable cash outflows and stabilize interest expense. These derivatives are used primarily in cash flow hedges to mitigate the impact of interest rate movements. The Company also relies on natural on-balance-sheet hedges, such as offsetting interest rate exposures between loans and investment securities and deposits and other interest-bearing liabilities. Additionally, the investment securities portfolio is utilized to manage interest rate exposure and sensitivity within the guidelines set by the Asset-Liability Committee (ALCO). The Company periodically reviews and may adjust its hedging strategies, incorporating expected interest rate movements and simulation analyses to achieve a desired risk profile while adhering to capital and liquidity guidelines. Derivatives are used only in a non-speculative manner, and their use is documented to ensure compliance with regulatory requirements.","The Company manages its exposure to interest rate risk by using derivative financial instruments such as interest rate swaps, which are designed to economically hedge certain risks. These derivatives are not designated for hedge accounting and changes in their fair value are recorded in earnings.",4.5,0.6822388006282898,1.0,1.0,1.0
What is the significance of the fair value option election for certain financial assets and liabilities?,"The fair value option election allows entities to measure certain eligible financial assets and liabilities at fair value, both initially and subsequently. This election is made on an instrument-by-instrument basis and is irrevocable once chosen. It enables the reporting of unrealized gains and losses in earnings and requires assets and liabilities measured at fair value to be reported separately in the consolidated balance sheets. The election helps mitigate accounting mismatches between the carrying value of instruments and related assets and liabilities consolidated at fair value, ensures consistency across residential loans, and is applied to items with short-term holding periods such as mortgage loans held-for-sale.","The fair value option election allows the Company to make an irrevocable election to measure certain eligible financial assets and liabilities at fair value. Unrealized gains and losses on items for which the fair value option has been elected are reported in earnings, which helps to mitigate accounting mismatches between the carrying value of the instruments and the related assets and liabilities that the Company consolidates at fair value.",4.5,0.8562106665363611,1.0,1.0,1.0
How does the Company account for acquisitions of real estate with in-place leases?,"The Company accounts for acquisitions of real estate with in-place leases by allocating the purchase price to net tangible and identified intangible assets based on fair values. This includes recording above-market and below-market in-place lease values based on the present value of the difference between contractual lease amounts and estimated fair market lease rates, measured over the remaining noncancellable lease term, including probable fixed renewal periods. Above-market lease values are amortized as a reduction of rental income, while below-market lease values are amortized as an increase to rental income over the respective lease terms. Additionally, other intangible assets include in-place leases, reflecting the cost to execute similar leases, which is amortized over the remaining lease terms and any fixed-rate renewal periods. Direct acquisition costs are capitalized if an acquisition is probable, and costs are written off if the acquisition is no longer probable. The purchase price is allocated to acquired assets and assumed liabilities as if the property were vacant, with fair values determined using cash flow projections, discount rates, and market information.","For acquisitions of real estate with in-place leases where substantially all of the fair value of the assets acquired is concentrated in either a single identifiable asset or group of similar identifiable assets, the Company applies the asset acquisition provisions of ASC 805, resulting in the acquired properties being recognized initially at their purchase price inclusive of acquisition costs.",4.5,0.6697428875457706,1.0,0.875,1.0
What is the Company's approach to managing credit risk in its investment portfolio?,"The company manages credit risk in its investment portfolio by using bond ratings published by independent agencies to measure credit risk. The investments in the portfolio consist of U.S. government-sponsored entity securities, tax-free securities, or other securities with ratings from “AAA” to “Not Rated.” All securities, except those not rated, are rated by at least one of the nationally recognized statistical rating organizations.","The Company manages credit risk by regularly evaluating the extent and impact of any credit deterioration associated with the performance and/or value of the underlying collateral, the financial and operating capability of the borrower, and the overall economic environment. It utilizes third-party database services to provide industry losses as benchmarks for determining expected credit losses.",3.0,0.5447160444568601,1.0,0.875,1.0
How has Stifel Financial Corp. adopted new accounting standards for credit losses?,"Stifel Financial Corp. adopted the new accounting standard for credit losses by implementing ASU 2016-13, which introduced the current expected credit loss (CECL) model. This model requires the recognition of allowances based on lifetime expected credit losses for assets measured at amortized cost, resulting in more timely recognition of losses. The company adopted this standard effective January 1, 2020, and it was codified into ASC 326, Financial Instruments—Credit Losses. The adoption did not have a material impact on the consolidated financial statements.","Stifel Financial Corp. adopted the new accounting standard for credit losses on January 1, 2020, which requires the measurement of the allowance for credit losses to be based on management’s best estimate of lifetime expected credit losses inherent in the Company’s relevant financial assets.",5.0,0.8725231576126161,1.0,0.875,1.0
How does Stifel Financial Corp. manage its off-balance sheet credit risk?,"Stifel Financial Corp. manages its off-balance sheet credit risk through a combination of credit policies, monitoring of commitments, and the adoption of accounting standards designed to evaluate and mitigate potential losses. The company issues standby letters of credit, which are conditional commitments to guarantee customer performance under non-financial contractual obligations. The credit risk associated with these letters is comparable to that of extending loans, and the company may seek reimbursement from the customer if it is obligated to perform. At the end of 2020 and 2019, outstanding letters of credit totaled $31.8 million and $38.3 million, respectively, with most expiring within one year.

Additionally, Stifel provides unused lines of credit to commercial and consumer borrowers, which aggregate $2.5 billion and $1.5 billion at the end of 2020 and 2019, respectively. These lines are granted under the same credit policies applied to on-balance sheet instruments. Commitments to originate loans are also extended, totaling $889.0 million and $384.5 million at the end of 2020 and 2019, with disbursements generally scheduled in the following three months. These commitments are subject to the borrower’s creditworthiness and may require collateral based on a case-by-case evaluation.

Effective January 1, 2020, the company adopted a new accounting standard for credit losses, which mandates an evaluation of expected losses and the recognition of an allowance for credit losses when applicable. This standard includes the recognition of a reserve for unfunded lending commitments, which was $20.4 million at adoption, with expected credit losses for unfunded commitments amounting to $23.3 million as of December 31, 2020. This framework allows the company to proactively manage and account for potential credit losses tied to off-balance sheet activities.

Furthermore, in its mortgage loan origination and sale activities, Stifel may be required to repurchase loans or indemnify investors in the event of breaches of representations and warranties, inadequate underwriting, or fraud. This exposure to credit risk associated with sold loans is monitored and managed as part of the company's broader credit risk strategy.","Stifel Financial Corp. manages its off-balance sheet credit risk through various strategies, including position and credit limits, continuous monitoring of collateral, requiring additional collateral when appropriate, and using interest rate derivative contracts to manage exposures arising from business activities.",4.0,0.7342848785046406,1.0,0.875,1.0
What are the key factors considered in the valuation of Stifel Financial Corp.'s financial instruments?,"The key factors considered in the valuation of Stifel Financial Corp.'s financial instruments include the use of quoted market prices when available, bid and ask prices observed in the marketplace, and the determination of fair value based on the best available information for instruments without readily determinable fair values. This includes the types of financial instruments, current financial information, restrictions on dispositions, fair values of underlying instruments, and quotations for similar instruments. Valuation models and techniques may be used, with adjustments permitted based on management's judgment, considering factors such as the complexity of the instrument, the market in which it is traded, and underlying risk uncertainties. The level of observability of inputs can vary, impacting the degree of judgment required and potentially leading to transfers among fair value hierarchy levels.","The key factors considered in the valuation of Stifel Financial Corp.'s financial instruments include observable market prices, contractual terms, market parameters, credit ratings, and the value of underlying collateral. The valuation techniques used vary depending on the level of pricing observability.",4.5,0.8335834412019134,1.0,0.875,1.0
How does Stifel Financial Corp. report its quarterly financial information?,"Stifel Financial Corp. reports its quarterly financial information in Note 30, which is titled ""Quarterly Financial Information (Unaudited)."" This note provides the quarterly financial data, and it is part of the notes to the consolidated financial statements.","Stifel Financial Corp. reports its quarterly financial information in a summarized format, providing key financial metrics such as revenues, net income, and earnings per share for each quarter of the fiscal year.",4.5,0.8559152444247011,1.0,0.875,1.0
What is the primary method used to evaluate the effectiveness of the Partnership’s internal control over financial reporting?,The primary method used to evaluate the effectiveness of the Partnership’s internal control over financial reporting is the framework set forth in the report entitled “Internal Control-Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).,The Partnership uses the framework set forth in the report entitled “Internal Control-Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).,5.0,0.8480450357577446,1.0,1.0,1.0
What is the purpose of the commercial paper program maintained by the Partnership?,"The commercial paper program is used to issue unsecured commercial paper notes, which are backed by the borrowing capacity under the credit facility. These notes are used to fund acquisitions, investments, and general corporate purposes. The program allows the partnership to raise short-term capital, with proceeds typically used to support working capital needs and to act as a backstop for future increases in commercial paper borrowings.","The commercial paper program allows the Partnership to issue up to $3.0 billion in privately placed, unsecured commercial paper notes, which are primarily used for short-term financing needs such as working capital.",4.0,0.9147776904482778,1.0,0.875,1.0
How does the Partnership allocate net income for partners’ capital presentation purposes?,"The Partnership allocates net income for partners’ capital presentation purposes by applying the allocation methodology in its partnership agreement. Net income is allocated 100% to common unitholders, after accounting for income allocations related to cash distributions to Series A preferred unitholders and guaranteed payments attributable to Series B preferred unitholders. Additionally, Series A preferred unitholders are not allocated income for paid-in-kind distributions for partners’ capital presentation purposes.",Net income is allocated 100% to common unitholders after giving effect to income allocations for cash distributions to Series A preferred unitholders and guaranteed payments attributable to Series B preferred unitholders.,5.0,0.8659508351833384,1.0,1.0,1.0
"How did Loews Corporation assess the effectiveness of its internal control over financial reporting as of December 31, 2020?","Loews Corporation assessed the effectiveness of its internal control over financial reporting as of December 31, 2020, based on criteria established in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). This assessment was conducted by the company's management, who are responsible for maintaining effective internal control over financial reporting. The assessment is included in the accompanying Management’s Report on Internal Control over Financial Reporting.",Loews Corporation's management assessed the effectiveness of its internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control - Integrated Framework (2013).,5.0,0.8884722915908171,1.0,0.875,1.0
"What significant accounting changes did Loews Corporation adopt on January 1, 2020?","Loews Corporation adopted the new lease standard on January 1, 2020. The adoption of this guidance did not have a material impact on the Company’s Consolidated Financial Statements.","On January 1, 2020, Loews Corporation adopted ASU 2016-13, ""Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,"" which required changes to the recognition of credit losses on financial instruments not accounted for at fair value through net income.",2.0,0.7675023010344052,1.0,0.875,1.0
How did the adoption of ASU 2016-13 affect Loews Corporation's financial statements?,"The adoption of ASU 2016-13, which introduced the Current Expected Credit Loss (CECL) model, resulted in a cumulative effect adjustment for Loews Corporation. This adjustment led to a decrease in beginning retained earnings of $56 million, net of taxes, as of January 1, 2020. The change was primarily due to the transition to the CECL model, which requires recognition of expected credit losses on financial assets measured at amortized cost, reflecting a more forward-looking approach compared to the previous incurred loss model. While the adoption did result in this adjustment, it did not have a significant impact on the company's financial position, statement of cash flows, results of operations, or disclosures.","The adoption of ASU 2016-13 resulted in a $5 million decrease in Retained earnings, after tax and noncontrolling interests, and the establishment of an allowance for credit losses of $6 million for available-for-sale fixed maturity securities that were purchased with credit deterioration.",3.5,0.5656278412367357,1.0,0.875,1.0
"What was the impact of Diamond Offshore's deconsolidation on Loews Corporation's financial statements for the year ended December 31, 2020?","The deconsolidation of Diamond Offshore from Loews Corporation's financial statements resulted in the recognition of a loss of $1.2 billion ($957 million after tax) during the year ended December 31, 2020. This loss was reported within Investment gains (losses) on the Consolidated Statements of Operations and represented the difference between the carrying value and the estimated fair value of Loews Corporation’s investment in equity securities of Diamond Offshore as of the Filing Date.","The deconsolidation of Diamond Offshore resulted in the recognition of a loss of $1.2 billion ($957 million after tax) during the year ended December 31, 2020, which is reported within Investment gains (losses) on the Consolidated Statements of Operations.",5.0,0.8863233508916758,1.0,1.0,1.0
How did Boardwalk Pipelines' acquisition of common units affect its financial position?,"The acquisition of common units by Boardwalk GP, LP, the general partner of Boardwalk Pipelines, resulted in the purchase of all outstanding common units not already owned by the General Partner or its affiliates. This transaction, completed on July 18, 2018, led to the consolidation of Boardwalk Pipelines under Loews Corporation's wholly owned subsidiary, Boardwalk Pipelines Holding Corp. As a result, the purchase price was lower than the carrying value of the noncontrolling interests, which led to an increase in Additional paid-in capital by $658 million, an increase in deferred income tax liabilities by $213 million, and a decrease in Accumulated Other Comprehensive Income (AOCI) by $29 million. These adjustments reflect the impact on the financial position due to the reclassification and consolidation of the entity.","Boardwalk Pipelines' acquisition of common units resulted in an increase to Additional paid-in capital of $658 million, an increase to deferred income tax liabilities of $213 million, and a decrease to AOCI of $29 million.",5.0,0.7785901946745155,1.0,1.0,1.0
What are the potential risks associated with relying on third-party manufacturers for the supply of our product candidates?,"Relying on third-party manufacturers for the supply of product candidates involves several potential risks. These include dependence on the third party for compliance with FDA and DEA regulations and quality assurance, the possibility of misappropriation of proprietary information such as trade secrets and know-how, and the costs and disruptions associated with changing suppliers, including additional regulatory filings. There is also the risk of a third party breaching, terminating, or not renewing the manufacturing agreement at a time that is costly or inconvenient. Delays or an inability to secure or expand manufacturing capacity, along with quality issues related to scaling up production, may occur. Additional risks include the costs and validation required for new equipment and facilities during scale-up, difficulty in negotiating manufacturing agreements on commercially reasonable terms, and the potential for termination or nonrenewal of agreements in a damaging or costly manner. The reliance on a limited number of sources, sometimes single sources, for key product components could lead to supply shortages if those components are unavailable. Furthermore, carrier disruptions or increased costs beyond control may impact supply chains. These risks could lead to clinical trial delays, failure to obtain regulatory approval, or an inability to successfully commercialize products. The FDA may take action, including injunctions, recalls, seizures, or suspensions of production, if these issues arise. Additionally, third-party manufacturers must comply with cGMP and other regulatory standards, and any failure to meet these requirements could result in sanctions, product recalls, or delays in approval. The limited number of manufacturers capable of meeting cGMP standards increases competition for access to these facilities, potentially hindering clinical development and commercialization efforts.","Relying on third-party manufacturers exposes us to risks including potential delays in product supply, quality control issues, and dependency on the manufacturers' compliance with regulatory requirements. Any failure by these manufacturers could delay our product development and commercialization efforts.",5.0,0.7947249205274959,1.0,1.0,1.0
How does the COVID-19 pandemic potentially impact the company's business operations?,"The COVID-19 pandemic may impact the company's business operations in several ways. It can disrupt the supply chain by affecting the ability to source necessary equipment, components, and materials, both for the company and its customers, potentially leading to higher inventory levels. Compliance with governmental measures related to the pandemic can result in additional costs and risks of penalties, which may restrict business activities. The shift to remote work has increased demand on IT systems and raised cybersecurity risks, such as phishing attacks and the need to secure more devices, with any failure in managing these risks potentially affecting operations. Additionally, public concern about contracting the virus may reduce customer demand.

For companies involved in clinical trials, the pandemic could disrupt ongoing and planned activities due to delays in site initiation, recruitment difficulties, and interruptions in drug supply manufacturing and delivery. Healthcare resource diversion, changes in local regulations, travel restrictions, and limitations on employee resources may hinder trial conduct. Delays in interactions with regulatory and ethics bodies, as well as potential refusal by agencies like the FDA to accept data from trials in affected areas, could further disrupt operations. The pandemic's broader economic and health impacts may also influence consumer behavior and business continuity.","The COVID-19 pandemic could have a material adverse impact on the company's business, financial condition, and results of operations, including disruptions to clinical trials, manufacturing, supply chain, and commercialization efforts, as well as potential delays in regulatory approvals and market introduction of products.",5.0,0.7023705362497783,1.0,0.875,1.0
How does the company's reliance on third-party manufacturers affect its operations?,"The company's reliance on third-party manufacturers affects its operations in several ways. It increases the risk of not having sufficient quantities of its product candidates or products at an acceptable cost or quality, which could delay, prevent, or impair development and commercialization efforts. The company depends on these third parties for key functions such as manufacturing, regulatory compliance, quality assurance, product development, analytical testing, and data generation to support regulatory applications. Additionally, disruptions to the third-party manufacturers' operations—such as those caused by the COVID-19 pandemic, bankruptcy, regulatory actions, or breach of agreement—could impact supply and timelines. Other risks include potential misappropriation of proprietary information, termination of agreements at inconvenient times, carrier disruptions, and failure to meet storage and delivery requirements. Furthermore, the limited number of specialized manufacturers, long lead times, and difficulty securing financial capital for manufacturing arrangements can hinder the company's ability to establish or maintain adequate production capabilities. Long-term agreements with exclusivity or termination penalties also reduce operational flexibility. Overall, any issues with third-party manufacturing could affect the company’s ability to meet market demand and attract partners, including larger pharmaceutical companies and academic institutions.","The company's reliance on third-party manufacturers for the production of octreotide capsules exposes it to risks such as potential supply disruptions, quality control issues, and regulatory compliance challenges. Any failure by these manufacturers to meet quality standards or regulatory requirements could delay product development and commercialization, leading to increased costs and potential loss of market opportunities.",5.0,0.7307279357766706,1.0,1.0,1.0
"What are the financial implications of the company's Revenue Interest Financing Agreement with Healthcare Royalty Partners IV, L.P.?","The Revenue Interest Financing Agreement with Healthcare Royalty Partners IV, L.P. involves the company receiving $65.0 million in funding, with an additional $10.0 million potentially available in early 2022, contingent upon certain conditions. In exchange, the company is obligated to make tiered quarterly royalty payments in the low double digits on worldwide net revenues from MYCAPSSA and any future products, with these payments subject to step-downs upon reaching specific annual revenue thresholds. 

The agreement expires upon the first occurrence of April 7, 2030, the Maturity Date, or when HCR receives aggregate payments equaling 195% of the total funded amount, referred to as the Hard Cap. If HCR has not reached the Hard Cap by the Maturity Date and no event of default has occurred, the company must pay HCR a specified amount based on the total amount funded as of that date. 

In the event of an event of default, such as the withdrawal, suspension, or termination of the FDA approval of MYCAPSSA for acromegaly that prevents marketing for sixty days, HCR may accelerate payments up to the Hard Cap. Additionally, if certain material adverse events or material breaches occur—though not considered events of default—HCR may terminate the agreement and require the company to pay the funded portion of the investment, minus previously received payments, plus a specified annual rate of return.

This arrangement could restrict the company’s ability to commercialize MYCAPSSA, limit cash flow available for operations, and expose it to risks that could negatively affect its business, financial condition, and results of operations.","The Revenue Interest Financing Agreement imposes significant financial obligations on the company, including tiered quarterly royalty payments based on product revenues, potential gross-up payments, and restrictions on incurring additional indebtedness. These obligations could limit the company's financial flexibility and increase its operating costs, potentially impacting its ability to invest in growth initiatives and maintain profitability.",5.0,0.6082697987314327,1.0,1.0,1.0
How does the company plan to address the risk of product liability lawsuits?,"The company plans to address the risk of product liability lawsuits primarily through obtaining product liability insurance. It currently maintains $10.0 million in aggregate product liability insurance coverage, although it acknowledges that this may not be sufficient to cover all potential liabilities. The company also recognizes that obtaining and maintaining adequate insurance coverage at reasonable costs is challenging and may not always be possible. In the absence of sufficient insurance, the company could face significant financial and operational challenges, including substantial liabilities, diversion of management resources, and potential limitations on commercialization. Additionally, the company has established internal procedures to minimize risks associated with quality issues and regulatory compliance, though it cannot eliminate the inherent risks of product liability in its operations.","The company maintains product liability insurance coverage to mitigate the financial impact of potential product liability claims. However, it recognizes that insurance coverage may not be sufficient to cover all costs and liabilities that could arise from such claims, and it may face significant legal expenses, reputational damage, and potential financial losses if it is unable to defend against or settle these claims successfully.",4.5,0.7942243781136954,1.0,1.0,1.0
How does the company's dependence on a limited group of suppliers and manufacturers impact its business?,"The company's reliance on a limited number of suppliers and manufacturers exposes it to significant business risks. These include reduced control over pricing, availability, quality, and delivery schedules, especially given the company's smaller size and limited negotiation leverage compared to larger competitors. The company may face supply interruptions if suppliers fail to meet its needs or if a sole or limited-source supplier is disrupted, which could materially impair the ability to manufacture product candidates. Delays in securing alternative sources, particularly due to strict licensing requirements in the industry, could hinder development and commercialization efforts, including clinical trials and regulatory approvals. Additionally, transitioning to new suppliers involves significant costs, time, and effort to qualify new sources and ensure product consistency. The company also faces the risk that acquired suppliers might no longer provide services, and the inability to maintain sufficient inventory levels could further threaten continuity. These factors collectively increase operational risk and could negatively impact the company's financial performance and market position.","The company may incur significant product development costs or experience material delivery delays if there is an interruption in supply from any one of these suppliers or manufacturers, which could materially impact sales of its products.",4.5,0.584077570550673,1.0,1.0,1.0
"What are the implications of the company being a ""controlled company"" under Nasdaq rules?","Being a ""controlled company"" under Nasdaq rules means the company is eligible for exemptions from certain corporate governance requirements. Specifically, the company may choose not to comply with rules that require a majority of the board of directors to consist of independent directors, the formation of a governance committee composed entirely of independent directors with a written charter, or the formation of a compensation committee composed entirely of independent directors with a written charter. Additionally, the company is not required to have a nominations committee made up entirely of independent directors or to follow specific processes for director nominations. As a result, stockholders may not have the same protections afforded to those in companies subject to all Nasdaq corporate governance requirements.","As a controlled company, the company qualifies for exemptions from certain corporate governance requirements, which may limit the protections afforded to shareholders and could impact the company's stock price and trading volume.",5.0,0.7892876263035629,1.0,1.0,1.0
What is the primary risk factor mentioned regarding investment in the company's shares?,"The primary risk factor mentioned regarding investment in the company's shares is the high degree of risk associated with the investments made in accordance with the investment objective, which may result in higher volatility and potential loss of principal. This includes the speculative and aggressive nature of investments in portfolio companies, particularly within the technology sector, which are subject to significant volatility, intense competition, shortened product life cycles, and regulatory changes. Additionally, the potential for substantial dilution in shareholders' ownership and the impact of external factors such as changes in regulatory policies, economic conditions, and the departure of key personnel further contribute to the overall risk.","The primary risk factor mentioned is that an investment in the company's shares involves a high degree of risk, and the occurrence of any of the risks listed could have a material adverse effect on the company's business, financial condition, results of operations, and future growth prospects.",4.0,0.7140360120578433,1.0,0.875,1.0
How has the COVID-19 pandemic impacted the company's business operations and clinical development timelines?,"The COVID-19 pandemic has significantly disrupted the company's business operations and clinical development timelines. It has led to delays in patient enrollment across clinical trial sites, with some sites suspending enrollment due to facility closures, travel restrictions, and quarantine measures. As a result, the company has experienced slower-than-expected patient recruitment, which has caused delays in clinical trial results and impacted overall trial timelines. Certain clinical trial activities, such as site visits and investigator meetings, have been limited or conducted remotely, further affecting progress.

The pandemic has also led to operational changes, including the adoption of telecommuting and staggered work shifts to protect employees while maintaining business continuity. Supply chain disruptions have emerged as a concern, with quarantines and travel restrictions potentially hindering the ability of third-party suppliers to manufacture and deliver clinical supplies, which could lead to delays in trial execution. Additionally, the uncertainty surrounding the pandemic's progression continues to create challenges, including potential delays in regulatory approvals and clinical site initiation.

These disruptions have contributed to increased development costs, raised the risk of abandoning clinical trials, and may impair the company's ability to secure additional financing. Overall, the pandemic has had a material adverse effect on business operations, financial condition, and the timely development of product candidates.","The COVID-19 pandemic has affected the company's business operations and clinical development timelines by impacting patient recruitment, enrollment, and follow-up visits at clinical sites. Government orders and restrictions to control the spread of the disease have also caused delays and uncertainties in the company's operations.",5.0,0.7525223849407908,1.0,1.0,1.0
What measures has the company taken to protect its intellectual property rights?,"The company has taken several measures to protect its intellectual property rights, including relying on a combination of patent, trademark, and trade secret laws, as well as license and access agreements and other contractual provisions. It requires employees, consultants, and certain contractors to sign confidentiality and assignment of inventions agreements to safeguard its proprietary information. Additionally, the company uses non-disclosure agreements with employees, strategic partners, and consultants, and relies on copyright and trade secret protection for software not covered by patents. To further protect its technology, the company also employs trade secrets, copyrights, unfair competition laws, and contractual agreements with suppliers and partners, including confidentiality and intellectual property assignment provisions.","The company seeks to protect its intellectual property rights by filing patent applications in the United States and abroad, entering into confidentiality agreements with parties who have access to its proprietary information, and maintaining physical and electronic security of its information technology systems.",4.5,0.6942352352440445,1.0,1.0,1.0
What are the risks associated with the company's reliance on third-party manufacturers for the production of its product candidates?,"The company faces several risks due to its reliance on third-party manufacturers for producing its product candidates. These include the inability to establish agreements with manufacturers on acceptable terms, potential breaches or terminations of manufacturing agreements by third parties, and dependence on these parties for compliance with regulatory requirements, quality assurance, and safety reporting. There is also a risk of misappropriation of proprietary information, including trade secrets and know-how. Additionally, disruptions such as catastrophic events at manufacturing sites, supply chain issues, or carrier disruptions can impact production and delivery. The company may face delays or failures in clinical development or regulatory approval if manufacturers fail to comply with cGMP regulations, scale up production, or meet specifications. The limited number of qualified manufacturers increases competition for capacity, and the lack of redundant supply arrangements leaves the company vulnerable to shortages or delays. Furthermore, the inability to qualify alternative manufacturers quickly could lead to additional costs and development setbacks.","The risks include the inability to meet product specifications and quality requirements consistently, delays in obtaining sufficient manufacturing capacity, potential non-compliance with regulatory requirements, and the possibility of increased costs and operational challenges if the company needs to find alternative manufacturers.",5.0,0.6655219886674874,1.0,1.0,1.0
"What was the opinion of KPMG LLP on the Company's internal control over financial reporting as of December 31, 2020?","KPMG LLP expressed an unqualified opinion on the Company’s internal control over financial reporting as of December 31, 2020, stating that the Company maintained effective internal control over financial reporting in all material respects based on criteria established in the Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.","In their opinion, KPMG LLP stated that the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO framework.",5.0,0.8735135784443856,1.0,1.0,1.0
How did the Company support its liquidity and capital resources during the crisis in March 2020?,"The Company supported its liquidity and capital resources during the crisis in March 2020 by issuing four series of senior notes totaling ¥57.0 billion. Additionally, it utilized its unsecured revolving credit facilities with available liquidity of $1.0 billion and ¥100.0 billion, and took advantage of the Federal Home Loan Bank of Atlanta (FHLB) borrowing limit increase to $800 million, designating $300 million for short-term liquidity needs of U.S. insurance subsidiaries, subject to collateral availability and other conditions. The Company also maintained the ability to adjust cash flow from other sources, such as reinvestment cash flows and selling investments.",The Company supported its liquidity and capital resources by issuing four series of senior notes totaling ¥57.0 billion and issuing $1.0 billion in senior notes through public debt offerings under its U.S. shelf registration statement. The Company also has available liquidity in its unsecured revolving credit facilities of $1.0 billion and ¥100.0 billion and currently has no borrowings under either of these facilities.,4.5,0.75318106195091,1.0,1.0,1.0
What are the significant accounting policies of Aflac Incorporated?,"The significant accounting policies of Aflac Incorporated include the description of its business operations, which involve selling supplemental health and life insurance primarily in the United States and Japan. The company's insurance business is marketed and administered through American Family Life Assurance Company of Columbus in the U.S. and Aflac Life Insurance Japan Ltd. in Japan, effective April 1, 2018. Prior to this date, the business in Japan was operated as a branch of Aflac. The company's operations are divided into two reportable business segments: Aflac U.S. and Aflac Japan. Additionally, Aflac's policies are mostly individually underwritten and marketed through independent agents, with group products managed through Continental American Insurance Company. The financial statements and supplementary data also note that Aflac Japan contributed significantly to total revenues, with a notable portion derived from investment portfolio gains and losses.","The significant accounting policies of Aflac Incorporated include foreign currency translation, insurance revenue and expense recognition, cash and cash equivalents, investments, deferred policy acquisition costs, goodwill, policy liabilities, reinsurance, income taxes, treasury stock, share-based compensation, earnings per share, and reclassifications.",2.0,0.7354054419202498,1.0,0.75,1.0
How does the Company account for foreign currency translation?,"The Company accounts for foreign currency translation by recording the revenues, expenses, and financial results of its subsidiaries in their respective functional currencies, which are primarily pounds sterling and euros. These financial statements are translated into U.S. dollars using current exchange rates, with gains or losses, net of tax as applicable, included in the cumulative translation adjustment account, a component of equity. Assets and liabilities are translated at year-end exchange rates, while income and expense accounts are translated at average exchange rates during the fiscal year. Translation adjustments are presented as a separate component of other comprehensive income and are included in net income only upon the sale or liquidation of the underlying foreign subsidiary or associated company.","The functional currency of Aflac Japan is the Japanese yen. The Company translates its yen-denominated financial statement accounts into U.S. dollars as follows: assets and liabilities are translated at end-of-period exchange rates, realized gains and losses on security transactions are translated at the exchange rate on the trade date, and other revenues, expenses, and cash flows are translated using average exchange rates for the period. The resulting currency translation adjustments are reported in accumulated other comprehensive income.",4.0,0.5608382226937324,1.0,1.0,1.0
What is the basis for KPMG LLP's opinion on the consolidated financial statements?,"KPMG LLP's opinion on the consolidated financial statements is based on an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB). The firm's responsibility is to express an opinion on the financial statements based on this audit. The audit was performed to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. This included assessing the risks of material misstatement, performing procedures to respond to those risks, examining evidence regarding the amounts and disclosures in the financial statements, evaluating the accounting principles used, and assessing significant estimates made by management. The firm believes that the audit provides a reasonable basis for its opinion.","KPMG LLP's opinion on the consolidated financial statements is based on their audits conducted in accordance with the standards of the PCAOB. Those standards require that they plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.",5.0,0.8697286973750293,1.0,1.0,1.0
How did the Company support its liquidity and capital resources during the crisis in March 2020?,"The Company supported its liquidity and capital resources during the crisis in March 2020 by actively raising deposits, short-term borrowings through securities sold under repurchase agreements, and borrowing from the FHLB. These actions were taken to meet the elevated demand for commercial loans while maintaining adequate liquidity and increasing cash.",The Company supported its liquidity and capital resources by issuing four series of senior notes totaling ¥57.0 billion and issuing $1.0 billion in senior notes through public debt offerings under its U.S. shelf registration statement. The Company also has available liquidity in its unsecured revolving credit facilities of $1.0 billion and ¥100.0 billion and currently has no borrowings under either of these facilities.,2.0,0.4980451336731842,1.0,1.0,1.0
What are the significant accounting policies of Aflac Incorporated?,"The significant accounting policies of Aflac Incorporated are detailed in the Notes to the Consolidated Financial Statements, specifically under the section titled ""1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES."" This section provides an overview of the methods and principles used by the company to prepare its financial statements. It covers aspects such as the recognition, measurement, presentation, and disclosure of financial information, which are essential for understanding the company's financial position, performance, and cash flows. However, the specific details of the policies are not provided in the given text.","The significant accounting policies of Aflac Incorporated include foreign currency translation, insurance revenue and expense recognition, cash and cash equivalents, investments, deferred policy acquisition costs, goodwill, policy liabilities, reinsurance, income taxes, treasury stock, share-based compensation, earnings per share, and reclassifications.",3.0,0.6806280817315611,1.0,0.75,1.0
How does the Company account for foreign currency translation?,"The Company translates the assets and liabilities of its foreign subsidiaries from their respective functional currency to U.S. dollars using the year-end exchange rates. Income and expense accounts are translated at the average exchange rates during the fiscal year, while equity accounts are translated at historical rates. The resulting translation adjustment is reported in the statements of comprehensive income and recorded as part of accumulated other comprehensive income. Translation adjustments are included in net income only upon the sale or liquidation of the underlying foreign subsidiary or associated company.","The functional currency of Aflac Japan is the Japanese yen. The Company translates its yen-denominated financial statement accounts into U.S. dollars as follows: assets and liabilities are translated at end-of-period exchange rates, realized gains and losses on security transactions are translated at the exchange rate on the trade date, and other revenues, expenses, and cash flows are translated using average exchange rates for the period. The resulting currency translation adjustments are reported in accumulated other comprehensive income.",4.0,0.6061863861530148,1.0,1.0,1.0
What was the outcome of the PJM Transmission Enhancement Settlement for DP&L?,"The outcome of the PJM Transmission Enhancement Settlement for DP&L was a reduction in transmission costs through PJM beginning in August 2018, including credits to reimburse DP&L for amounts overcharged in prior years. DP&L estimates the prior overcharge by PJM to be $40.8 million, with approximately $32.1 million repaid by December 31, 2020. The remaining $1.7 million is classified as current in ""Accounts receivable, net"" and $7.0 million as non-current in ""Other non-current assets"" on the Consolidated Balance Sheet. Refunds received are to be returned to customers via the transmission cost rider.","The PJM Transmission Enhancement Settlement resulted in a reduction of DP&L’s transmission costs through PJM, including credits to reimburse DP&L for amounts overcharged in prior years, which will be passed to customers through the TCRR.",4.5,0.8574156956195995,1.0,0.875,1.0
What was the impact of the adoption of ASC 326 on DP&L's financial statements in 2020?,"The adoption of ASC 326, ""Financial Instruments - Credit Losses,"" in 2020 impacted DP&L's financial statements by requiring the use of the Current Expected Credit Loss (CECL) model for financial assets measured at amortized cost. This change resulted in earlier recognition of an allowance for credit losses, particularly affecting the calculation of expected credit losses in gross customer trade accounts receivable. DP&L applied the modified retrospective method, implementing the transition provisions starting from the date of adoption.","The adoption of ASC 326, which updates the impairment model for financial assets, did not have a material impact on DP&L's Consolidated Financial Statements in 2020.",3.0,0.7861331262407207,1.0,1.0,1.0
What methods were used to determine the fair value of the acquired intangible assets in the Caesars Entertainment Corporation acquisition?,"The fair value of the acquired intangible assets in the Caesars Entertainment Corporation acquisition was determined using the relief from royalty method, the excess earnings method under the income approach, and the replacement cost market approach.","The fair value of acquired intangible assets was determined using various income approaches, including the relief from royalty method and excess earnings method.",4.0,0.8048014359197302,1.0,0.875,1.0
What were the key terms of the CEI Revolving Credit Facility?,"The CEI Revolving Credit Facility, established on July 20, 2020, provided for an aggregate principal amount of $1.2 billion and was a five-year facility maturing in 2025. It included a letter of credit sub-facility of $250 million. The interest rate was determined at the Company’s option, either as LIBOR adjusted for certain additional costs with a 0% floor or as a base rate based on the highest of the federal funds rate plus 0.50%, the prime rate, or the one-month adjusted LIBOR rate plus 1.00%, plus an applicable margin. The margin was 3.25% per annum for LIBOR loans and 2.25% for base rate loans, subject to three 0.25% step-downs based on the Company’s total leverage ratio. Additionally, a commitment fee of 0.50% was charged on unused commitments, which could step down to 0.375% depending on the leverage ratio.","The CEI Revolving Credit Facility provided for a five-year senior secured revolving credit facility in an aggregate principal amount of $1.2 billion, with interest rates based on LIBOR or a base rate plus an applicable margin, and a commitment fee on unused commitments.",5.0,0.8777550045020697,1.0,1.0,1.0
How did the Company's annual goodwill and indefinite-lived intangible asset impairment analysis result in 2020?,"The Company performed its annual goodwill and indefinite-lived intangible asset impairment analysis as of October 1, 2020. The analysis indicated that the fair value of the Former Caesars reporting units and indefinite-lived intangible assets did not significantly exceed their respective carrying values. Additionally, two of the Company’s other reporting units in the Regional Segment with goodwill totaling $208 million had fair values that did not significantly exceed their respective carrying values. As a result, the Company recorded $100 million of goodwill impairments related to five other reporting units in the Regional Segment and $22 million of indefinite-lived intangible asset impairments related to tradenames for the year ended December 31, 2020.","The Company recognized impairment charges in the Regional segment related to goodwill and trade names totaling $100 million and $16 million, respectively, due to declines in recent performance and the expected impact on future cash flows as a result of COVID-19.",4.5,0.6782407374903815,1.0,1.0,1.0
What was the nature of the litigation involving Harrah’s New Orleans and the Department of Revenue?,"The litigation involved a dispute over whether Harrah’s New Orleans was required to pay state sales taxes, as well as district and New Orleans occupancy taxes, on discounted or complimentary rooms provided to patrons or guests at its own hotel and certain third-party hotels. The Department of Revenue argued that such rooms were taxable, while Harrah’s New Orleans contested this. The matter went through multiple stages, including a trial court ruling, an appeal to the Louisiana Court of Appeal, and a petition to the Louisiana Supreme Court. The Supreme Court ultimately upheld the requirement for Harrah’s to pay taxes on complimentary rooms at its own property but reversed the ruling regarding third-party hotels. The case is now set for trial to determine the amount of taxes owed.","Harrah’s New Orleans was involved in litigation with the Department of Revenue related to sales taxes on hotel rooms, parking, and entertainment complimentaries for the periods from 2004 through 2016. The litigation is ongoing, and the Company has accrued contingent liabilities of $43 million as of December 31, 2020.",4.5,0.6911911444686479,1.0,1.0,1.0
What were the key terms of the Golf Course Use Agreement with VICI Properties L.P.?,"The Golf Course Use Agreement with VICI Properties L.P. had a 35-year term, including all renewal periods. The agreement required annual payments of $10 million, subject to escalation, an annual use fee of $3 million that began escalating from the second year, and certain per-round fees. The term of the agreement was extended to have 15 years remaining until the expiration of the initial term.","The Golf Course Use Agreement with VICI Properties L.P. provided for an annual payment of $10 million, an annual use fee of $3 million, and certain per-round fees, with a 35-year term inclusive of all renewal periods.",4.0,0.9709379613755051,1.0,0.875,1.0
What is the primary responsibility of Meredith management as stated in the financial report?,"The primary responsibility of Meredith management, as stated in the financial report, is the preparation, integrity, and objectivity of the financial information included in the Annual Report on Form 10-K for the year ended June 30, 2020.","Meredith management is responsible for the preparation, integrity, and objectivity of the financial information included in the Annual Report on Form 10-K for the year ended June 30, 2020.",5.0,0.931630814695611,1.0,1.0,1.0
How are the consolidated financial statements of Meredith prepared?,"The consolidated financial statements of Meredith are prepared by including the accounts of Meredith and its wholly-owned and majority-owned subsidiaries, after eliminating all significant intercompany balances and transactions.",The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include amounts based on informed judgments and estimates.,4.0,0.6123472693563375,1.0,0.75,1.0
Who audits the consolidated financial statements of Meredith Corporation?,"The consolidated financial statements of Meredith Corporation are audited by KPMG LLP, an independent registered public accounting firm.",The consolidated financial statements and the effectiveness of the Company’s internal control over financial reporting have been audited by an independent registered public accounting firm in accordance with the standards of the Public Company Accounting Oversight Board (United States).,4.0,0.6479272806783797,1.0,1.0,1.0
How did the adoption of the new leasing standard affect Meredith's financial statements?,"The adoption of the new leasing standard affected Meredith's financial statements by requiring the recognition of right-of-use (ROU) assets and lease liabilities for leases with terms longer than twelve months, which were previously not recorded on the balance sheet. Lease expenses are recognized on a straight-line basis over the lease term. The Company uses its incremental borrowing rate to determine the present value of lease payments unless the implicit rate is readily determinable. Lease agreements may include variable payments, such as those tied to inflation or maintenance costs, and certain options like renewals or terminations are included in the lease term if their exercise is reasonably certain. The Company also opted to exclude leases with an initial term of twelve months or less from balance sheet recognition and chose not to separate lease and non-lease components for any asset classes in its current portfolio. Prior years’ amounts remain unadjusted and are reported under the historical accounting policies.","Upon adoption, $509.9 million and $541.0 million were recorded for operating lease assets and liabilities, respectively, which included the impact to previously recorded liabilities associated with deferred rent and exit or disposal costs, and impairments of certain operating lease assets related to conditions that existed prior to adoption, which resulted in a decrease of $5.8 million to retained earnings as of July 1, 2019.",4.0,0.41649966303300173,1.0,0.75,1.0
"What was the total amount of long-term debt for Meredith Corporation as of June 30, 2020?","The context information does not provide the total amount of long-term debt for Meredith Corporation as of June 30, 2020.","The total amount of long-term debt for Meredith Corporation as of June 30, 2020, was $2.5 billion.",1.0,0.8241223698722487,1.0,0.75,1.0
"What was the total comprehensive income (loss) for Meredith Corporation for the year ended June 30, 2020?","The total comprehensive income (loss) for Meredith Corporation for the year ended June 30, 2020, cannot be determined from the provided context. The context includes information about other comprehensive income (loss) and segment reporting but does not provide specific numerical values for comprehensive income (loss) for the stated period.","The total comprehensive income (loss) for Meredith Corporation for the year ended June 30, 2020, was a loss of $252.3 million.",2.0,0.772663979121245,1.0,0.5,1.0
"What was the total amount of cash and cash equivalents for Meredith Corporation as of June 30, 2020?","The provided context does not contain information about the total amount of cash and cash equivalents for Meredith Corporation as of June 30, 2020.","The total amount of cash and cash equivalents for Meredith Corporation as of June 30, 2020, was $122.3 million.",1.0,0.7887060117522527,1.0,0.5,1.0
"What is the primary objective of New York City REIT, Inc.'s use of derivative financial instruments?","The primary objective of New York City REIT, Inc.'s use of derivative financial instruments is to minimize the risks and costs associated with the Company’s operating and financial structure, as well as to hedge specific anticipated transactions.","The primary objective of using derivative financial instruments is to hedge all or a portion of the interest rate risk associated with its borrowings, to minimize risks and costs associated with the Company’s operating and financial structure, and to hedge specific anticipated transactions.",4.5,0.7322895447093893,1.0,0.875,1.0
What measures did the Company take to address potential breaches of debt service coverage and debt yield covenants?,"The Company may remain in breach of covenants for up to four consecutive quarters and has the ability to cure the covenants after achieving two consecutive quarters of maintaining the required debt service coverage and debt yield for the property. The Company is currently in discussions with the lender and evaluating options under the loan contract and other alternative options related to the property. In the near term, the Company anticipates funding any interest shortfalls on the loan using cash on hand.","The Company is currently in breach of a debt service coverage provision and a reserve fund reserve provision under its non-recourse mortgage secured by the 1140 Avenue of the Americas property, requiring excess cash to be held in a segregated account as additional collateral under the loan. The Company is also evaluating options under the loan pursuant to the contract and other alternative options associated with the property.",4.0,0.6185940264991289,1.0,0.875,1.0
"What accounting principle did i3 Verticals, Inc. adopt on October 1, 2019, and how did it affect revenue recognition?","i3 Verticals, Inc. adopted the new revenue recognition standard, ASU 2014-09, on October 1, 2019, using a modified retrospective basis. This change required more judgment and estimates in applying the standard, particularly in estimating variable consideration and the expected periods of benefit for certain costs. The company determined that the timing of revenue recognition under the new standard for its revenue categories—such as discount fees, software licensing subscriptions, ongoing support, and other POS-related solutions—was similar to the previous guidance under ASC 605. Additionally, the adoption resulted in a cumulative increase of $1,345 to equity, driven by changes in the amortization of capitalized costs to obtain contracts with clients, which are now amortized over the expected life of the client rather than the specific contract life. The most significant ongoing impact was due to changes in principal versus agent considerations, particularly affecting the presentation of payment authorization services net of interchange and network fees.","i3 Verticals, Inc. adopted Accounting Standards Codification Topic 606, ""Revenue from Contracts with Customers,"" which changed the timing of certain revenue and expenses recognition under various arrangement types. Revenue is now recognized as each performance obligation is satisfied, and more judgment and estimates are required when applying the requirements of the new standard.",5.0,0.740733466702155,1.0,1.0,1.0
"How does i3 Verticals, Inc. account for the costs to obtain and fulfill a contract?","i3 Verticals, Inc. capitalizes incremental costs to obtain new contracts and contract renewals, amortizing these costs on a straight-line basis over the benefit period, which is generally the contract term. However, if a commensurate payment is not expected at renewal, the costs are expensed as incurred. The company also capitalizes costs to fulfill a contract that are expected to be recovered within the contract period. For broking pre-placement costs, the company estimates fulfillment costs and amortizes them over the period of benefit, typically less than a year. In system implementation and consulting arrangements, amortization periods may extend beyond the initial contract term based on the likelihood of renewals. The company records commissions expense for these costs as incurred.","i3 Verticals, Inc. capitalizes incremental costs to obtain new contracts and contract renewals and amortizes these costs on a straight-line basis as an expense over the benefit period, which is generally the contract term. These costs include commissions paid to obtain new sales.",4.5,0.8518142913900915,1.0,1.0,1.0
"What is the impact of the Tax Receivable Agreement (TRA) on i3 Verticals, Inc.'s financial position?","The Tax Receivable Agreement (TRA) impacts i3 Verticals, Inc.'s financial position by creating both deferred tax assets and corresponding liabilities. As of September 30, 2019, the deferred tax asset and Tax Receivable Agreement liability were $26,736 and $23,229, respectively. These balances increased to $31,626 and $27,565 as of September 30, 2020, reflecting the recognition of additional deferred tax assets and liabilities due to transactions involving the acquisition of common units and exchanges with Continuing Equity Owners. These transactions resulted in increases to the tax basis of the investment in i3 Verticals, LLC, leading to higher deferred tax benefits. Under the TRA, 85% of the tax benefits realized from these transactions are payable to the Continuing Equity Owners. Payments under the agreement are expected to be made over the next 25 years, ranging from $0 to $2,460 per year, and are subject to change based on the final determination of U.S. federal and state income tax returns. The amounts recorded approximate current estimates of expected tax savings, but they may be adjusted after tax filings. This creates a long-term obligation for the company and influences its cash flow and financial reporting, as the liabilities are recognized based on anticipated future benefits.","The Tax Receivable Agreement (TRA) requires i3 Verticals, Inc. to pay 85% of certain tax benefits to the Continuing Equity Owners. This has resulted in the recognition of deferred tax assets and corresponding liabilities, which affect the company's financial position by increasing its deferred tax assets and liabilities.",5.0,0.8837038043947056,1.0,1.0,1.0
"What are the quarterly trends in i3 Verticals, Inc.'s revenue and net income for the years ended September 30, 2020 and 2019?","The provided context does not contain specific information about the quarterly trends in i3 Verticals, Inc.'s revenue and net income for the years ended September 30, 2020 and 2019. While there are references to quarterly information and financial results, no detailed figures or trends related to revenue and net income are included in the given content.","For the year ended September 30, 2020, quarterly revenue trends showed an increase from $49,431 in Q1 to $57,606 in Q4, with net income ranging from $2,151 to $6,031. For the year ended September 30, 2019, quarterly revenue increased from $42,222 in Q1 to $50,851 in Q4, with net income ranging from $1,403 to $4,585.",1.0,0.4771724388285241,1.0,0.75,1.0
"How did the adoption of ASC 842 impact the Company's balance sheet as of April 1, 2019?","The adoption of ASC Topic 842 resulted in the recognition of right-of-use (ROU) assets and lease liabilities on the Company's balance sheet as of the adoption date, January 1, 2019. Specifically, the Company recorded ROU assets and lease liabilities of $82.2 million at the commencement date. These amounts were recorded on an equal basis, representing the present value of future lease payments for existing operating leases. The adoption did not require restatement of comparative periods, and the Company applied a modified retrospective transition method, which allowed for the recognition of these items without a cumulative-effect adjustment to retained earnings. As a result, the balance sheet reflected the new lease accounting model, providing increased transparency by bringing lease obligations and related assets onto the balance sheet that were previously off-balance-sheet under the prior guidance.",The adoption of ASC 842 resulted in the recording of $13.3 million of additional lease liabilities and right-of-use assets to the beginning balance of the Company’s Consolidated Balance Sheet.,3.0,0.7940733622464877,1.0,0.0,1.0
"What was the impact of the Redomestication on Global Indemnity Group, LLC's class A common shares?","The Redomestication resulted in Global Indemnity Group, LLC's class A common shares being deemed registered under Section 12(b) of the Exchange Act pursuant to Rule 12g-3(a). The issuance of these shares was exempt from registration under the Securities Act by virtue of Section 3(a)(10). Additionally, the class A common shares began trading on Nasdaq under the same symbol, ""GBLI,"" that was previously used by Global Indemnity Limited ordinary shares.","The Redomestication resulted in the shareholders of Global Indemnity Limited becoming the holders of all of the issued and outstanding common shares of Global Indemnity Group, LLC. The class A common shares of Global Indemnity Group, LLC began trading on Nasdaq under the symbol ""GBLI"" at the commencement of trading on August 28, 2020.",3.0,0.8552567952217303,1.0,1.0,1.0
What are the principal terms of the 7.875% Subordinated Notes due 2047 issued by Global Indemnity Limited?,"The 7.875% Subordinated Notes due 2047 issued by Global Indemnity Limited have the following principal terms:

- The notes were issued on March 23, 2017, through an underwritten public offering, with an initial aggregate principal amount of $120.0 million.
- An over-allotment option was exercised by the underwriters, increasing the aggregate principal amount to $130.0 million, with the additional $10 million closing on March 30, 2017.
- The notes bear interest at an annual rate of 7.875%, payable quarterly on January 15, April 15, July 15, and October 15 of each year, beginning July 15, 2017.
- The maturity date is April 15, 2047.
- The Company has the right to redeem the notes in $25 increments, in whole or in part, on or after April 15, 2022, or on any subsequent interest payment date, at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest up to the redemption date.
- The notes are subordinated unsecured obligations and rank:
  - Senior to the Company’s existing and future capital stock,
  - Senior in right of payment to future junior subordinated debt,
  - Equal in right of payment to any existing or future unsecured subordinated debt that ranks equally with the notes,
  - Subordinate in right of payment to any future senior debt.
- The notes are structurally subordinated to all existing and future indebtedness, liabilities, and obligations of the Company’s subsidiaries, including the margin borrowing facility.
- The notes do not include financial covenants, such as maintenance of financial ratios, net worth, or liquidity, nor do they restrict the Company from incurring additional indebtedness, including senior debt.
- There is no right to accelerate the maturity in the event of default on payments or other obligations, and holders may only accelerate payment in the event of the Company’s bankruptcy, insolvency, or reorganization.
- Deferred issuance costs of $4.2 million are being amortized over the life of the notes, and interest expense, including amortization, was $10.4 million annually for the years 2018, 2019, and 2020.","The principal terms of the 7.875% Subordinated Notes due 2047 include:
   - Annual interest rate of 7.875%, payable quarterly.
   - Maturity date of April 15, 2047.
   - The Company has the right to redeem the notes in whole or in part on or after April 15, 2022, at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest.",5.0,0.7703638476094885,1.0,1.0,1.0
How is Berkshire Hathaway Energy's operations organized?,"Berkshire Hathaway Energy's operations are organized into eight business segments: PacifiCorp, MidAmerican Funding (which primarily consists of MidAmerican Energy), NV Energy (which primarily consists of Nevada Power and Sierra Pacific), Northern Powergrid (which primarily consists of Northern Powergrid (Northeast) plc and Northern Powergrid (Yorkshire) plc), BHE Pipeline Group (which primarily consists of BHE GT&S, Northern Natural Gas and Kern River), BHE Transmission (which consists of BHE Canada (which primarily consists of AltaLink) and BHE U.S. Transmission), BHE Renewables, and HomeServices.","BHE's operations are organized into eight business segments: PacifiCorp, MidAmerican Funding, NV Energy, Northern Powergrid, BHE Pipeline Group, BHE Transmission, BHE Renewables, and HomeServices.",5.0,0.8936439582737372,1.0,1.0,1.0
How many miles of transmission lines does BHE own?,"BHE U.S. Transmission indirectly owns a 50% interest in ETT, which includes approximately 1,900 miles of transmission lines. Additionally, BHE U.S. Transmission acquired 132 line miles in the U.S. of the 214-mile 230 kV line through MATL LLP. It also owns a 25% interest in Prairie Wind Transmission, which includes a 108-mile, 345-kV transmission project. Summing these, BHE directly or indirectly owns 1,900 + 132 + 108 = 2,140 miles of transmission lines.","BHE owns approximately 36,000 miles of transmission lines.",2.0,0.8106319334519699,1.0,0.875,1.0
What is the total natural gas mains and service lines length for MidAmerican Energy?,"MidAmerican Energy's natural gas distribution facilities included 24,100 miles of natural gas main and service lines as of December 31, 2020.","The natural gas distribution facilities of MidAmerican Energy included 24,100 miles of natural gas main and service lines as of December 31, 2020.",5.0,0.9788719091937368,1.0,1.0,1.0
How does NV Energy manage its energy supply function?,"NV Energy manages its energy supply function through an approach that includes three primary elements. The first is a set of management guidelines for procuring and optimizing the supply portfolio, aligning with the requirements of a load-serving entity with a full requirements obligation and accounting for the growth of private generation serving customers with partial requirements. The second element involves an energy risk management and control framework that ensures a clear separation between day-to-day risk management and compliance monitoring, as well as a distinction between policy setting and execution. The third element is ongoing regulatory involvement, where NV Energy seeks acknowledgment and engagement with regulatory bodies regarding its resource portfolio management plans. Additionally, the company relies on long-term power purchase contracts with suppliers using renewable resources, natural gas, and coal to ensure reliable and continuous energy delivery.","NV Energy manages its energy supply function through four key components: IRPs, ESPs, DRPs, and action plans, which are filed with the PUCN for approval and operate in conjunction with the PUCN-approved 20-year IRP.",4.0,0.6664134974911213,1.0,1.0,1.0
What is the Emissions Reduction and Capacity Replacement Plan for Nevada Power?,"Nevada Power's Emissions Reduction and Capacity Replacement Plan (ERCR Plan) involves the retirement or elimination of coal-fueled generating capacity. Specifically, the plan includes retiring or eliminating 300 MWs by December 31, 2014, another 250 MWs by December 31, 2017, and an additional 250 MWs by December 31, 2019. The retired capacity is to be replaced with a combination of constructed, acquired, or contracted renewable and non-technology specific generating units. The plan also outlines the timeline and costs associated with decommissioning the coal-fueled generating units. The Public Utilities Commission of Nevada (PUCN) has the authority to approve or modify the plan. Additionally, Nevada Power has acquired 536 MWs of natural gas generating resources, executed long-term power purchase agreements for 200 MWs of renewable energy capacity, and constructed a 15-MW solar photovoltaic facility. There is also an option to acquire 35 MWs of renewable energy capacity in the future, subject to PUCN approval.","The ERCR Plan includes the retirement of 255 MWs of coal-fueled generation in 2019, acquisition of 536 MWs of natural gas generating resources, execution of long-term power purchase agreements for 200 MWs of nameplate renewable energy capacity, and construction of a 15-MW solar photovoltaic facility.",4.0,0.7479130702269604,1.0,0.875,1.0
What is the role of the Northern Powergrid Distribution Companies?,"The Northern Powergrid Distribution Companies are responsible for building, maintaining, and operating the electricity distribution network in their service area, which includes the north-east of England. They receive electricity from the national grid transmission system and directly connected generators, then distribute it to end-users' premises using transformers, switchgear, distribution lines, and cables. They charge fees to electricity suppliers for using their distribution systems, and their role ensures that electricity is delivered to end-users through their networks.","The Northern Powergrid Distribution Companies build, maintain, and operate the electricity distribution network through which end-users receive a supply of electricity. They charge fees for the use of their distribution systems to the suppliers of electricity.",5.0,0.907739660102289,1.0,1.0,1.0
What is the market area design capacity of Northern Natural Gas?,The market area design capacity of Northern Natural Gas is 6.3 billion cubic feet per day.,Northern Natural Gas' pipeline system has a Market Area design capacity of 6.3 Bcf per day.,5.0,0.8960966171317168,1.0,1.0,1.0
What is the transmission system of the Nevada Utilities part of?,The transmission system of the Nevada Utilities is part of the Western Interconnection.,"The Nevada Utilities' transmission system is part of the Western Interconnection, a regional grid in the United States that includes the interconnected transmission systems of 14 western states, two Canadian provinces, and parts of Mexico.",4.0,0.9362092766991095,1.0,1.0,1.0
What are the key components of the energy supply planning process for the Nevada Utilities?,"The key components of the energy supply planning process for the Nevada Utilities include the Integrated Resource Plan (IRP), Energy Supply Plans (ESP), Distributed Resource Plans (DRP), and Action plans. The IRP is a comprehensive, 20-year plan developed in compliance with Nevada laws and regulations, requiring joint filings by Nevada Power and Sierra Pacific. It aims to balance minimizing costs and reducing volatility while reliably meeting customer energy needs. The ESP serves as an intermediate-term resource procurement and risk management plan with a one- to three-year horizon, establishing supply portfolio strategies and requiring PUCN approval for contracts longer than three years. The DRP provides a formal process for integrating distributed resources into the utility's distribution and transmission systems cost-effectively. Action plans focus on tactical execution activities over a one-month to twelve-month period and operate in conjunction with the approved IRP and ESP. All these plans are subject to PUCN approval and are designed to ensure reliable, efficient, and cost-effective energy supply.","The key components are IRPs, ESPs, DRPs, and action plans, which are filed with the PUCN for approval and operate in conjunction with the PUCN-approved 20-year IRP.",5.0,0.6762449991943024,1.0,0.875,1.0
What is the impact of California Senate Bill 100 on California's RPS?,"California Senate Bill 100, also known as the 100 Percent Clean Energy Act of 2018, significantly expanded the state's Renewable Portfolio Standard (RPS). It mandated that retail sellers meet an RPS target of 60% by 2030 and established a long-term goal for 100% of total California retail sales to come from eligible renewable energy resources and zero-carbon resources by December 31, 2045.","California Senate Bill 100 increased the RPS target to 60% by 2030 and enabled a longer-term planning target for 100% of total California retail sales to come from eligible renewable energy resources and zero-carbon resources by December 31, 2045.",5.0,0.885495661019525,1.0,0.75,1.0
What is the role of the AESO in Alberta's electricity industry?,"The AESO is responsible for directing the safe, reliable, and economic operation of the Alberta Interconnected Electric System (AIES), including long-term transmission system planning. It assesses current and future transmission system capacity needs, monitors compliance with reliability standards, and submits applications to the Alberta Utilities Commission (AUC) for approval of transmission expansions or enhancements. The AESO also charges wholesale tariffs approved by the AUC to promote fair and open access to the electricity market and facilitate competition. Additionally, it plays a key role in planning the expansion and enhancement of the transmission system in Alberta, selecting transmission providers for construction and operation, and ensuring compliance with applicable laws and reliability standards.","The AESO's mandate is defined in the Electric Utilities Act (Alberta) and requires the AESO to assess both current and future needs of Alberta's interconnected electrical system. The AESO uses the 2019 Long-term Outlook, which is the AESO's forecast of Alberta's load and generation over the next 20 years, as one input to guide the AESO in planning Alberta's transmission system.",5.0,0.8110229278330933,1.0,1.0,1.0
What is the regulatory framework for BHE's regulated subsidiaries and certain affiliates?,"BHE's regulated subsidiaries and certain affiliates are subject to comprehensive governmental regulation that significantly influences their operating environment, prices charged to customers, capital structure, costs, and their ability to recover costs and earn a reasonable return on invested capital. The regulatory framework includes oversight from various state, federal, and local agencies, particularly for domestic regulated public utility subsidiaries. State regulatory commissions typically set retail electric and natural gas rates on a cost-of-service basis, allowing utilities to recover reasonable costs and earn a fair return on investment. These commissions may review and adjust rates based on factors such as a utility's revenue and expenses during a test period, its level of investment, and changes in income tax laws. They have the authority to review and change rates either on their own initiative or upon request from the utility, customers, or customer advocacy groups.","BHE's regulated subsidiaries and certain affiliates are subject to comprehensive governmental regulation, which significantly influences their operating environment, prices charged to customers, capital structure, costs, and ultimately their ability to recover costs and earn a reasonable return on invested capital.",4.5,0.7925858655626821,1.0,0.75,1.0
How has the COVID-19 pandemic affected the company's financial performance in 2020?,"The COVID-19 pandemic significantly impacted the company's financial performance in 2020. While the company implemented precautionary measures such as restricting business travel, temporarily closing offices, and furloughing employees to mitigate risks, these actions were part of a broader response to the economic and operational disruptions caused by the pandemic.

In terms of business operations, the pandemic led to a decline in testing volume in the company’s base business (excluding COVID-19 molecular and antibody testing), driven by factors such as reduced physician office visits, canceled elective procedures, and widespread closures of businesses. This decline was partially offset by growing demand for COVID-19 molecular and antibody testing, which became a key driver of revenue during the year.

Financially, cost of services increased by $767 million in 2020 compared to the prior year, primarily due to higher variable expenses related to increased testing volume, higher supply costs for COVID-19 testing, and additional pandemic-related expenses such as employee safety measures and compensation for pandemic-related costs. These increases were partially offset by cost-saving measures, including temporary salary reductions, furloughs, and reduced hours for employees, which helped manage workforce costs.

Selling, general, and administrative (SG&A) expenses increased by $93 million, mainly due to higher performance-based compensation and costs associated with acquisitions. Despite challenges, the company demonstrated resilience by adjusting operations and managing its workforce effectively, with the majority of furloughed employees recalled by the end of the third quarter as testing volumes recovered. The company also maintained sufficient supplies to conduct its business throughout the year.

Overall, while the pandemic negatively affected certain segments and operations, the company’s financial performance was influenced by a combination of challenges and opportunities, particularly in the expansion of COVID-19 testing services.","The COVID-19 pandemic significantly impacted the company's financial performance in 2020, leading to a decrease in net income by $98.6 million or 35%, primarily due to a $107.9 million increase in the provision for credit losses and a $37.7 million decrease in net interest income.",4.0,0.4935419527721256,1.0,1.0,1.0
"How has the Hawaii economy been impacted by COVID-19, and what are the implications for the company?","The Hawaii economy has been significantly impacted by the COVID-19 pandemic, resulting in a substantial decrease in commercial activity both locally and nationally. This decline has led to disruptions in the ability of customers, vendors, and counterparties to meet their payment and other obligations. The tourism industry, a key component of Hawaii’s economy, has been particularly affected, with the recovery of air travel and tourism highly uncertain. Recovery depends on factors such as declining case numbers globally and in Hawaii, visitor acceptance of pre-travel testing requirements, the absence of subsequent infection waves, and the availability of vaccines, treatments, or testing. As the economy gradually reopens, local consumption is expected to resume over time, but the pace of recovery remains uncertain. These economic pressures have influenced consumer and business spending, borrowing, and saving behaviors, affecting demand for the company's loans and other financial products and services. Additionally, the company has established contingency plans, including remote work and a redundant operations center, to maintain service continuity.","The Hawaii economy has been significantly impacted by COVID-19, with a 75.2% decrease in visitor arrivals and a 9.3% unemployment rate in December 2020. This has affected the company's operations and customer base, leading to increased credit risk and potential decreases in non-interest income.",4.0,0.6492353300829509,1.0,1.0,1.0
What are the key factors that could impact the company's profitability in future reporting periods?,"Key factors that could impact the company's profitability in future reporting periods include changes in interest rates, housing market conditions, unemployment levels, market volatility, energy prices, and the ability to attract and retain loans and deposits from customers. These factors can influence trading and other revenue, net interest income, loan volume, loss provision, and ultimately the company's results of operations. Additionally, the successful implementation of business strategies is critical to maintaining financial condition and results of operations.","Key factors that could impact the company's profitability include continued adverse economic conditions due to the COVID-19 pandemic, changes in interest rates, increased credit risk, and potential decreases in non-interest income.",4.0,0.693324495608857,1.0,0.75,1.0
How has the company's investment in high-grade investment securities evolved during 2020?,"The company significantly increased its investment in high-grade investment securities during 2020. The total fair value of the investment securities portfolio grew to $6.1 billion as of December 31, 2020, representing a $2.0 billion increase, or 49%, compared to December 31, 2019. This growth was primarily driven by redeploying excess balance sheet liquidity. The portfolio included securities such as collateralized mortgage obligations issued by Ginnie Mae, Fannie Mae, and Freddie Mac. Additionally, the company expanded its investment securities through the merger with CSFL, which added $1.2 billion, and by purchasing an additional $2.4 billion in securities during the year. These purchases were partially offset by maturities, calls, paydowns, and sales totaling $1.1 billion. The company strategically allocated excess funds from deposit growth to increase its investment in high-grade securities.","The company increased its investment in high-grade investment securities, primarily collateralized mortgage obligations, with the total fair value of the investment securities portfolio rising by 49% to $6.1 billion as of December 31, 2020.",5.0,0.8106238528244327,1.0,1.0,1.0
"What is the primary purpose of the allowance for credit losses (ACL) at First Hawaiian, Inc.?","The primary purpose of the allowance for credit losses (ACL) at First Hawaiian, Inc. is to reflect management's best estimate of expected credit losses on the loan portfolio, based on past events, current conditions, and reasonable and supportable forecasts. It serves as a valuation account deducted from the amortized cost basis of loans and leases to present the net amount expected to be collected. This allowance is used to absorb credit losses in the total loan and lease portfolio, with losses charged against it when uncollectibility is confirmed.","The primary purpose of the ACL is to estimate and reserve for expected credit losses on loans and leases, ensuring that the net carrying value of these assets reflects the amount expected to be collected.",5.0,0.7694902158122553,1.0,1.0,1.0
"How did the adoption of the Current Expected Credit Losses (CECL) model impact First Hawaiian, Inc.'s financial statements in 2020?","The adoption of the Current Expected Credit Losses (CECL) model impacted First Hawaiian, Inc.'s financial statements in 2020 by changing the method of accounting for its allowance for credit losses. This change was due to the adoption of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No., which requires the measurement of expected credit losses over the life of financial instruments. As a result, the company's financial statements reflect this updated approach to estimating credit losses, which may have affected the reported allowance for credit losses, potentially increasing or decreasing the provision for credit losses depending on the expected credit losses of the loan portfolio. However, specific financial impacts would be detailed in Note 1 to the financial statements.","The adoption of CECL in 2020 required a cumulative effect adjustment to retained earnings as of January 1, 2020, reflecting changes in the allowance for credit losses and the reserve for unfunded commitments.",4.0,0.5166595314286261,1.0,0.75,1.0
"How does First Hawaiian, Inc. manage its interest rate risk?","First Hawaiian, Inc. manages its interest rate risk primarily through a strategy that includes the use of derivatives to mitigate exposure to interest-rate changes. The company enters into derivatives to manage interest-rate-risk exposures in otherwise unhedged assets and liabilities, aligning with its risk-management objectives. These derivatives are used in accordance with FHFA regulations, which prohibit speculative use, and are only employed for non-speculative purposes. The company may use derivatives to change the coupon repricing characteristics of assets and liabilities from fixed-rate to floating-rate, hedge the mark-to-market sensitivity of existing assets or liabilities, offset or neutralize embedded options, and hedge potential yield variability of anticipated transactions.

In addition to derivatives, the company employs natural and offsetting economic hedges by managing its investment securities portfolio to reduce the need for off-balance sheet derivative instruments. The Asset-Liability Committee (ALCO) oversees these strategies, periodically reevaluating hedging techniques and adjusting them as needed based on expected interest rate movements and simulation analyses. The goal is to achieve an optimal risk profile while adhering to capital and liquidity guidelines.","First Hawaiian, Inc. manages interest rate risk through the use of interest rate swaps designated as either fair value hedges or cash flow hedges, which help to offset potential adverse impacts on interest expense and net interest margin.",4.5,0.7324601383934269,1.0,1.0,1.0
"What was the impact of the Visa Class B restricted shares on First Hawaiian, Inc.'s financial statements in 2020?","The impact of the Visa Class B restricted shares on First Hawaiian, Inc.'s financial statements in 2020 involved a payment of approximately $0.3 million made in October 2019 to the buyer as a result of the reduction in the Visa Class B conversion rate, which was effective September 27, 2019. This payment was made following Visa's additional funding of its litigation escrow account on September 27, 2019, which reduced the conversion rate from 1.6298 to 1.6228. This event was a consequence of the agreement entered into in 2016 when the Company sold 274,000 Visa Class B restricted shares. There was no mention of any credit losses recognized on these securities in 2020.","The Visa Class B restricted shares resulted in a revaluation adjustment, leading to losses in other noninterest income of $4.8 million in 2020, as the Company made monthly payments based on changes in Visa's conversion rate.",3.0,0.6142965520992317,1.0,0.875,1.0
"What are the regulatory capital requirements for First Hawaiian, Inc., and how did the company perform against these requirements as of December 31, 2020?","The provided context does not contain information about First Hawaiian, Inc., or its regulatory capital requirements and performance. The documents discuss Huntington and its subsidiaries, including their regulatory capital ratios and compliance with Basel III standards, but there is no mention of First Hawaiian, Inc. Therefore, it is not possible to answer the query based on the given information.","First Hawaiian, Inc. is required to maintain minimum amounts and ratios of Common Equity Tier 1 (CET1) capital, Tier 1 capital, and total capital to risk-weighted assets, as well as a minimum leverage ratio. As of December 31, 2020, the Company was classified as well-capitalized and exceeded the capital conservation buffer.",1.0,0.42976986007479717,1.0,0.0,1.0
"What measures has First Hawaiian, Inc. taken in response to the COVID-19 pandemic, particularly concerning loan modifications and troubled debt restructurings (TDRs)?","First Hawaiian, Inc. implemented loan modifications on a case-by-case basis to support borrowers affected by the economic impacts of the COVID-19 pandemic, aiming to maximize loan collectability while addressing borrower financial needs. In response to the pandemic, the company adhered to the CARES Act and interagency regulatory guidance, which provided flexibility in accounting for certain loan modifications. Specifically, loan modifications meeting the criteria under the CARES Act, as well as short-term forbearance arrangements, were not required to be treated as troubled debt restructurings (TDRs) under U.S. GAAP. First Hawaiian, Inc. elected to suspend TDR accounting for $506 million of COVID-19 related loan modifications as of December 31, 2020, because these modifications were eligible under either the CARES Act, interagency guidance, or constituted short-term forbearance. This approach helped avoid classifying these modifications as TDRs, thereby reducing the need for detailed disclosures associated with such restructurings. The company continues to evaluate loan modifications in its mortgage loan (MML) and residential mortgage loan (TRE) portfolios, with the impact of modifications on financial results being immaterial as of the end of 2020. Additionally, the company continues to accrue interest income on loans with deferred payments, consistent with the FASB’s guidance, and maintains a process to reclassify assets to nonaccrual status when appropriate based on payment performance.","In response to the COVID-19 pandemic, First Hawaiian, Inc. adopted provisions of the CARES Act and Interagency Statements, which allowed for temporary relief from TDR reporting for certain loan modifications made on a good faith basis in response to borrower impacts from COVID-19.",5.0,0.8125236210927389,1.0,0.875,1.0
What are the potential risks associated with the company's reliance on third-party manufacturers for Oxbryta and its product candidates?,"The potential risks associated with the company's reliance on third-party manufacturers for Oxbryta and its product candidates include:

- Reliance on the third party for regulatory compliance and quality assurance.
- The possibility of breach or termination of the manufacturing agreement by either the third party or the company, which could occur at a time that is costly or inconvenient.
- The inability of the third party to meet ordering requirements regarding quality, quantity, and price, including disruptions from public health risks such as the COVID-19 pandemic.
- The potential misappropriation of proprietary information, including trade secrets and know-how.
- The unwillingness of the third party to extend or renew agreements when desired.
- Challenges related to the transfer of technology, particularly for biologic products like inclacumab, and the need for FDA approval of Investigational New Drug applications from new manufacturing sites.
- The company's lack of experience in manufacturing biologic products, leading to greater reliance on the expertise of third-party manufacturers.
- The exposure of third-party manufacturers to regulatory and market risks due to their involvement in supplying or manufacturing products for other companies.","Risks include reliance on the third party for regulatory compliance and quality assurance, potential breach or termination of the manufacturing agreement, inability to satisfy ordering requirements as to quality, quantity, and price, and the unwillingness of the third party to extend or renew terms with the company.",4.5,0.759656765125126,1.0,1.0,1.0
How does the company plan to manage its intellectual property risks?,"The company plans to manage its intellectual property risks by relying on a combination of patent, trademark, and trade secret laws, along with license and access agreements and other contractual provisions. To protect its intellectual property, the company requires employees, consultants, and certain contractors to sign confidentiality and assignment of inventions agreements. Additionally, it enters into confidentiality agreements, material transfer agreements, and other similar contracts with third parties, such as advisors, employees, and consultants, to limit the use or disclosure of proprietary information. However, the company acknowledges that these measures provide only limited protection and that enforcement may require litigation, which could involve significant costs and distractions. Despite these efforts, risks remain due to the potential for breach of agreements, unauthorized disclosure, and the difficulty of monitoring compliance.","The company seeks to protect its proprietary position by filing patent applications in the United States and abroad related to Oxbryta and its product candidates. However, it acknowledges the uncertainty and complexity involved in obtaining and enforcing biopharmaceutical patents.",4.5,0.39466419544901044,1.0,1.0,1.0
What are the potential risks associated with the company's international operations?,"Operating internationally involves several risks, including multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, and regulatory requirements. There is also the risk of failing to obtain or maintain regulatory approvals for product use in various countries, along with additional third-party patent rights. Intellectual property protection and enforcement can be complex and difficult. Staffing and managing foreign operations present challenges, as do managing multiple payor reimbursement regimes, government payors, or patient self-pay systems. Penetration of international markets may be limited, and financial risks include longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises, and exposure to foreign currency exchange rate fluctuations. Other risks include natural disasters, political and economic instability, wars, terrorism, disease outbreaks, boycotts, trade restrictions, and certain expenses such as travel, translation, and insurance. Additionally, there are regulatory and compliance risks related to the U.S. Foreign Corrupt Practices Act, including books and records provisions and anti-bribery provisions, as well as risks from the United Kingdom’s withdrawal from the European Union affecting global economic conditions and financial markets.","Risks include compliance with complex and changing laws and regulations, difficulties in obtaining and maintaining regulatory approvals for sales or use of products in various countries, complexities in enforcing intellectual property rights, and financial risks such as longer payment cycles and exposure to foreign currency exchange rate fluctuations.",5.0,0.8153171592389422,1.0,1.0,1.0
What are the financial implications of the Orphan Drug Designation for Oxbryta in the United States?,"The Orphan Drug Designation for Oxbryta in the United States provides several financial benefits. It qualifies the drug for an exemption from the PDUFA application fee, which reduces the financial burden of the regulatory approval process. Additionally, the designation enables the company to claim tax credits for qualifying clinical trials, offering financial incentives for research and development. These benefits support the cost-effective development and commercialization of Oxbryta for the treatment of sickle cell disease.","The Orphan Drug Designation for Oxbryta in the United States provides several financial incentives, including tax credits for qualifying clinical trials, exemption from the PDUFA application fee, and a substantial period of regulatory market exclusivity, which will expire on November 25, 2026.",4.5,0.8718061535882526,1.0,1.0,1.0
How does the company's dependence on a limited number of customers affect its operating results?,"The company's dependence on a limited number of customers makes its operating results vulnerable to the loss of any significant customer, which could adversely affect its financial performance. A substantial majority of the company's income currently comes from a small group of customers, such as power utilities, railroad companies, and industrial end-users, particularly in the Caribbean. This concentration means that the company's revenue and operational success are heavily reliant on maintaining sales of LNG, natural gas, steam, and power to these key customers. Additionally, after the proposed merger, the company will be subject to risks associated with the Sergipe Terminal and Sergipe Power Plant, further tying its financial outcomes to a narrow customer base and specific markets. If the company fails to diversify and expand its customer base, it may struggle to recover from such losses, potentially leading to negative impacts on its business, results of operations, and overall financial condition.","The company's operating results are contingent on maintaining LNG, natural gas, steam, and power sales to these customers. The loss of a significant customer could adversely affect operating results.",4.5,0.7551941246511665,1.0,1.0,1.0
How does the company's limited operating history impact its ability to evaluate business prospects?,"The company's limited operating history makes it difficult to evaluate the success of its business to date and to assess its future viability. This is because the company has not yet demonstrated its ability to complete clinical trials, obtain marketing approvals, manufacture commercial-scale products, or conduct sales, marketing, and distribution activities necessary for successful product commercialization. As a result, predictions about its future success or viability may not be as accurate as they would be if the company had a longer operating history.","The limited operating history provides a less reliable basis for evaluating business prospects, as the company continues to develop policies and procedures and build its team.",4.0,0.7881268490112758,1.0,1.0,1.0
How did the acquisition of MBT Financial Corp. affect First Merchants Corporation's balance sheet?,"The acquisition of MBT Financial Corp. on September 1, 2019, resulted in the issuance of approximately 6.4 million shares of common stock valued at $229.9 million, which increased the Corporation's equity. The merger led to the addition of $21,664,000 in premises and equipment to the balance sheet. Additionally, the transaction created $98,563,000 in goodwill, including a $719,000 measurement period adjustment recorded in the fourth quarter of 2019. As a result of the acquisition, the Corporation's total assets and liabilities expanded to reflect the acquired assets and assumed liabilities, with the fair value of net tangible and intangible assets being recorded at the acquisition date.","The acquisition of MBT Financial Corp. resulted in the addition of $98,563,000 of goodwill and $16,527,000 of core deposit intangibles to First Merchants Corporation's balance sheet.",4.0,0.7515347665952634,1.0,0.875,1.0
What are the key components of First Merchants Corporation's defined-benefit pension plans?,"First Merchants Corporation's defined-benefit pension plans include non-qualified plans for certain employees, former employees, and former non-employee directors. These plans cover approximately 10 percent of the Corporation’s employees. In 2005, the Board of Directors approved a curtailment of the accumulation of defined benefits for future services for certain participants, meaning no additional pension benefits have been earned by employees who had not attained both the age of 55 and accrued at least 10 years of vesting service as of March 1, 2005. The benefits are primarily based on years of service and employees’ pay near retirement. Contributions are made to cover both benefits attributed to service-to-date and those expected to be earned in the future. Additionally, the funded status of the plans is assessed at December 31, with adjustments made to the liability due to factors such as changes in discount rates.","The key components include service costs, interest costs, expected return on plan assets, amortization of prior service costs, and actuarial gains/losses.",2.5,0.3226570483515571,1.0,1.0,1.0
How does First Merchants Corporation manage its exposure to credit risk in financial instruments?,"First Merchants Corporation manages its exposure to credit risk in financial instruments by focusing on several key practices. The corporation’s counterparties are typically well-capitalized financial institutions with credit ratings at or above investment grade, and risk is controlled through quarterly financial reviews, comparison of mark-to-market values with policy limits, credit ratings, and collateral pledging. 

The corporation also has agreements with certain derivative counterparties that include provisions allowing for termination or full collateralization of derivative contracts if the corporation fails to maintain its well- or adequately capitalized status, or if it defaults on its indebtedness. As of December 31, 2020, the termination value of derivatives in a net liability position related to these agreements was $77.0 million, and collateral of $75.8 million was posted. If these provisions were breached, the corporation could be required to settle its obligations at their termination value.

Additionally, the corporation uses fair value measurements to record adjustments to certain assets and liabilities and to determine fair value disclosures. These processes help to monitor and mitigate credit risk exposure effectively.","First Merchants Corporation manages its exposure to credit risk by maintaining an allowance for loan losses, conducting regular credit quality reviews, and implementing credit policies and underwriting criteria for all loans.",4.0,0.7408492824271229,1.0,1.0,1.0
What is the primary purpose of the funds held in the trust account?,The primary purpose of the funds held in the trust account is to benefit the public stockholders of the company.,"The primary purpose of the funds held in the trust account is to be used for completing an initial business combination with a target business. If a business combination is not completed within the specified time frame, the funds are to be distributed to public stockholders.",3.0,0.7911124219320822,1.0,0.5,1.0
What are the potential risks associated with the ability of public stockholders to redeem their shares for cash?,"The potential risks associated with the ability of public stockholders to redeem their shares for cash include the possibility that if too many shareholders exercise their redemption rights, the company may not be able to meet the closing conditions required for the initial business combination, potentially preventing the transaction from proceeding. Additionally, the company cannot redeem shares in a way that would cause its net tangible assets to fall below $5,000,001 upon consummation of the business combination or any higher threshold required by the transaction agreement, which could lead to the abandonment of the combination and a need to seek an alternate target. This situation may also discourage prospective targets from entering into a business combination with the company, as they would be aware of these risks. Furthermore, since the number of shares to be redeemed is uncertain at the time of agreement, the company must structure the transaction based on expectations, which may result in suboptimal capital structure or require reserving cash from the trust account or securing third-party financing, thereby affecting financial flexibility. Finally, if stockholders fail to comply with the redemption procedures or do not receive the necessary materials, their shares may not be redeemed, leaving them unable to liquidate their investment without selling on the open market, potentially at a loss.","The potential risks include making the company's financial condition unattractive to potential business combination targets, difficulty in entering into an initial business combination with a target, and the possibility of not meeting certain closing conditions if too many public stockholders exercise their redemption rights.",4.5,0.7780691083157539,1.0,1.0,1.0
What are the implications of the company being deemed an investment company under the Investment Company Act?,"Being deemed an investment company under the Investment Company Act would impose a variety of substantive requirements that significantly impact the company’s operations. These include limitations on capital structure, restrictions on specified investments, prohibitions on transactions with affiliates, and compliance with reporting, record-keeping, voting, and proxy disclosure rules. Additionally, such designation would increase operating expenses and could lead to breaches of representations and warranties in credit and other agreements, resulting in defaults, legal actions, or regulatory proceedings. It could also result in a court-appointed receiver taking control of the business and liquidating operations. Furthermore, being classified as an investment company could negatively affect the company's financial condition, liquidity, results of operations, and ability to make distributions to shareholders.","If the company is deemed an investment company, it may be subject to burdensome compliance requirements, restrictions on the nature of its investments, and limitations on the issuance of securities, which could make it difficult to complete an initial business combination and could result in its liquidation.",5.0,0.7796311959121118,1.0,1.0,1.0
What is the primary responsibility of KeyCorp's management in relation to the financial statements?,The primary responsibility of KeyCorp's management is to maintain effective internal control over financial reporting and to assess the effectiveness of internal control over financial reporting included in the accompanying financial statements.,"KeyCorp's management is responsible for the preparation, content, and integrity of the financial statements and other statistical data compiled for the annual report.",4.0,0.8035788595580885,1.0,1.0,1.0
What is the role of the Audit Committee in KeyCorp's financial reporting process?,The provided context does not contain any information about the role of the Audit Committee in KeyCorp's financial reporting process.,"The Audit Committee meets regularly with Management, internal audit, and the independent registered public accounting firm to review the scope of their audits and discuss the evaluation of internal accounting controls and financial reporting matters.",1.0,0.36016410756107514,0.0,0.5,1.0
How does KeyCorp assess the effectiveness of its internal control over financial reporting?,"KeyCorp assesses the effectiveness of its internal control over financial reporting through a formal evaluation process that includes understanding, testing, and assessing the design and operating effectiveness of internal controls. This assessment is based on the criteria established in the Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), commonly referred to as the COSO criteria. Management is responsible for this assessment, which is included in the financial statements. The evaluation considers whether controls are operating effectively in all material respects as of the assessment date, December 31, 2020, and is supported by a report from an independent registered public accounting firm, Ernst & Young LLP, which conducted an audit in accordance with the standards of the Public Company Accounting Oversight Board (PCAOB).","KeyCorp assesses the effectiveness of its internal control over financial reporting using criteria described in ""Internal Control - Integrated Framework"" issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework).",5.0,0.8606769858802661,1.0,0.75,1.0
What was the impact of adopting ASU 2016-13 on KeyCorp's financial statements?,"The adoption of ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), resulted in a change in KeyCorp's method of accounting for credit losses in 2020. This change necessitated a reassessment of the allowance for loan and leases losses (ALLL), which was identified as a critical audit matter due to its complexity, subjective judgments involved, and significance to the financial statements. The new accounting guidance required a forward-looking approach to estimate expected credit losses, impacting the measurement and disclosure of credit risk, which influenced the financial position and results of operations.","The adoption of ASU 2016-13 resulted in a $230 million decrease in retained earnings as of January 1, 2020, net of deferred taxes of $71 million, for the cumulative effect of adopting the new accounting standard for expected credit losses.",3.0,0.5610248134614397,1.0,0.75,1.0
What is the significance of the allowance for loan and lease losses (ALLL) in KeyCorp's financial statements?,"The allowance for loan and lease losses (ALLL) is significant in KeyCorp's financial statements as it represents management’s current estimate of lifetime credit losses inherent in the loan portfolio at the balance sheet date. This allowance is crucial because it reflects the potential losses that may arise from borrowers’ failure to repay loans, and it is composed of three components: asset-specific or individual loan reserves, quantitative (formulaic or pooled) reserves, and qualitative (judgmental) reserves. The ALLL is determined using internal and external information, including past events, current economic conditions, and forecasts, and involves complex loss forecasting models and significant judgment, particularly in adjusting for economic conditions and idiosyncratic risk factors. As of December 31, 2020, the ALLL was $1.6 billion on a loan and lease portfolio of $101.2 billion, highlighting its material impact on the financial condition and performance of the company.","The ALLL represents KeyCorp's current estimate of lifetime credit losses inherent in the loan portfolio at the balance sheet date, which is a critical component in reflecting the expected credit losses in the financial statements.",4.5,0.697082395437133,1.0,1.0,1.0
How does KeyCorp manage its exposure to credit risk on derivative contracts?,"KeyCorp manages its exposure to credit risk on derivative contracts by monitoring counterparty credit risk on each contract to determine appropriate limits on total credit exposure across all product types. It reviews collateral positions daily and exchanges collateral with counterparties in accordance with standard ISDA documentation, central clearing rules, and other related agreements. Collateral is held in the form of cash and highly rated securities issued by the U.S. Treasury, government-sponsored enterprises, or GNMA. 

To mitigate risk, KeyCorp enters into bilateral collateral and master netting agreements with counterparties, particularly with broker-dealers and banks, and clears certain derivative transactions through central clearing organizations. It also uses swap execution facilities, which reduce exposure to counterparty credit risk. Additionally, certain derivative contracts include credit risk contingent features that require collateral posting when positions are in a net liability position, with amounts based on net liability, credit ratings, and thresholds defined in Credit Support Annexes. Counterparties may have the right to terminate agreements if ratings fall below specified levels. As of December 31, 2020, $30 million in cash and securities collateral was posted to cover derivative positions with credit risk contingent features.","KeyCorp mitigates credit risk on derivative contracts by entering into bilateral collateral and master netting agreements that allow for the net settlement of all contracts with a single counterparty in the event of default, and by monitoring counterparty credit risk exposure.",5.0,0.8082751064024604,1.0,1.0,1.0
What are the key components of KeyCorp's deferred tax assets and liabilities?,"KeyCorp's deferred tax assets and liabilities arise from temporary differences between book and tax reporting, including state net operating loss (NOL) carryforwards, timing differences, and adjustments related to acquisitions. As of December 31, 2020, the Corporation had approximately $19.3 million of state NOL carryforwards available to offset future state taxable income, which begin expiring in 2022. These carryforwards, combined with normal timing differences, result in total state deferred tax assets of $5.0 million. Additionally, the Corporation has restricted additional paid-in capital from acquisitions of CFS and Ameriana, approximately $13.4 million and $11.9 million respectively, which could result in deferred tax liabilities of about $5.3 million if distributions occur or if the Corporation no longer qualifies as a bank for income tax purposes.","KeyCorp's deferred tax assets and liabilities are determined based on temporary differences between financial statement asset and liability amounts and their respective tax bases, and are measured using enacted tax laws and rates expected to apply in the periods in which the deferred tax assets or liabilities are realized.",4.5,0.6921679264653166,1.0,0.875,1.0
How have the COVID-19 pandemic and government measures impacted the company's operations?,"The COVID-19 pandemic and related government measures have adversely impacted the company's operations, as well as those of its borrowers, customers, portfolio companies, and business partners. The extent of this impact depends on various uncertain factors, including the duration and scope of the pandemic, government actions to manage its financial and economic effects, travel advisories and restrictions, and disruptions to supply chains and economic activity. Government quarantine measures, travel restrictions, and precautionary actions have led to significant operational challenges, potentially causing temporary or permanent disruptions. Additionally, concerns over the health of personnel have contributed to business continuity issues. The pandemic is expected to continue having a negative effect on operations.","The COVID-19 pandemic has caused disruptions in operations, including delays in clinical trials, difficulties in patient enrollment, and potential impact on the cost and timelines of the Phase 3 program.",4.0,0.608724954528016,1.0,0.75,1.0
What are the potential risks associated with relying on third-party manufacturers for the production of ensifentrine?,"Relying on third-party manufacturers for the production of ensifentrine involves several potential risks. These include the possibility that the third parties may fail to achieve or maintain compliance with regulatory laws, regulations, and standards, which could lead to suspension of manufacturing or revocation of approvals. There is also the risk that these third parties may breach agreements due to factors beyond the company's control, such as financial difficulties or changes in business priorities, potentially leading to delays in clinical trials or harm to commercial activities. Additionally, the company is dependent on suppliers, CMOs, and other third parties for the manufacture, storage, and distribution of ensifentrine and its derived products, which means it may have limited ability to prevent, detect, or control manufacturing defects. 

Furthermore, the company does not have direct control over the process or timing of supply acquisition by these third parties, nor can it guarantee the quality or quantity of the supplies. There is currently no agreement in place for commercial production of these supplies, and interruptions could occur with no assurance of timely, cost-effective, or quality-alternative sources. The limited number of suppliers for raw materials and drug delivery devices increases the vulnerability to supply chain disruptions.

The reliance on third-party CMOs also means the company is dependent on their ability to obtain necessary regulatory approvals, provide sufficient quantities of product in a timely manner, and maintain acceptable quality and pricing. Moreover, the company has limited personnel with manufacturing experience and does not own manufacturing facilities, which could impair the advancement of research and development programs and impact commercialization efforts. Finally, the company may not be able to control the amount and timing of resources the collaborator dedicates to development, or may be required to relinquish key rights, including marketing, distribution, and intellectual property rights, if collaboration agreements are entered into.","Risks include potential delays in supply, quality control issues, and the possibility of third-party manufacturers failing to comply with regulatory requirements, which could delay or prevent the commercialization of ensifentrine.",4.5,0.8524391114640535,1.0,1.0,1.0
How did the COVID-19 pandemic affect South State Corporation's operations and financial results in 2020?,The provided context does not contain information about the impact of the COVID-19 pandemic on South State Corporation's operations or financial results in 2020.,"The COVID-19 pandemic led to increased provisions for credit losses, changes in customer behavior affecting deposit and loan activities, and operational challenges such as branch closures and remote work setups, which collectively impacted financial results and operational efficiency in 2020.",1.0,0.3948644226830334,1.0,0.75,1.0
What measures did South State Corporation implement in response to the COVID-19 pandemic to support its customers and maintain operational continuity?,"South State Corporation implemented several measures in response to the COVID-19 pandemic to support its customers and maintain operational continuity. In March 2020, the company closed all banking lobbies and shifted to conducting most business through drive-thru tellers and electronic and online platforms. To ensure employee safety, a majority of non-customer-facing staff were allowed to work from home. In October 2020, banking lobbies were reopened at branch locations, but many support staff continued to work remotely.

To assist customers, loan payment deferrals were offered for 90 to 180 days for both consumer and commercial customers. For those directly impacted by the pandemic, the company suspended foreclosure sales, evictions, and involuntary automobile repossessions and provided fee waivers, payment deferrals, and other expanded assistance for various lending products. As of December 31, 2020, $255.2 million in loan deferrals were in place, representing 1.12% of the total loan portfolio, excluding loans held for sale and PPP loans.

For commercial loans, deferral options included 90 days for both principal and interest, 120 days of principal only, or 180 days of interest only. For consumer and mortgage loans, the standard deferral was 120 days of both principal and interest or 180 days of interest only.

Additionally, the company adapted to changing consumer behaviors by closing 26 branch locations temporarily and four permanently in November 2020, while reopening 18 temporarily closed branches since June 2020. To ensure operational continuity, a redundant operations center was established for administrative functions. The company also continued to provide services across Hawaii, Guam, and Saipan, despite reduced customer traffic due to stay-at-home orders.","South State Corporation implemented loan modification programs, payment deferrals, and fee waivers for affected customers. Internally, the bank closed banking lobbies, moved to drive-thru and online services, and allowed non-customer-facing employees to work from home to ensure operational continuity.",5.0,0.7816331449002712,1.0,1.0,1.0
"How did South State Corporation's capital adequacy ratios change post-merger with CSFL, and what factors influenced these changes?","Post-merger with CSFL, South State Corporation's capital adequacy ratios experienced a decline. The Tier 1 leverage ratio and the Tier 1 risk-based capital ratio both decreased compared to December 31, 2019. This decline was primarily due to the merger with CSFL, which led to a greater percentage increase in average assets for regulatory capital purposes and risk-based weighted assets than the increase in Tier 1 risk-based capital. At the holding company level, the decline was more pronounced because of the removal of $115.0 million in trust preferred debt from Tier 1 capital, a result of the merger, and the Company's asset base exceeding $15.0 billion. Additionally, the repurchase of 320,000 shares of common stock at a cost of $24.7 million, a common stock dividend of $98.3 million, and a $44.8 million reduction in retained earnings from an accounting principle change contributed to the reduction in Tier 1 risk-based capital. Despite these changes, the capital ratios remained well above minimum regulatory standards, maintaining the ""well capitalized"" classification.","Post-merger, South State Corporation's capital ratios, particularly the Tier 1 leverage ratio and Tier 1 risk-based capital ratio, decreased due to the significant increase in assets and risk-weighted assets. However, the total risk-based capital ratio increased, influenced by the inclusion of additional Tier 2 capital from subordinated debt and trust preferred securities acquired through the merger.",4.5,0.8282532533723526,1.0,1.0,1.0
How did the merger with CenterState Bank Corporation (CSFL) impact South State Corporation's loan portfolio at the time of acquisition?,"The merger with CenterState Bank Corporation (CSFL) resulted in South State Corporation acquiring $13.0 billion of loans at fair value, net of a $239.5 million discount, representing a 1.82% estimated discount to the outstanding principal balance. The acquisition involved the application of purchase accounting, with loans segmented into those exhibiting evidence of credit deterioration (PCD loans) and performing loans at the time of the merger.","The merger with CSFL resulted in South State Corporation acquiring $13.0 billion of loans, including PPP loans, at fair value, net of $239.5 million, or 1.82%, estimated discount to the outstanding principal balance, representing 113.9% of the Company’s total loans at December 31, 2019.",4.0,0.8864801596280095,1.0,0.875,1.0
What was the impact of the COVID-19 pandemic on South State Corporation's evaluation of goodwill for impairment in 2020?,"The COVID-19 pandemic led South State Corporation to assess the economic impact and market conditions during 2020, particularly at March 31, June 30, and September 30, 2020. These assessments included evaluating the general uncertainty regarding the extent of the pandemic and its effects on economic recovery. Despite the decline in market capitalization and share price due to the pandemic, the Corporation concluded that goodwill was not impaired during those periods. The annual goodwill impairment test conducted as of October 1, 2020, incorporated various valuation considerations, including comparable peer data, precedent transaction comparables, discounted cash flow analysis, financial performance, and share price, resulting in the determination that the fair value of the Corporation had not declined below its carrying value. Additionally, the subsequent increase in the stock price in December 2020, which remained above carrying value, supported the conclusion that the earlier decline was temporary and not indicative of impairment.","South State Corporation evaluated the carrying value of goodwill as of April 30, 2020, considering the effects of COVID-19, and obtained a third-party valuation during the fourth quarter of 2020, concluding that no impairment charge was necessary.",4.0,0.6960352788702221,1.0,1.0,1.0
What are the potential consequences of the company's failure to maintain REIT qualification?,"If the company fails to maintain REIT qualification, it would be subject to corporate-level income taxes, including applicable state and local taxes, on all of its taxable income at federal and state tax rates. Distributions to shareholders would not be deductible in computing the company's taxable income. This could result in substantial corporate tax liability, reducing the amount of cash available for distribution to shareholders and potentially adversely impacting the value of the company's common shares. Additionally, unless relief is granted under certain Internal Revenue Code provisions, the company would be disqualified from REIT taxation for the four taxable years following the year it ceased to qualify. The company may also face increased tax burdens due to taxes on undistributed income, income from activities like foreclosures, and various state or local taxes, all of which would further decrease cash available for distribution.","If the company fails to maintain its REIT qualification, it would be subject to corporate-level income taxes on all of its taxable income, which would significantly reduce the amount of cash available for distribution to shareholders. This could negatively affect the value of its common shares and the sustainability of its business model.",5.0,0.9201649892668178,1.0,1.0,1.0
How does the company mitigate interest rate risk and what are the potential drawbacks of its hedging strategies?,"The company mitigates interest rate risk by using derivatives such as financial forwards, futures contracts, options, and interest rate swap contracts. These instruments are employed to manage interest rate risk within the loan portfolio and to hedge the value of mortgage servicing rights and mortgage pipelines. The company also enters into interest rate swaps with commercial banking customers to support their risk management strategies, which are then hedged by offsetting swaps with third parties to minimize net risk exposure. Additionally, derivatives are used to change the repricing characteristics of assets and liabilities, hedge mark-to-market sensitivity, offset embedded options, and manage yield variability of anticipated transactions. These activities are guided by risk management policies and procedures aligned with regulatory requirements.

However, hedging strategies come with potential drawbacks. Hedging instruments often lack regulation, exchange guarantees, or oversight, increasing counterparty risk. The cost of interest rate hedging can be high, especially during periods of rising or volatile rates. There may be a mismatch between the duration of the hedge and the underlying asset or liability, and the hedging instruments may not perfectly correspond to the interest rate risk being mitigated. Credit quality of the counterparty may deteriorate, impairing the ability to sell or assign the hedging transaction, and there is a risk of default by the counterparty. Furthermore, any failure to efficiently execute, re-calculate, or adjust hedges may result in adverse effects on results of operations and cash flows. A liquid secondary market may not exist, leading to potential losses if positions must be held until expiration. Changes in interest rates could result in worse investment performance than if no hedging were undertaken. Additionally, changes in the fair value of derivatives, particularly those not meeting hedge accounting requirements, are recognized in earnings, increasing financial volatility.","The company uses derivative financial instruments, such as swaps, options, and futures, to hedge against interest rate risk. However, these hedging activities can be expensive, may not perfectly correlate with the risks being hedged, and could result in worse overall investment performance if unanticipated changes in interest rates occur.",5.0,0.7554703368488624,1.0,0.875,1.0
What are the cybersecurity risks the company faces and how could they impact its operations?,"The company faces cybersecurity risks including cyberattacks, unauthorized access, data breaches, and disruptions to information technology systems. These risks stem from both internal and external threats, such as malicious code, insider threats, phishing scams, and sophisticated nation-state actors. The company also relies heavily on computer systems for business operations, making it vulnerable to disruptions that could impair its ability to communicate, conduct business, or maintain data integrity and confidentiality.

Potential impacts on operations include financial losses, regulatory penalties, litigation, reputational damage, and client dissatisfaction. A breach could lead to the exposure of sensitive personal data, trade secrets, or proprietary information, damaging the company's reputation and leading to liability. Additionally, if systems become inoperable due to compromised security measures or failure of disaster recovery systems, the company may experience prolonged operational disruptions, affecting its ability to serve customers. These events could also result in increased costs associated with remediation and damage control.","The company faces risks of cyber incidents, including unauthorized access, data breaches, and system disruptions. These could lead to compromised confidential information, operational disruptions, financial losses, litigation, and damage to business relationships, all of which could negatively impact its financial results and reputation.",5.0,0.6868461091013972,1.0,1.0,1.0
"What is the primary investment objective of Barings BDC, Inc.?","The primary investment objective of Barings BDC, Inc. is to generate current income by investing directly in privately-held middle-market companies to help these companies fund acquisitions, growth, or refinancing.","The primary investment objective of Barings BDC, Inc. is to generate current income by investing directly in privately-held middle-market companies to help these companies fund acquisitions, growth, or refinancing.",5.0,1.0,1.0,1.0,1.0
"What was the total amount of new commitments made by Barings BDC, Inc. subsequent to December 31, 2020?","The provided context does not contain information about new commitments made by Barings BDC, Inc. after December 31, 2020. The documents only detail financial activities and investments up to and including the year ended December 31, 2020, with no data extending beyond that date. Therefore, it is not possible to determine the total amount of new commitments made after December 31, 2020 based on the given information.","Subsequent to December 31, 2020, the Company made approximately $224.1 million of new commitments, of which $202.2 million closed and funded.",1.0,0.5515368177879663,1.0,1.0,1.0
How did the Company account for the COVID-19 pandemic in its financial statements?,"The Company accounted for the COVID-19 pandemic in its financial statements by recognizing pandemic pay costs in Costs of goods sold and accruing a pandemic pay liability in Other accrued liabilities, amounting to $4.8 million in the fiscal year ended March 31, 2020. Additionally, lease concessions related to the effects of the pandemic were accounted for as though enforceable rights and obligations existed, reflected within variable rent expense, provided the total payments under the modified contract were substantially the same as or less than the original. The Company also considered potential impacts on asset impairments, receivables collectability, fair value disclosures, and internal controls, but determined there was no triggering event for impairment or adverse change in collectability during the year ended December 31, 2020. The impact of the pandemic on financial results remains uncertain and could be material in future periods.","The Company temporarily closed its retail locations due to the COVID-19 pandemic, which it expects to have an unfavorable impact on its sales, results of operations, and cash flows in fiscal 2020.",5.0,0.5383732475247283,1.0,0.875,1.0
What was the impact of the adoption of the new lease accounting standard (ASUs) on the Company’s consolidated balance sheet?,"The adoption of the new lease accounting standard resulted in the recognition of right-of-use assets and lease liabilities on the consolidated balance sheet for leases previously classified as operating leases. This change increased transparency and comparability by requiring lessees to recognize these items on the balance sheet, with the right-of-use asset representing the lessee's right to use the leased asset and the lease liability representing the present value of future lease payments. The transition was applied using a modified retrospective approach, with no restatement of comparative periods, and the impact on the consolidated financial statements was not material.","The adoption of the ASUs resulted in the recognition of lease right-of-use assets and corresponding lease liabilities, as well as adjustments to opening retained earnings and other balance sheet items.",5.0,0.7115809296115928,1.0,1.0,1.0
What were the key factors considered by the Company in determining the fair value of its reporting units for impairment testing?,"The Company considered several key factors in determining the fair value of its reporting units for impairment testing. These included the use of either a discounted cash flows analysis or a market approach to calculate fair value. The discounted cash flows analysis involved unobservable inputs such as forecasts of expected future cash flows, long-term growth rates, discount rates commensurate with economic risks, assumed income tax rates, and estimates of capital expenditures and working capital. The discount rate used reflected a weighted average cost of capital plus an appropriate risk premium based on the reporting unit being valued. Additionally, the Company considered publicly available information regarding its market capitalization, financial projections, future prospects, growth opportunities, operational improvements, and comparable sales prices if available. The assumptions and estimates used were based on the best available information and reflected common valuation practices.","The Company considered factors such as revenues, expenses, fixed asset and working capital requirements, the impact of updated tax legislation, and other subjective inputs in determining the fair value of its reporting units.",4.5,0.608762676577139,1.0,1.0,1.0
How has the COVID-19 pandemic impacted the company's operations and financial outlook for fiscal 2020?,"The COVID-19 pandemic has impacted the company's operations by disrupting business activities due to the spread of the disease and government-mandated shutdowns, leading to temporary measures such as remote work and reduced in-person meetings. These disruptions have contributed to adverse effects on global economic conditions, which may negatively affect the company's financial condition and ability to secure financings. While the full extent of the impact on fiscal 2020 is uncertain, the pandemic has already had an adverse effect on operations and is expected to continue affecting the business, including its financial outlook, due to ongoing uncertainties related to the duration, scope, and containment measures of the pandemic.","The COVID-19 pandemic has significantly disrupted the company's operations, leading to temporary store closures and substantial uncertainty about the timing and manner of returning to normal business operations. The company has withdrawn all prior guidance and outlook statements for fiscal 2020 due to the unpredictable nature of the pandemic's impact.",4.0,0.6946529582803211,1.0,0.75,1.0
What are the key strategies the company is focusing on to drive growth in its business?,"The company is focusing on several key strategies to drive growth in its business. These include expanding operations in international markets outside the United States, although this comes with challenges due to limited experience in foreign marketing, sales, and support. The company is also pursuing growth through acquisitions, licenses, investments, and other commercial arrangements in companies or technologies, as demonstrated by past acquisitions such as NuTech Medical and CPN Biosciences. Additionally, the company is investing in the expansion of its IT infrastructure, financial and accounting systems, and controls to manage rapid operational growth. It is also emphasizing the need to attract, train, and retain qualified personnel, particularly in areas like software engineering, sales, marketing, customer support, and management. Furthermore, the company is working to scale its capabilities to meet increasing demand, especially in telehealth, and to effectively implement solutions for large and demanding clients.","The company is focusing on several key strategies to drive growth, including transforming its real estate platform, pursuing international expansion, expanding its merchandise assortment and market share, growing its integrated hospitality experience, and architecting a new operating platform to enhance customer experience and operational efficiency.",4.0,0.6036122342011377,1.0,0.875,1.0
How does the company assess the performance of its business?,"The company assesses the performance of its business by evaluating management’s identification of reporting units, considering components of its operating segments, the availability of discrete financial information that is regularly reviewed by management, and the suitability of aggregating components. Additionally, the company evaluates the reasonableness of management’s forecasts by comparing them to historical results, internal communications, press releases, analyst and industry reports, and by analyzing and comparing forecasts to the Company’s revenue backlog and sales pipeline. The impact of changes in these forecasts on impairment test dates during the fiscal year is also evaluated. Furthermore, the company assesses fair value factors such as discount rates, performance-metric multiples, and reconciles the fair value of reporting units to the Company’s market capitalization, with assistance from fair value specialists.","The company assesses the performance of its business using various financial and operating measures, including net revenues, gross profit, selling, general, and administrative expenses, adjusted operating income, adjusted EBITDA, and adjusted net income. These measures help the company evaluate its operating performance consistently over time.",3.0,0.5413088817090259,1.0,0.75,1.0
"What are the company's primary sources of liquidity, and how has the COVID-19 crisis affected its liquidity position?","The company's primary sources of liquidity include cash flow from operations, access to debt and equity capital, and the ability to raise funds through offerings of securities, borrowing additional capital, selling assets, or adjusting dividend practices. The COVID-19 crisis has adversely affected the company's liquidity position by creating uncertainties in financial markets, disrupting access to capital, increasing liquidity needs, and reducing the ability to manage debt obligations. The pandemic has also led to a general decline in business activity and demand for real estate-related transactions, further impacting the company’s ability to source investments and redeploy proceeds from repayments. Additionally, store closures and operational difficulties have negatively affected financial condition, while the effectiveness of government interventions like the CARES Act remains uncertain. As a result, the company is focusing on preserving and building liquidity to address potential challenges.","The company's primary sources of liquidity are cash flows from operations, net cash proceeds from the issuance of convertible senior notes, and borrowings under its credit facilities. The COVID-19 crisis has introduced significant uncertainty regarding the company's liquidity requirements and has prompted the company to implement cost-saving measures and negotiate with lenders and landlords to preserve financial flexibility.",4.5,0.7766248248656344,1.0,1.0,1.0
"How has the company's approach to real estate transformation evolved, and what impact has it had on the business?","The company's approach to real estate transformation has evolved from a legacy retail footprint to a portfolio of Design Galleries tailored to the potential of each market and the size of its assortment. This shift has allowed the company to develop a new multi-tier market approach that optimizes market share and return on invested capital. A key development in this evolution is the creation of a new RH prototype Design Gallery, which serves as an innovative and flexible blueprint. This prototype enables the company to more quickly introduce its disruptive product assortment and immersive retail experience into new markets. The transformation has also led to the inclusion of integrated amenities such as restaurants, wine vaults, and barista bars in several Design Galleries, enhancing the customer experience. Overall, this strategic evolution supports the company’s goal of significantly increasing sales through targeted and scalable real estate development.","The company has evolved its real estate approach by adopting a multi-tier market strategy, including the development of prototype Design Galleries, larger Bespoke Design Galleries in top metropolitan markets, indigenous Bespoke Galleries in second home markets, and smaller Galleries in secondary markets. This strategy aims to optimize market share and return on invested capital, with recent openings showing positive results in terms of profitability and brand statement.",5.0,0.6961022626719134,1.0,0.875,1.0
What are the risks associated with the company's reliance on third-party manufacturers for the production of its product candidates?,"The company faces several risks due to its reliance on third-party manufacturers for the production of its product candidates. If these third parties stop providing quality manufacturing and related services and suitable replacements cannot be secured in a timely manner, the company’s ability to manufacture products or product candidates in sufficient quality and quantity for commercial, pre-clinical, clinical, or expanded access programs would be negatively impacted. This could hinder various research, development, and commercialization efforts.

Any issues in the manufacturing process or problems at the contracted facilities can make the company a less attractive collaborator for potential partners, including large pharmaceutical companies and academic institutions, which may limit access to additional development programs. Additionally, such problems restrict the company's ability to meet market demand.

Given the limited number of third parties with the expertise required to produce the products and candidates, and considering the lead time and material availability, the company may not be able to establish or maintain sufficient manufacturing arrangements on commercially reasonable terms. Furthermore, obtaining the significant financial capital needed for such arrangements may also be challenging.

Even after engaging third parties, there is no guarantee that these manufacturers will comply with agreed terms and timelines, which could impact the company's ability to execute business plans on expected schedules. Long-term agreements with exclusivity provisions or substantial termination penalties further limit operational flexibility.

A significant outbreak of COVID-19 at a partner site could cause delays in manufacturing. The company has not secured alternate suppliers, so if the current manufacturer is unable to meet demand or problems occur, and alternative sources cannot be arranged promptly or on commercially reasonable terms, the company may be unable to complete product candidate development or effectively market and distribute them.

Relying on third-party manufacturers also introduces risks such as dependence on the third party for regulatory compliance and quality assurance, the possibility of breach of agreement due to factors beyond the company's control—including failure to manufacture according to specifications—and the risk of termination or nonrenewal of agreements based on the third party’s business priorities. The FDA and other regulatory authorities require products to be manufactured under cGMP and similar standards, necessitating ongoing compliance, registration, and periodic inspections. Changes to manufacturing processes require regulatory approval, and deviations from cGMP must be investigated and corrected, imposing reporting and documentation requirements on both the company and its third-party manufacturers.","The risks include potential delays in manufacturing, quality control issues, and the possibility of the third-party manufacturer failing to meet demand or terminating the relationship, which could impact the company's ability to supply its product candidates for clinical trials or commercialization.",4.5,0.7368351445147081,1.0,1.0,1.0
What are the provisions in the company's corporate charter that could potentially discourage a takeover?,"The company's corporate charter includes provisions that may make it difficult for a third-party to obtain control. These include classifying the Board into three classes with staggered three-year terms, authorizing the Board to classify or reclassify shares of stock into one or more classes or series, allowing the issuance of additional shares, enabling amendments to the charter without stockholder approval, and permitting adjustments to the number of shares the company is authorized to issue. These provisions, along with other charter and bylaw provisions, may delay, defer, or prevent a transaction or change in control.","The company's corporate charter includes provisions such as a classified board of directors, advance notice requirements for stockholder proposals, and a requirement for a supermajority vote to amend certain provisions, which could make a takeover more difficult.",4.5,0.8476163614010489,1.0,1.0,1.0
What is the significance of the company's exclusive forum provision in its certificate of incorporation?,"The company's exclusive forum provision in its certificate of incorporation designates specific courts as the sole and exclusive forums for certain litigation initiated by stockholders. For most claims brought by stockholders, the Court of Chancery of the State of Delaware is the exclusive forum, unless the company consents in writing to an alternative forum. Additionally, the federal district courts of the United States are the exclusive forum for claims arising under the Securities Act. These provisions are intended to provide greater consistency in the application of Delaware law and federal securities laws by judges and chancellors experienced in corporate and securities matters, enable more efficient case administration on an expedited schedule, and reduce the burden of multi-forum litigation. However, the provisions may also discourage lawsuits against directors and officers, and their enforceability has been challenged in legal proceedings, with the possibility that courts may find them inapplicable or unenforceable in certain situations.","The exclusive forum provision designates the Court of Chancery of the State of Delaware as the sole forum for certain types of actions and disputes between the company and its stockholders, which could limit stockholders' ability to choose a preferred judicial forum for such disputes.",5.0,0.8354792320599796,1.0,1.0,1.0
What are the potential financial and operational impacts of the company becoming involved in securities class action litigation?,"Securities class action litigation could lead to substantial costs, including significant legal fees and other expenses. It may also divert management’s and the Board’s attention and resources away from business operations, potentially harming the company's performance. Such litigation could result in perceived uncertainties about the company’s future, negatively affecting relationships with service providers and making it harder to attract and retain qualified personnel. Additionally, the company's stock price could experience significant fluctuations or be adversely affected by the events and uncertainties surrounding the litigation.","Securities class action litigation could be expensive, divert management's attention and resources, and adversely affect the company's business and financial condition. Insurance coverage may not be sufficient to cover all costs and damages.",4.5,0.8671903563887013,1.0,0.875,1.0
What are the principal risks related to the economy that could negatively affect the company's portfolio companies and results of operations?,"Unfavorable economic conditions could increase funding costs, limit access to capital markets, and lead to lenders refusing to extend credit, which may hinder investment growth and harm operating results. Adverse economic conditions may also reduce the demand for and value of intellectual property held by portfolio companies, potentially impairing the company's ability to recover loan amounts in the event of bankruptcy or foreclosure. Additionally, portfolio companies may struggle to repay or refinance debt at maturity, especially if loan agreements do not require principal repayment prior to maturity. Rising interest rates increase the risk of default, as portfolio companies may be unable to meet escalating interest payments, potentially triggering defaults and cross-defaults under other agreements. Furthermore, political and economic instability in countries where portfolio companies operate, as well as disruptions from natural disasters, public health concerns, or political unrest, could negatively impact their business, financial condition, and results of operations.","The principal risks include public health crises, economic recessions, capital market disruptions, and the inability to obtain additional capital due to regulatory or market constraints.",4.5,0.5935633516659098,1.0,1.0,1.0
"What specific risks are associated with the company's subsidiary, NSBF, being an SBLC licensed by the SBA?","The specific risks associated with NSBF being an SBLC licensed by the SBA include the potential adverse impact on results of operations if NSBF fails to maintain its PLP status or its SBA 7(a) license. Loss of PLP status would negatively affect marketing efforts and loan origination volume, reducing servicing spreads and earned premiums. Additionally, there is no assurance that NSBF will be able to maintain its current status or license, which could lead to a decline in the volume and profitability of government guaranteed loans. Furthermore, loans under the Section 7(a) Loan Program carry a high risk of default, which could also adversely affect results of operations.","NSBF must maintain minimum regulatory capital and comply with SBA regulations, including potential liability for SBA guaranty denials or repairs, which could transfer liability to NSBF.",4.0,0.6857808959131179,1.0,0.875,1.0
"How does the company plan to maintain its tax treatment as a RIC, and what are the potential consequences of failure?","The company plans to maintain its tax treatment as a RIC by complying with the requirements set forth in Subchapter M of the Internal Revenue Code, including meeting the source of income, asset diversification, and annual distribution requirements. To ensure compliance, the company must obtain at least 90% of its income from dividends, interest, and gains from the sale of securities or similar sources, and it must meet certain asset diversification criteria at the end of each quarter. Additionally, the company must distribute at least 90% of its net ordinary income and net short-term capital gains annually to stockholders.

Failure to qualify for or maintain RIC tax treatment could result in the company being subject to corporate-level income tax, which would reduce net assets, limit the amount of income available for distribution to stockholders, and decrease the actual amount of distributions. Such a failure could have a material adverse effect on the company’s financial condition, net asset value, and the total return to investors. Furthermore, to preserve RIC status, the company may need to sell investments at disadvantageous prices, raise additional debt or equity capital, or forgo new investment opportunities, which could negatively impact operations and financial performance.","To maintain RIC status, the company must meet source-of-income, asset diversification, and distribution requirements. Failure could subject the company to corporate-level income tax, reducing net assets and available income for distribution.",5.0,0.8494180625834787,1.0,0.875,1.0
What are the risks related to the company's investments in technology-related companies?,"The company's investments in technology-related companies are subject to several risks. These include volatility, intense competition, shortened product life cycles, changes in regulatory and governmental programs, and periodic downturns, which could result in the loss of all or part of an investment. Many of these companies have narrow product lines and small market shares, making them more vulnerable to competitive actions and market conditions, as well as general economic downturns. Revenues, income, and valuations of such companies can fluctuate suddenly and dramatically due to abrupt business cycles and intense competition. Overcapacity and cyclical economic downturns may lead to substantial decreases in market capitalization, which could be significant and not temporary. Additionally, rapid technological change often results in decreasing average selling prices for products and services, potentially adversely affecting operating results, debt obligations, and equity valuations. These factors could materially impact the company's business, financial condition, and results of operations. Investments in sustainable and renewable technology companies also carry operational risks, such as underestimated cost projections, unanticipated maintenance expenses, loss of government subsidies, and challenges in delivering cost-effective energy solutions compared to traditional options. Furthermore, the company's investments are concentrated in certain industries, with a significant portion of its portfolio in the Software, Drug Discovery & Development, and Internet Consumer & Business Services sectors, exposing it to greater risk if any of these sectors experience a downturn.","Risks include potential obsolescence of intellectual property, equipment, and inventory due to technological advancements, which could impair the collateral value of loans made to these companies.",5.0,0.5363552424397867,1.0,1.0,1.0
How does the company's status as a BDC affect its ability to raise additional capital and the way it does so?,"The company's status as a Business Development Company (BDC) affects its ability to raise additional capital and the manner in which it does so through various regulatory constraints and requirements. As a BDC, the company is subject to the Investment Company Act of 1940 (the 1940 Act), which limits its ability to raise capital by restricting the amount of senior securities—such as debt securities, preferred stock, or borrowings from banks—that it can issue. Specifically, the company is permitted to issue senior securities up to a level where its asset coverage ratio, as defined by the 1940 Act, remains at least 150% of gross assets less all liabilities and indebtedness not represented by senior securities after each issuance. This requirement can pose challenges if the value of the company's assets declines, as it may then be unable to meet the coverage ratio, potentially forcing the company to sell investments or repay debt under disadvantageous conditions. Additionally, raising capital may expose the company to typical leverage risks, which can impact its financial stability. The company must also ensure compliance with other 1940 Act requirements, such as investing at least 70% of its gross assets in specified securities, and failure to comply could result in enforcement actions or loss of BDC status, leading to greater regulatory scrutiny. Furthermore, the company is generally prohibited from issuing common stock below net asset value per share, which can limit its capital-raising options. These factors collectively influence the company's strategies and flexibility in securing additional capital.","As a BDC, the company is subject to restrictions on issuing common stock below net asset value and must maintain an asset coverage ratio for senior securities. These constraints affect its capital raising flexibility and methods.",5.0,0.7744220009862225,1.0,1.0,1.0
How does Newtek Business Services Corp. determine the fair value of its investments?,"Newtek Business Services Corp. determines the fair value of its investments by applying fair value accounting in accordance with ASC Topic 820 - Fair Value Measurement. The company categorizes its financial instruments carried at fair value into a three-level fair value hierarchy based on the priority of the valuation technique. The determination considers observable inputs such as market assumptions, and when such inputs are not readily available, the company uses its own assumptions reflecting those management believes market participants would use. The level of judgment is greatest for financial instruments classified as Level 3 due to less observable or unobservable inputs. Any changes to the valuation methodology are reviewed by management and the Board for appropriateness.","Newtek Business Services Corp. determines the fair value of its investments using unobservable inputs and assumptions, classifying them as Level 3 within the fair value hierarchy. This involves significant judgments about valuation methodologies and inputs such as revenue and EBITDA multiples, market yields, discounts for lack of marketability, underlying cash flows, and the impact of economic conditions.",4.0,0.9089690769820098,1.0,1.0,1.0
What critical audit matter was communicated regarding the valuation of investments?,"The critical audit matter communicated was the valuation of level 3 investments in the valuation hierarchy, which involved significant judgment by management due to the use of unobservable inputs and pricing models. This led to a high degree of auditor subjectivity and judgment, requiring specialized professionals to assist in the procedures and evaluation of evidence. The audit included testing controls over the valuation process, obtaining independent pricing for a sample of securities, and developing an independent range of prices for comparison with management’s estimates.","The critical audit matter communicated was the valuation of investments, which involves judgments necessary for management to select and apply valuation techniques and assumptions, the high degree of auditor judgment involved, and the extensive audit effort involved in testing the valuations.",4.5,0.862982939461812,1.0,1.0,1.0
What is the total principal amount of PPP loans funded by NSBF during the duration of the PPP?,$1.19 billion,"NSBF funded approximately 10,570 PPP loans totaling $1.19 billion during the duration of the PPP.",3.0,0.5179299934056683,1.0,1.0,1.0
How does the CARES Act affect existing SBA 7(a) borrowers?,"The CARES Act provides subsidies to certain existing SBA 7(a) borrowers by having the SBA pay all principal, interest, and fees on existing performing SBA 7(a) loans for six months, beginning with the borrowers' April 2020 payments.","The CARES Act provided an over $2.0 trillion stimulus package, including subsidies to certain existing SBA 7(a) borrowers where the SBA paid all principal, interest, and fees on existing performing SBA 7(a) loans for six months beginning with such borrowers’ April 2020 payments.",5.0,0.942627201260682,1.0,1.0,1.0
How does Newtek Business Services Corp. account for its equity-based compensation plan?,"Newtek Business Services Corp. accounts for its equity-based compensation plan by recognizing the fair value of all stock-based payments to employees and directors in its financial statements. The fair value of service-based stock option awards is estimated on the grant date using a Black-Scholes-Merton valuation model, while awards with market conditions are valued using a Monte Carlo simulation model. The fair value of restricted stock units (RSUs), including performance-based RSUs, is determined on the grant date based on the closing price of the company's stock. Compensation expense is recorded net of estimated forfeitures and is recognized over the requisite service period. The company uses the straight-line method for service-based stock options and RSUs, and a graded-vesting method for market performance-based stock options and performance-based RSUs. The expense is included in salaries and benefits in the consolidated statements of comprehensive income.","Newtek Business Services Corp. accounts for its equity-based compensation plan using the fair value method, as prescribed by ASC 718. For restricted stock awards, the Company measures the grant date fair value based upon the market price of its common stock on the date of the grant and amortizes this fair value to salaries and benefits over the requisite service period.",4.5,0.8281002365101355,1.0,1.0,1.0
How does Fusion plan to address the risk of third-party claims of intellectual property infringement?,"Fusion plans to address the risk of third-party claims of intellectual property infringement by defending against such claims through litigation if necessary. While the company may attempt to resolve disputes through license agreements, which could involve paying royalties and fees, there is no guarantee that licenses will be available on commercially reasonable terms or at all. Fusion also relies on agreements with employees and contractors to assign intellectual property rights to the company, though enforcement of these agreements may require legal action. Additionally, Fusion may face significant costs, distraction of management, and potential operational disruptions if litigation occurs, and the uncertainty surrounding these claims could impact the company's financial condition and prospects.","Fusion plans to manage this risk by ensuring compliance with patent laws and regulations, potentially obtaining licenses when necessary, and defending against any claims through legal proceedings if needed.",4.5,0.716715077777162,1.0,0.875,1.0
How does Fusion mitigate the risk of product liability claims?,"Fusion mitigates the risk of product liability claims through the use of product liability insurance, which is considered adequate for its needs. The company also has internal procedures in place to minimize risks related to quality issues with its products and third-party components. Additionally, Fusion manages risks associated with production through adherence to strict company and government standards for manufacturing and storage, as well as by maintaining control over specialized facilities and raw materials. However, the insurance is subject to deductibles and coverage limits, and there is a risk that claims could exceed coverage or be excluded from policy terms. Fusion also acknowledges the potential for claims to occur during preclinical and clinical testing and upon commercialization, and it must ensure it has sufficient insurance to support product development and commercialization.","Fusion mitigates this risk by maintaining product liability insurance, ensuring strict quality control in manufacturing, and adhering to regulatory standards in the development and marketing of its products.",4.0,0.7690394031085801,1.0,0.75,1.0
What is the primary focus of the company's business?,"The primary focus of the company's business is providing comprehensive waste management environmental services across North America, including collection, transfer, disposal, recycling, and resource recovery. The company also develops, operates, and owns landfill gas-to-energy facilities, contributing to the creation of clean, renewable energy.","The company is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, particularly through its Targeted Alpha Therapies (TAT) platform.",1.0,0.3928329635057763,1.0,0.875,1.0
"What strategic collaboration has the company entered into, and what are the key terms of this collaboration?","The company has entered into a strategic collaboration agreement with AstraZeneca. Under this agreement, the two parties will jointly discover, develop, and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for cancer treatment globally. The collaboration leverages the company's TATs platform and expertise in radiopharmaceuticals alongside AstraZeneca’s portfolio of antibodies and cancer therapeutics, including DDRis. Each party retains full ownership of its existing assets.

For novel TATs, the company will use its Fast-Clear linker technology to bind the alpha-emitting isotope Actinium-225 to specific antibodies from AstraZeneca’s oncology portfolio. The parties may develop up to three novel TATs. The company will lead preclinical development and clinical studies for safety (Stage 1 Development), while AstraZeneca will handle subsequent clinical development (Stage 2 Development). Development costs will be shared equally, with each party responsible for its own supply costs. Either party can opt out of the co-development and co-commercialization arrangement at predetermined timepoints, obtaining exclusive rights to a novel TAT in exchange for milestone payments of up to $145.0 million and royalty payments on future sales, depending on the timing of the opt-out.

The company received an upfront payment of $5.0 million and is eligible for up to $40.0 million in future payments, including clinical milestones. The agreement includes exclusivity provisions, where after target selection and payment of an exclusivity fee by AstraZeneca, the company will not conduct preclinical or clinical studies combining its TAT platform with the same combination target during the evaluation period. AstraZeneca has the exclusive right to further clinical or preclinical combination studies within a specified time after initiation of the evaluation period by paying exclusivity fees.

The agreement expires on a TAT-by-TAT and combination-by-combination basis, either upon the expiration of development and exclusivity obligations or upon the expiration of the commercial life of a product if commercialized. Both parties may terminate the agreement for the other’s uncured material breach, or for reasons such as commercial viability or material safety concerns related to a specific TAT or combination product.","The company has entered into a strategic collaboration agreement with AstraZeneca to jointly discover, develop, and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The collaboration leverages Fusion’s TATs platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio of antibodies and cancer therapeutics, including DDRis. Both companies will retain full rights to their respective assets.",5.0,0.7407005683510137,1.0,1.0,1.0
How does the company plan to address the potential for reduced profitability due to government and third-party payor reimbursement policies?,"The company acknowledges the challenges posed by potential reductions in reimbursement from government programs like Medicare and Medicaid, as well as from private payors, which may result from cost containment measures, healthcare reforms, or pricing regulations. These factors could limit revenue, impact profitability, and affect the commercialization of its product candidates. The company recognizes that there is no uniform reimbursement policy across payors, and coverage decisions vary significantly, requiring time-consuming and costly support efforts for each payor. In addition, the company faces risks from legislative and regulatory changes, including increased scrutiny of pricing, post-approval requirements, and restrictions on promotional activities. To mitigate these risks, the company intends to provide scientific and clinical support to secure coverage and reimbursement for its products, although it cannot assure consistent or timely approvals. It also recognizes that private payors may follow government program reimbursement reductions, and that regulatory and pricing pressures, both domestically and internationally, could further impact financial performance. The company is also aware of the increased compliance burden associated with potential fraud and abuse laws, particularly as its operations expand following product approvals. However, the context provided does not include specific proactive strategies the company plans to implement beyond ensuring compliance and supporting reimbursement decisions.","The company must engage in a time-consuming and costly process to provide scientific and clinical support for the use of its products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. The company may also need to negotiate lower prices for its products to be covered by government health programs and commercial insurance, which could impact profitability.",4.5,0.36821766853724264,1.0,0.875,1.0
What is the company's approach to intellectual property protection for its products and technologies?,"The company relies on a combination of patent, trademark, and trade secret laws, along with license and access agreements and other contractual provisions, to protect its intellectual property and proprietary rights. To safeguard its technologies, it requires employees, consultants, and certain contractors to sign confidentiality and assignment of inventions agreements. Additionally, it uses non-disclosure agreements with strategic partners, consultants, and suppliers, and applies trade secrets, know-how, and copyright protection where applicable. The company also files trademark applications in various countries and, in some cases, depends on third-party trademarks. Despite these measures, the protection provided is limited, and enforcement challenges exist, particularly due to the difficulty in monitoring unauthorized use, the potential for breaches of agreements, and the risk of independent development or misappropriation by competitors.","The company seeks to protect its products and technologies by filing U.S. and foreign patent applications related to its proprietary technology, inventions, and improvements. It also relies on trade secrets, know-how, continuing technological innovation, and in-licensing of third-party intellectual property to develop and maintain its proprietary position.",4.5,0.5731252537950794,1.0,1.0,1.0
What significant changes did Jefferies Financial Group Inc. make to its operating segments in the first quarter of 2020?,"In the first quarter of 2020, Jefferies Financial Group Inc. made significant changes to its operating segments by appointing co-Presidents of Asset Management and creating a separate operating segment for asset management. This new segment was formed by consolidating the asset management activity that was previously included in the Investment Banking, Capital Markets and Asset Management segment, along with asset management activities from the Merchant Banking segment. As a result, the company recast its prior period segment results to align with the new presentation for comparison purposes.","In the first quarter of 2020, Jefferies Financial Group Inc. appointed co-Presidents of Asset Management and created a separate operating segment for asset management activities previously included in the Investment Banking, Capital Markets, and Asset Management segment, as well as those previously included in the Merchant Banking segment.",5.0,0.9151682283765918,1.0,1.0,1.0
How does Jefferies Financial Group Inc. manage its exposure to credit risk associated with derivative activities and securities financing transactions?,"Jefferies Financial Group Inc. manages its exposure to credit risk associated with derivative activities and securities financing transactions through several key practices. For derivatives, the company records OTC derivative assets and liabilities net of collateral received or pledged in its Consolidated Statements of Financial Condition. At November 30, 2020, cash collateral received was $216.8 million, and cash collateral pledged was $459.3 million. Derivative fair values are computed with counterparty netting within product categories, and amounts are netted against receivable and payable balances for the same counterparty within product categories across maturities. The company also uses internal credit ratings determined by its Risk Management department, which are generally consistent with external rating agency methodologies, to assess counterparty credit quality.

For securities financing transactions, Jefferies engages in repurchase agreements and securities borrowing and lending arrangements, which are recorded at cost, a reasonable approximation of fair value due to their short-term nature. The company monitors the fair value of securities loaned and borrowed daily in comparison to related payables or receivables and adjusts collateral by requesting additional collateral or returning excess collateral as necessary. Additionally, the company pledges financial instruments as collateral under various secured arrangements, including repurchase agreements and clearing arrangements.

Derivative instruments may include contingent features that require the company’s debt to maintain an investment grade credit rating. If this requirement is violated, counterparties could demand immediate payment or full overnight collateralization. The company monitors the fair value of derivative instruments in liability positions, including potential additional collateral requirements if such contingent features were triggered. Overall, these practices help mitigate credit risk exposure in both derivative activities and securities financing transactions.","Jefferies Financial Group Inc. manages its exposure to credit risk through master netting agreements, master securities lending agreements, master repurchase agreements, or similar agreements and collateral arrangements with counterparties. These agreements provide protection in bankruptcy in certain circumstances and enable receivables and payables with the same counterparty to be settled or otherwise eliminated by applying amounts due against all or a portion of an amount due from the counterparty or a third-party.",4.5,0.6321168171950685,1.0,0.875,1.0
What is the significance of the foreign currency translation adjustments in Jefferies Financial Group Inc.'s financial statements?,"Foreign currency translation adjustments are not explicitly discussed in the provided context. However, it is mentioned that gains or losses from Jefferies Group's foreign currency transactions are included in Principal transactions revenues in the Consolidated Statements of Operations. This indicates that foreign currency movements impact the company's reported revenues, particularly in its principal transactions segment. Additionally, Jefferies Group has entered into agreements to indemnify Jefferies Finance against foreign currency exposure for non-U.S. dollar loans to certain clients, which suggests that managing foreign currency risk is a material aspect of its operations. While the specific impact of translation adjustments on equity or comprehensive income is not detailed, the inclusion of foreign currency gains and losses in revenues reflects the significance of currency fluctuations in the group's financial performance.",Foreign currency translation adjustments result from translating the financial statements of foreign subsidiaries from their functional currency into the reporting currency (U.S. dollars). These adjustments are included in accumulated other comprehensive income (loss) and can significantly impact the company's equity and financial position.,3.0,0.4645854335469915,1.0,0.75,1.0
How does SuRo Capital Corp value its investments at fair value?,"SuRo Capital Corp values its investments at fair value in accordance with GAAP and the AICPA’s Audit and Accounting Guide for Investment Companies. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The company uses a fair value hierarchy that classifies inputs into three levels:

- **Level 1**: Valuations based on unadjusted quoted prices for identical assets or liabilities in an active market that the company can access at the measurement date.
- **Level 2**: Valuations based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in less active markets, or other inputs that are observable or can be corroborated by observable market data for the full term of the assets or liabilities.
- **Level 3**: Valuations based on unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date, considering the risks inherent in the valuation technique and the inputs.

The company values its assets on a quarterly basis, or more frequently if required under the 1940 Act. For investments with readily available market quotations, the company may use quotes obtained from pricing services, brokers, or dealers, provided the quote is sufficient under GAAP. For securities without reliable market quotations or where the pricing source does not provide a reliable valuation, the company follows a multi-step valuation process:

1. Initial valuation by investment professionals responsible for the portfolio investment.
2. Documentation and discussion of preliminary valuations with senior management.
3. Engagement of an independent third-party valuation firm to conduct appraisals and review management’s preliminary valuations.
4. The Valuation Committee discusses the valuations and recommends fair values to the Board of Directors based on input from management and the third-party firm.
5. The Board of Directors reviews the recommendations and determines in good faith the fair value of each investment in the portfolio.

In making these determinations, the company considers valuation methodologies consistent with industry practice.","SuRo Capital Corp values its investments at fair value using a hierarchy that prioritizes the inputs to valuation techniques. Level 1 assets are valued based on unadjusted quoted prices in active markets for identical assets. Level 2 assets use observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities. Level 3 assets use unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability.",5.0,0.8399267939664496,1.0,0.875,1.0
What measures has SuRo Capital Corp taken to ensure compliance with the RIC tax provisions of the Code?,"SuRo Capital Corp has taken several measures to ensure compliance with the RIC tax provisions of the Code. The company has elected to be treated as a RIC under the Code starting with the 2015 tax year and operates in a manner intended to continue qualifying for the tax treatment applicable to RICs. To maintain this status, the company meets certain source of income and asset diversification requirements and ensures the timely distribution of at least 90% of its investment company taxable income to its stockholders each tax year. The distributions are determined by the Board of Directors each quarter based on annual earnings estimates provided by management. Additionally, the company accrues excise tax on any estimated excess taxable income that is retained and not distributed in the current year, as required by law, to avoid penalties. The company also continuously evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law, and new authoritative rulings to maintain compliance.",SuRo Capital Corp has elected to be treated as a RIC under Subchapter M of the Code and intends to qualify for tax treatment as a RIC. The Company is required to meet certain income and asset diversification tests and distribute dividends of an amount generally at least equal to 90% of its investment company taxable income to its stockholders. The Company has taxable subsidiaries that hold certain portfolio investments to limit potential legal liability and comply with source-income type requirements.,5.0,0.7241273124652006,1.0,1.0,1.0
What are the key features of Waste Management's Employee Stock Purchase Plan (ESPP)?,"The key features of Waste Management's Employee Stock Purchase Plan (ESPP) include two offering periods each year, running from January through June and July through December. At the end of each offering period, enrolled employees purchase shares of common stock at a price equal to 85% of the lesser of the stock's market value on the first or last day of the offering period. These purchases are funded through payroll deductions made during the offering period. Employees may elect to have up to 10% of their base pay deducted, subject to plan and IRS limitations. In recent years, approximately 570,000, 537,000, and 582,000 shares were issued in 2020, 2019, and 2018, respectively. As of January 2021, 3.2 million shares remained available for issuance, including 3.0 million additional shares approved by stockholders in May 2020. The plan results in annual compensation expense, with amounts of $13 million, $10 million, and $9 million reported for 2020, 2019, and 2018, respectively.","The key features of Waste Management's ESPP include employees being able to purchase shares of common stock at a discount, with purchases made at the end of offering periods with funds accumulated through payroll deductions. The discount is 85% of the lesser of the market value of the stock on the first and last day of the offering period.",5.0,0.813519057814149,1.0,0.875,1.0
How does Waste Management assess and manage its long-lived assets for potential impairment?,"Waste Management assesses its long-lived assets, including landfill assets, for potential impairment by evaluating events or changes in circumstances that may indicate impairment. These assessments are conducted at least annually, using a measurement date of October 1, and more frequently if necessary. The company performs a qualitative assessment to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying value. If a possible impairment is indicated, a quantitative review is conducted, comparing the estimated fair value to the carrying amount, including goodwill. 

For the fair value estimation, Waste Management typically uses an income approach based on long-term projected future cash flows of the reporting units, discounted to present value using a weighted average cost of capital that reflects market assumptions, cash flow timing, and associated risks. This approach considers the reporting units’ expected long-term performance under prevailing economic and market conditions. In certain cases, the market approach may also be used, which involves measuring the aggregate market value of publicly-traded companies with similar characteristics as a multiple of their reported earnings. An impairment charge is recognized if the estimated fair value is less than the carrying amount of the asset.","Waste Management assesses its long-lived assets for potential impairment by monitoring the carrying value for potential impairment indicators. If an impairment indicator occurs, the company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If the carrying value exceeds the undiscounted cash flows, the company measures the impairment by comparing the fair value of the asset or asset group to its carrying value.",4.5,0.7756570478437724,1.0,0.875,1.0
"What are the primary sources of revenue for Waste Management, and how do they contribute to the overall revenue mix?","The primary sources of revenue for Waste Management include tipping fees from landfill operations, which are based on the type, weight, or volume of waste disposed, and fees from transfer stations that account for loading, transporting, and disposing of waste. Recycling revenues consist of tipping fees and the sale of recycling commodities to third parties. These are complemented by additional services provided through segments such as Strategic Business Solutions, Energy and Environmental Services, recycling brokerage, landfill gas-to-energy, and other expanded service offerings. Revenue from lease arrangements for compactors and balers is also included, though it is not material, contributing approximately 1% of total revenue. The company recognizes revenue as services are performed or products are delivered, with advance billings recorded as deferred revenues and recognized in the period the service is provided. The overall revenue mix is predominantly driven by solid waste collection, transfer, disposal, and recycling services, with additional contributions from ancillary and expanded service offerings.","The primary sources of revenue for Waste Management are collection, landfill, transfer, and recycling services. These services contribute to the overall revenue mix, with collection and landfill services typically being the most significant contributors.",4.5,0.8505560890604261,1.0,0.75,1.0
"How does Waste Management handle its environmental remediation liabilities, and what was the total amount of such liabilities as of December 31, 2020?","Waste Management recognizes and accrues for estimated remediation liabilities when they are both probable and reasonably estimable. The company determines the method and ultimate cost of remediation based on a number of assumptions, and in cases where there is a range of reasonable estimates, it uses the best estimate within that range. If no amount within the range is considered a better estimate, the low end of the range is used. As of December 31, 2020, the total amount of remediation liabilities recorded in the Consolidated Balance Sheet was $230 million.","Waste Management handles its environmental remediation liabilities by recognizing and accruing for an estimated remediation liability when it determines that such liability is both probable and reasonably estimable. The total amount of environmental remediation liabilities as of December 31, 2020, was $230 million.",5.0,0.9037106131191694,1.0,0.875,1.0
"What are the key financial covenants associated with Waste Management's debt agreements, and how does the company ensure compliance?","The key financial covenant associated with Waste Management's debt agreements is the Leverage Ratio, which must be maintained at 3.75 to 1 for at least one fiscal quarter between Elevated Leverage Ratio Periods. There can be no more than two Elevated Leverage Ratio Periods during the term of the $3.5 billion revolving credit facility. The company has not elected to increase the Leverage Ratio for an Elevated Leverage Ratio Period since the acquisition of Advanced Disposal, reflecting confidence in its financial position to maintain significant headroom within the Leverage Ratio covenant.

In addition to the Leverage Ratio, the company's financing arrangements include certain restrictions on the ability of its subsidiaries to incur additional indebtedness, as well as restrictions on the company and its subsidiaries regarding the incurrence of liens, engaging in sale-leaseback transactions, and participating in mergers and consolidations. The company monitors compliance with these covenants and restrictions and assesses that they do not significantly impact its ability to enter into typical investing or financing arrangements for its business. As of December 31, 2020 and 2019, the company was in compliance with all covenants and restrictions that could have a material effect on its consolidated financial statements.","The key financial covenant associated with Waste Management's debt agreements is the maximum total debt to consolidated earnings before interest, taxes, depreciation, and amortization (EBITDA) ratio (the ""Leverage Ratio""). The company ensures compliance by monitoring its financial position and maintaining significant headroom within the Leverage Ratio.",4.5,0.8838053831189441,1.0,0.875,1.0
How does ridinilazole aim to differentiate itself from existing treatments for CDI?,"Ridinilazole aims to differentiate itself from existing treatments for Clostridioides difficile infection (CDI) by targeting the infection more selectively. It is designed to specifically target C. difficile bacteria while preserving the gut microbiome, which is often disrupted by broader-spectrum antibiotics. This targeted approach may reduce the recurrence rates of CDI compared to current therapies like vancomycin, metronidazole, and fidaxomicin, which have broader antimicrobial activity and can impact beneficial gut bacteria. Additionally, ridinilazole is being developed as an orally administered small molecule with a novel mechanism of action, distinct from existing antibiotic classes, potentially offering improved stewardship and better patient outcomes.","Ridinilazole is designed to selectively target the bacterium Clostridioides difficile while preserving the gut microbiome, potentially reducing recurrence rates and improving sustained clinical response rates compared to broad-spectrum antibiotics like vancomycin.",5.0,0.8038369189286574,1.0,1.0,1.0
What financial support has Summit Therapeutics received for the development of ridinilazole?,"Summit Therapeutics has received financial support from the Biomedical Advanced Research and Development Authority (BARDA) for the development of ridinilazole. In September 2017, the company was awarded a contract with a base period of approximately $32 million. The contract included three option work segments, which, if fully exercised, could increase the total funding to approximately $62 million. BARDA exercised the first option in August 2018 for $12 million, the second in June 2019 for $9.6 million, and in January 2020, the contract was increased by an additional $8.8 million. This raised the total contract value to up to $72.5 million, with a total of $62.4 million in committed funding. As of December 31, 2020, the company had received $53.3 million of the committed funding and recognized $46.2 million in cumulative income since the contract’s inception. The contract includes a cost-sharing arrangement where BARDA funds a specified portion of the development costs.",Summit Therapeutics has received a contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $72.5 million to support the ongoing Phase 3 clinical trials and potential regulatory applications for ridinilazole in the United States.,5.0,0.8953623814678152,1.0,1.0,1.0
What are the key competitive factors affecting the success of Summit Therapeutics' product candidates?,"The key competitive factors affecting the success of Summit Therapeutics' product candidates are their efficacy, safety, convenience, price, and the availability of coverage and reimbursement from government and other third-party payors.","The key competitive factors include efficacy, safety, convenience, price, and the availability of coverage and reimbursement from government and other third-party payors.",5.0,0.7113638247025071,1.0,1.0,1.0
"What are the potential risks associated with the company's reliance on government funding for its lead product candidate, ridinilazole?","The company's reliance on government funding for its lead product candidate, ridinilazole, carries several potential risks. Government funding from entities like BARDA may be terminated at any time, either in full or in part, which could disrupt development efforts. Changes in government budgets or research priorities may lead to reduced or delayed support for antibacterial product candidates such as ridinilazole. If the funding contract is not extended or the remaining options are not exercised, the company may need to seek alternative sources of financing, which may not be available on non-dilutive or favorable terms. This could force the suspension or termination of development activities. Additionally, government contracts may impose requirements that increase the costs of commercialization and production. The government may also direct delays in certain activities, requiring the company to invest additional time and resources before proceeding. These factors introduce uncertainty into the research and commercialization efforts, potentially impacting the timely development and market approval of ridinilazole.","Risks include the possibility of the government terminating the funding contract, changes in government budgets and research priorities, delays in development activities, and increased costs of commercialization and production due to imposed requirements. These factors could force the company to seek alternative funding sources, which may not be available on favorable terms.",5.0,0.7339115481651451,1.0,1.0,1.0
What are the key factors that contributed to the increase in net interest income during 2020?,"The increase in net interest income during 2020 was primarily driven by a rise in interest income, which increased by $319.2 million, and a decline in interest expense, which decreased by $3.0 million. While the yield on interest-earning assets declined due to lower interest rates, the cost of interest-bearing liabilities also decreased significantly, with the cost of interest-bearing deposits dropping by 40 basis points and the overall cost of all interest-bearing liabilities falling by 41 basis points. Despite the negative impact of lower yields on assets, the reduction in funding costs contributed positively to net interest income. Additionally, the growth in the size of the asset base supported higher interest income, leading to an overall increase in net interest income.","The increase in net interest income during 2020 was primarily due to lower interest expense from interest-bearing liabilities driven by lower rates paid and a shift in mix to lower cost deposits, as well as the favorable impact of higher average interest earning asset balances.",4.5,0.8733956842590239,1.0,1.0,1.0
How did the COVID-19 pandemic impact the provision for credit losses in 2020?,"The COVID-19 pandemic led to a significant increase in the provision for credit losses in 2020. For the commercial loan portfolio, the provision increased by $447 million, driven by deteriorating economic conditions that worsened economic forecasts used for calculating lifetime expected credit losses (ECL), client downgrades due to weakened financial conditions, and provisions for higher-risk exposures. In the consumer loan portfolio, the provision rose by $94 million, primarily due to worsening economic forecasts, higher delinquency levels, and provisions related to economic uncertainty and forbearance accounts. Additionally, growth in personal loan balances from new product promotions contributed to the increase, while a decline in credit card balances from reduced spending and changes in underwriting criteria partially offset the rise. The off-balance sheet credit exposures also saw a loss provision in 2020, consistent with the commercial loans, due to the pandemic's impact on economic conditions.","The COVID-19 pandemic significantly impacted the provision for credit losses in 2020 by causing a deterioration of economic conditions, which resulted in a worsening of the economic forecasts used for calculating expected credit losses and downgrades reflecting weakness in the financial condition of certain clients.",5.0,0.7575067323257945,1.0,1.0,1.0
What measures were taken by HSBC USA to manage liquidity and funding risk during the COVID-19 pandemic?,"HSBC USA actively monitored and controlled liquidity and funding risk in accordance with its policy during the COVID-19 pandemic. To manage elevated commercial loan demand in March, the bank raised deposits, increased short-term borrowings through securities sold under repurchase agreements, and borrowed from the Federal Home Loan Bank (FHLB). These actions supported client demand for loans while maintaining adequate liquidity and increasing cash. Additionally, the bank continuously monitored the impact of market events on its liquidity positions and adapted its framework as needed. HSBC USA also maintained a Liquidity Coverage Ratio (LCR) exceeding 100 percent under both European and U.S. rules, ensuring sufficient High Quality Liquid Assets to cover stressed cash outflows over 30 days. The bank did not utilize any Federal Reserve Bank (FRB) liquidity facilities, such as the Money Market Mutual Fund Liquidity Facility or the Paycheck Protection Program Liquidity Facility, and did not experience significant disruptions to its liquidity or funding capabilities.","During the COVID-19 pandemic, HSBC USA actively raised deposits, increased short-term borrowings in the form of securities sold under repurchase agreements, and borrowed from the Federal Home Loan Bank to support elevated client demand for loans while maintaining adequate liquidity.",5.0,0.8511486639998408,1.0,1.0,1.0
What was the impact of the LIBOR transition on HSBC USA's operations?,"The LIBOR transition impacted HSBC USA's operations by necessitating the establishment of a framework to limit the sale of LIBOR-based products and implementing risk disclosures for new LIBOR-based contracts across all business lines. The company incorporated the ARRC recommended fallback language into new contracts for syndicated loans, bilateral loans, floating rate notes, and adjustable rate mortgage loans, updating it in 2020 with revised hardwired fallback language. This transition also introduced risks such as conduct, execution, financial, and non-financial risks, which are monitored through a risk inventory with mitigating actions. Additionally, the transition could lead to legal proceedings related to contract enforceability and regulatory scrutiny regarding readiness for the transition.","The LIBOR transition process involved developing alternative rate product capabilities and transitioning legacy contracts. This transition could have a range of adverse impacts on HSBC USA's business, including legal proceedings or other actions regarding the interpretation and enforceability of provisions in LIBOR contracts and regulatory investigations or reviews.",4.5,0.7540707803034515,1.0,0.875,1.0
How did HSBC USA manage its credit risk during the economic uncertainty caused by the COVID-19 pandemic?,"HSBC USA managed its credit risk during the economic uncertainty caused by the COVID-19 pandemic by re-reviewing the credit ratings assigned to substantially all of its material commercial loans during the first half of 2020. The organization continued to monitor loan performance throughout the second half of 2020 and took necessary credit actions as conditions evolved. This approach was part of broader efforts to enhance resilience to market conditions, which included stress testing, refining early warning indicators, and adjusting business strategies such as discontinuing certain business lines or products, managing underwriting criteria, and investing in improved fraud prevention technologies.","HSBC USA managed its credit risk during the pandemic by re-reviewing the credit ratings assigned to substantially all of its material commercial loans, closely monitoring the performance of these loans, and taking necessary credit actions where warranted.",4.5,0.8963715417348938,1.0,0.875,1.0
"What was the strategic plan announced by HSBC USA in February 2020, and what were its expected financial impacts?","In February 2020, HSBC USA announced a strategic plan to restructure its operations. This plan was aligned with HSBC’s global strategy and aimed to refocus wholesale operations to better serve international corporate clients while restructuring retail operations to meet the needs of globally mobile and affluent clients. The plan also included streamlining functional and operations support by removing duplication and reducing the size of the balance sheet to better align with the scope and scale of the U.S. opportunity.

The expected financial impacts included pre-tax charges of approximately $520 million to $590 million over the two-year period of 2020–2021, which would result in after-tax charges of $390 million to $450 million. During 2020, pre-tax charges totaling $280 million were recorded as part of this restructuring.","The strategic plan announced in February 2020 aimed to restructure operations in alignment with HSBC’s global strategy, focusing on refocusing wholesale operations and restructuring retail operations. The expected financial impact included pre-tax charges of approximately $520-$590 million over the two-year period of 2020-2021.",5.0,0.8700190977552408,1.0,1.0,1.0
